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Abstract 
 
Introduction: The tumour microenvironment has been found to contribute to cancer 
survival and progression, and more specifically, the stromal microenvironment has 
been implicated in the drug resistant nature of cancers such as pancreatic cancer.  
This microenvironment consists of fibroblasts, pericytes, endothelial cells and the 
extracellular matrix, with the stellate cancer-associated fibroblast (CAF) being the 
most predominant cell type present. The aim of this study was to investigate the role 
of the cancer associated fibroblast in tumourigenesis in Pancreatic Ductal 
Adenocarcinoma (PDA) with specific reference to the mechanisms involved in 
chemoresistance via the stellate cancer associated fibroblast. 
 
Methods: I investigated the molecular pathogenesis of PDA assessing DNA copy 
number alterations (CNA) in selection of clinically relevant PDA cell lines (PANC-1, 
MiaPaCa-2, ASPC-1, SU86.86, HPAC, HS776T, PL5 and PL45), seven primary 
resected, non immortalised samples (PF3, PF7, PF8, PF9, PF16, PF18 and PF20) 
and an immortalised stellate cell line using array comparative genomic hybridization 
(aCGH). All cultures and cell lines were then screened in order to determine their 
sensitivity to currently used therapeutic compounds. Analysis was done using R 
software and Graph Pad Prism 5. 
 
Results: The non-immortalised stellate CAFs and formalin fixed paraffin embedded 
stromal fibroblast samples showed no homozygous genomic CNAs. The stellate 
cancer associated fibroblasts both primary and immortalised appear more 
responsive to the chemotherapeutic drugs in the compound library compared to the 
PDA cell lines. 
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Conclusions: This study suggests the absence of homozygous deletions that may 
lead to a change in phenotype in the stellate CAF. However, the presence of 
heterozygous deletions and epigenetic changes has not yet been excluded. Further 
experiments such as micro RNA and epigenetic studies, such as SNP arrays, may 
identify the presence of aberrations that have aetiological significance in 
carcinogenesis even if they do not result in CNVs. This higher sensitivity of the 
stellate CAF to the drugs in the chemotherapy library may favour them as potential 
targets for management of this hard to street subtype of disease.   
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Chapter 1: Introduction 
1.1 General Introduction 
Pancreatic cancer is known for its poor morbidity and high mortality rates. Its surgical 
management is complicated by its late presentation, early local invasion, distant 
metastasis of the tumour, and its resistance to the current chemotherapeutic agents. 
Despite the use of Gemcitabine as adjuvant therapy, the average survival still only 
ranges around 6 months for those with metastatic disease and 10 months for those 
with locally advanced disease (Benson et al 2011).  
 
Neither clinical response nor quality of life was improved with the 
Gemcitabine/Capecitabine combination when compared to Gemcitabine alone, 
(Bernhard et al, 2008). For those trials in which patients experienced an improved 
response rate or better median survival, the toxicity of the combinations regimes was 
too severe as was seen in Gemcitabine/ Erlotinib  vs. Gemcitabine alone, (Vervenne 
et al ,2008).  
 
The non-Gemcitabine regimen of Folforinox, Oxaliplatin and Irinotecan improved 
median survival but was toxic and patients presented with other complications such 
as febrile neutropenia, (Conroy et al, 2011).  Most trials using combination therapy 
have failed due to the severe toxicity and therefore Gemcitabine is still considered 
the mainstay therapy for metastatic and unresectable disease. As yet, radiotherapy 
has not proved beneficial and has added toxicity (Loehrer et al, 2008). These and 
further trials are discussed in detail in section 1.2.2. 
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The development of chemo-resistant tumours can be attributed to numerous factors 
including mutated signalling pathways such as the hedgehog signalling pathway, and 
selective clonal expansion of transformed cells. Although these factors are not 
mutually exclusive, it is becoming more evident that the stromal microenvironment 
plays a significant role in this setting. It was previously believed that tumour epithelial 
cells displayed the up-regulated pathways that stimulated stromal development, 
(Bailey et al, 2008). It has since been shown that these pathways are indeed 
upregulated in the stromal compartment and have an effect on tumour growth and 
development.  
 
 
The stromal desmoplasia is a dense proliferation of multiple cell types and 
vasculature that affects drug delivery to tumour sites. The most prominent cell type 
found, the cancer associated-Fibroblast (CAF) or activated fibroblast is a stellate cell 
that is suspected to play a role in chemo-resistance via multiple signalling pathways 
between the stroma and tumour. Pancreatic cancer specimens have been shown to 
be made up of more than 90% representation by these pancreatic stellate cells 
within the stromal microenvironment. This therefore makes it a suitable vehicle to 
study their role in tumour progression, metastasis and chemoresistance.  
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1.2 Pancreatic Ductal Adenocarcinoma 
1.2.1 The Pancreas, cancer, morbidity and mortality 
  
 
Figure 1.1 The Pancreas. 
 
 
The Pancreas, as represented in figure 1.1, is situated transversely across the 
posterior wall of the abdomen. It has a long irregular prismatic shape with a head 
(the broadest portion), neck, body and tail. Its length varies from 12.5 to 15cm and its 
weight from 60gms to 100gms. In the digestive system it is the organ responsible for 
the production of insulin and digestive juices containing digestive enzymes.  
Pancreatic adenocarcinoma is a malignant exocrine neoplasm of the pancreas. It is 
the tenth most common site of new cancers and the fourth leading cause of cancer 
deaths among men and women, being responsible for 6% of all cancer-related 
deaths,  (Anderson et al, 2006).   
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Internationally, pancreatic cancer ranks 13th in incidence and 8th as a cause of 
cancer death with an incidence rate of 8-12/100,000 people per year, (Anderson et 
al, 2006). Endocrine tumours of the pancreas or pancreatic neuroendocrine tumours 
(PNETs) as they are called, account for only 1% of pancreatic cancers. They arise 
from the amine precursor and uptake cells (APUD) of the pancreas. These stem 
cells are pluripotent cell found in the ducal epithelium of the pancreas and areas of 
the distal foregut. They are characterised into functional, if they produce clinical 
symptoms due to hypersecretion of hormones or non-functional.   
 
 
The majority of PNETs are non–functional (Halfdanarson et al 2008). Although they 
secrete pancreatic peptide (PP), this does not result in any syndrome related to its 
hypersecretion. The annual clinical incidence is low and most are benign.  According 
to British Society of Gastroenterology, the incidence of PNETs is around 0.2-0.4 per 
100,000. Insulinomas and Gastrinomas account for over 50% of cases. Vasoactive 
intestinal polypeptide-secreting tumours, (VIPomas) are one eighth and 
glucagonomas (secretes glucagon) are one seventeenth as common. 
Somatostatinomas, (secretes somatostatin), are rare and non-functional tumours 
account for 14-48% of all recognised PNETs (British Society of Gastroenterology, 
2012). 
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The remaining 99% of tumours however, arise from the exocrine pancreas. Of these, 
95% are adenocarcinomas and the remaining 5% include adenosquamous 
carcinomas, signet ring cell carcinomas, hepatoid carcinomas, colloid carcinomas, 
undifferentiated carcinomas and undifferentiated carcinomas with osteoclast-like 
giant cells, (WHO Cancer, 2009).  Most carcinomas of the pancreas occur within the 
head and neck, accounting for 75% of these tumours. About 15-20% occur in the 
body and the remaining 5-10% occur in the tail, (Dragovich et al, 2012). 
 
 
1.2.1.1 Risk factors 
Suspected risk factors include smoking 30%, dietary factors and obesity 20%. About 
40% of cases are estimated to be sporadic and only 5-10% of patients with 
pancreatic cancer are believed to be hereditary, (Raimondi et al 2009). The risk 
associated with alcohol is controversial but the risk increases significantly with 
longstanding chronic pancreatitis, (Lowenfels et al, 1993), which can occur as a 
result of excessive alcohol consumption.  
 
The molecular genetics of pancreatic adenocarcinoma have been well studied. Of 
these tumours, 80-95% have mutations in the KRAS2 gene; 85-98% have mutations, 
deletions, or hypermethylation in the CDKN2 gene; 50% have mutations in p53; and 
about 55% have homozygous deletions or mutations in Smad4, (Soto et al, 2006, 
Hahn et al, 1995, Shi et al, 2008). Some of these mutations can also be found in 
high-risk precursors of pancreatic cancer. For example, in chronic pancreatitis, 30% 
of patients have detectable mutations in p16 and 10% have K-ras mutations, 
(Dragovich et al, 2012). 
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1.2.1.2 Symptoms 
Symptoms of pancreatic cancer include epigastric and back pain, which is seen in up 
to 85% of patients with locally advanced disease, loss of appetite, nausea and 
vomiting, significant weight loss, painless jaundice and thrombophlebitis 
(Trousseau’s sign). Painless obstructive jaundice is present in 50% of patients with 
locally unresectable disease. Many patients develop diabetes mellitus in advance of 
the diagnosis of pancreatic cancer but this is not a definitive screening test. Patients 
diagnosed with pancreatic cancer have a very poor prognosis owing to the late 
presentation of symptoms at the time of diagnosis.  
 
 
1.2.1.3 Prognosis 
The median survival for patients with pancreatic cancer without treatment is 3-6 
months from the time of diagnosis. The 1 year relative survival rate for all stages 
combined is 24% (American Cancer society, 2009) and the overall 5 year survival is 
less than 5%, (Carpelan-Holmstrom et al, 2005). In the UK, 8364 people were 
diagnosed with pancreatic cancer in 2009 and around 7900 died from this disease in 
2010. Between 2005 and 2009 the 5 year survival rate was 4%, (Cancer Research 
UK, 2012). In about 20% of patients that have had a successful potentially curative 
resection, the median survival time ranges from 12-19 months, and the 5-year 
survival rate is 15-20%, (Dragovich et al, 2012). 
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1.2.1.4 Management 
Surgical resection of the tumour is the current treatment modality for pancreatic 
cancer depending on the stage at presentation.  Only about 15% of patients present 
early enough to be considered for resection and more than 80% of these re-present 
with local or metastatic disease within 2 years (Stathis/Moore, 2010; Sperti et al, 
2007). Currently the best predictors of long-term survival after surgery are a tumour 
diameter of less than 3 cm, no nodal involvement, negative resection margins, and 
diploid tumour deoxyribonucleic acid (DNA) content, (Allison et al, 1991).  
 
 
Most patients present at the stage of locally advanced or metastatic disease. For 
patients with extra-peritoneal disease, surgery can only be considered as palliative 
intervention. For those whom curative or palliative surgery is not an option, palliative 
chemotherapy, Gemcitabine being the gold standard since 1997, provides an 
alternative in order to improve quality of life and possibly gain a marginal survival 
benefit (Burris et al, 1997). 
 
 The current deterrent in management of pancreatic cancer resulting in its poor 
clinical outcome is the late stage at which patients present as well as the resistance 
of pancreatic cancer to the current treatment modalities. This drug resistance is 
proposed to be due to its aggressive desmoplastic reaction surrounding the tumour 
which appears to affect suitable drug delivery. Notably, the CAF is the most 
prominent cell found in this area of desmoplasia, (Armstrong et al, 2004, Watanabe 
et al, 2003).  
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1.2.2 Pancreatic cancer and current treatment modalities 
Surgical resection followed by adjuvant therapy is the standard management for 
patients with early stage or localised disease. This is usually about 10 -15 % of 
patients (Heinemann et al, 2008). For those with unresectable disease, 
chemotherapy is necessary adjuvant treatment. Over the last 14 years 
pharmaceutical companies and collaborative groups have embarked on clinical 
research to improve survival and prognosis of pancreatic cancer sufferers. This 
involved trials with Gemcitabine and a number of combination therapies.  
 
Currently, the response rate to first line treatment with Gemcitabine is only 20% 
(Funamizu et al., 2009). Despite the anti-tumour activity seen with several 
chemotherapeutic agents and novel molecular targeted therapies, these drugs have 
thus far failed to show significant effects against epithelial tumour cells in the clinical 
setting without toxic or deleterious effects to the patients. 
 
In patients with metastatic disease, combination therapy with Erlotinib has seen 
higher median and 1-year survival rates when compared to the use of Gemcitabine 
alone, (Vervenne et al, 2008), and has since been used in combination with 
Gemcitabine in advanced, unresectable pancreatic cancer. However, due to 
significant toxicity and only a small improvement in response rate, cautious use is 
recommended.  
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A randomised, multicenter, phase III clinical trial in 319 patients by the Central 
European Cooperative Oncology Group (ECOG) found that neither clinical response 
nor quality of life were improved when the Gemcitabine/Capecitabine combination 
was compared to Gemcitabine alone, (Bernhard et al, 2008). This contrasted with 
the results of the phase III National Cancer Research Institute GEMCAP trial in the 
UK, an open-label (both researchers and participants know which treatment is being 
administered). This randomised study of Gemcitabine alone versus Gemcitabine 
combined with Capecitabine involved 533 patients. Compared with Gemcitabine 
alone, treatment with the Gemcitabine/Capecitabine combination produced a 
significantly higher objective response rate (12.4% vs. 19.1%, respectively) and 
progression-free survival. (Cunningham et al, 2009).  
Other phase III trials have ruled out the benefits of combination therapy with 
Cisplatin, Oxaliplatin, Irinotecan and Docetaxel when compared to Gemcitabine 
alone. Therefore Gemcitabine remains the mainstay therapy for patients with 
metastatic disease. For those refractory to Gemcitabine, Capecitabine alone or 
Capecitabine plus Erlotinib may provide some benefit as second line therapy, (Kulke 
et al, 2007).  
In 2011 the NCCN made several recommendations with respect to the management 
of patients with unresectable disease. This included Gemcitabine monotherapy or 
patients with locally advanced or metastatic disease, the use of the GTX regimen 
(Gemcitabine, Docetaxel and Capecitabine) and the Gemcitabine/nab-paclitaxel 
combination regimen) for metastatic disease, (NCCN, 2011. 
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1.2.2.1 Clinical trials 
1.2.2.1.1 Adjuvant therapy 
Adjuvant therapy is treatment that is used following primary treatment, which is 
surgery in the case of pancreatic cancer, in order to reduce the risk of disease 
recurrence. It may be in the form of chemotherapy, hormone therapy, radiotherapy, 
targeted or biological therapy.  
The phase III National Cancer Research Institute GEMCAP trial in the UK was a 
randomised study of Gemcitabine versus Gemcitabine and Capecitabine in 533 
patients. This study was an open-label study in which both researchers and 
participants knew which treatment was being administered. Compared with 
Gemcitabine alone, treatment with the Gemcitabine/Capecitabine combination 
produced a significantly higher objective response rate (12.4% vs. 19.1%, 
respectively) and progression-free survival. (Cunningham et al, 2009). 
 
The results of a European phase III trial (ACCORD/PRODIGE) that compared the 
non-Gemcitabine regimen FOLFIRINOX (LV5-FU plus Oxaliplatin plus Irinotecan) to 
Gemcitabine were reported by Conroy et al. The median survival on the 
FOLFIRINOX arm was 11.1 months, versus 6.8 months for Gemcitabine alone. 
FOLFIRINOX proved more toxic with complications including febrile neutropenia 
despite the selection of patients with eastern cooperative oncology group (ECOG) 
performance status of 0-1 in this trial.  It has still been recommended by the NCCN 
for treatment of patients with metastatic or locally advanced unresectable disease 
with good performance status. 
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The European study group for pancreatic cancer (ESPAC)-3 trial, an adjuvant 
therapy trial involving 1088 patients, showed no significant outcome of survival 
between the groups of Gemcitabine or folinic acid and 5 Fluorouracil. The median 
survival differed by a mere 0.6 months between the two arms of this trial with 
Gemcitabine only treated patients having  less adverse affects, (Neoptolomos et al., 
2009).  
 
Phase III trials have also been done comparing Gemcitabine alone with Gemcitabine 
combined with Cisplatin (Heinemann et al., 2006, 2008; Coluccci et al., 2002, 2009), 
Capecitabine (Cunningham et al., 2005, 2009; Herrmann et al., 2007), Exatecan 
(Abou-Alfa et al., 2005), Irinotecan (Rocha Lima et al,. 2004; Statopoulos et al,. 
2006), Oxaliplatin (Louvet et al., 2005; Poplin et al., 2009) and Permetrexed (Oettle 
et al, 2005), with a median survival ranging between 5 to 7.5 months on the whole. 
These therapies have failed to show any overall survival benefit but in some of these 
trials there was a marginal effect on progression free survival for some patients 
(Anastasios et al, .2010).  
 
ESPAC-4 trial is currently underway. This trial is aimed at patients who have had 
total surgical resection of the tumour. It is looking at the efficacy of Gemcitabine and 
Capecitabine in this patient group administered within 10 weeks of surgical 
intervention with a two year follow up. (Liverpool Cancer Trial unit). 
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1.2.2.1.2 Neoadjuvant therapy 
This is therapy that is given to shrink a tumour before the primary treatment such as 
surgery is performed. This is done in the hope that there is an increased chance of 
removal or the whole tumour during surgery and result in a better overall survival. 
Studies performed by Pisters and colleagues using preoperative chemoradiation, 
intraoperative radiation and a preoperative paclitaxel/ radiation combination in 
patients with resectable disease. They showed the median survival of patients to be 
up to 19 months compared to that of 12 months with surgery alone, (Pisters et al., 
2002). There was, however, severe toxicity in these patients and currently 
insufficient data to support its use in the clinical setting.   
In a review by Raut and colleagues, they deduced that there was an increase in the 
rate of R0 (complete resection with no residual microscopic tumour) resections and a 
reduction in recurrence and metastases in patients having neoadjuvant therapy 
compared to immediate surgery, (Raut et al., 2004). The benefit of neoadjuvant 
therapy is currently obscure as the evidence is based on retrospective and phase II 
studies (Klautke et al, 2008). Loehrer and colleagues performed a phase III study of 
Gemcitabine and radiotherapy vs. Gemcitabine alone for patients with locally 
advanced unresectable disease. Gemcitabine plus radiotherapy was shown to have 
added toxicity and the progression free survival was a mere 0.2 months longer than 
the Gemcitabine only group, (Loehrer et al, 2008). The multicentre phase III 
NEOPAC trial is underway to ellucidate the efficay of neoadjuvant 
Gemcitabine/Oxaloplatin and adjuvant Gemcitabine versus adjuvant Gemcitabine 
alone. It aims to provide data un overall survival in patients post pancreatic head 
surgery. 
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1.2.2.1.3 Targeted therapies 
 
The identification of genetic changes that may occur in PDA and their effect on the 
signalling pathways involved in cell cycle regulation, DNA damage and repair, cell 
communication and development pathways have raised hope in identifying possible 
new target therapies. The phase III trials of Gemcitabine vs. combination therapy 
with either Tipifarnib (RAS family inhibitor), Van Cutsem et al., 2004, Marmisat (MMP 
inhibitor), Bramhall et al., 2001, Bavacizumab (VEGF inhibitor) Kindler et al and 
Erlotinib (EGFR inhibitors), Vervenne, W. et al.,2008, have all failed to show an 
improved overall survival when compared to Gemcitabine alone. Bay 12-9566, a 
specific inhibitor of MMP-2, MMP-3, MMP-9 and MMP13 was shown to have an even 
worse overall survival when compared to Gemcitabine, (Moore et al., 2003).  
 
The more recent trials have been focused on new combinations such as 
Gemcitabine/Lemalidomide (MEK inhibitor), Gemcitabine/GDC-0449 (Anti 
smoothened), (Von Hoff et al., 2011),   GEM/Nab- Paclitaxel vs. Gemcitabine and 
FOLFIRINOX (Fluorouracil, Leucovorin, Irinotecan, Oxaliplatin) -phase III. This last 
study showed a survival of 11.1 months compared with 6.8 months; a significant 
improvement thus far. 
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1.2.3 Pancreatic cancer and the stroma 
 
It has been established that cancers are the product of several somatic mutations 
that have developed in the epithelial cell. Their behaviour, however, is heavily 
influenced by the surrounding tumour microenvironment or stroma. The stroma is 
believed to play a significant role in the tumourigenesis of pancreatic cancer, 
especially in PDAs where there is a particularly dense stromal reaction. This dense 
reaction is a hallmark sign of pancreatic cancer.   
  
 
The complex stroma consists of a variety of cells including fibroblasts, pericytes, 
endothelial cells, smooth muscle cells, leucocytes, macrophages, mast cells and the 
extra-cellular matrix (ECM) as well as secreted growth factors and cytokines,  
(Lorusso et al, 2008). The vasculature of the tumour microenvironment, however, 
should not be ignored as its role is crucial in metastasis. Angiogenesis is supported 
by the secretion of endothelial growth factors e.g. vascular endothelial growth factor 
(VEGF) .Both tumour cells and stroma are sites of VEGF production (Fukumura et 
al, 1998). Targeted anti VEGF therapy, Bevacizumab in combination with 
chemotherapy has been approved as first line treatment in metastatic colorectal 
cancer, (Ferrara et al., 2004).   
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Within the tumour microenvironment stromal fibroblasts are largely responsible for 
the synthesis and deposition of the ECM. They also produce growth factors that act 
in an autocrine, (on the same cell), and paracrine, (on neighbouring cells), fashion to 
influence the growth of carcinoma cells. Although the exact role of the tumour stroma 
is not yet fully understood, there are a few who believe that the surrounding stroma 
is a host response to the invading cancer and acts to contain its growth, (Hartel et al, 
2004).  The predominant view, however, is that of a ‘Seed and Soil Hypothesis’ of 
carcinogenesis, proposed over a century ago, Paget, S., Lancet, 1889, supported by 
(Bhowmick et al, 2004), (Orimo et al, 2006) and (Hu et al, 2008), which suggests that 
stroma constituents are recruited by the tumour and hence generate a 
microenvironment for cancer cells to proliferate.  
 
 
The proof of this activation may be reflected in the modified extracellular matrix of 
the tumour stroma when compared to normal stroma, (Ronnov-Jessen et al 1995). 
Growth factors such as transforming growth factor beta (TGFß), insulin-like growth 
factor (ILGF) I and II, granulocyte macrophage–colony stimulating factor (GM-CSF) 
and platelet derived growth factor (PDGF) are some of the factors responsible for 
stromal activation. TGFß has been shown to be one of the main factors involved in 
the induction of myofibroblast transdifferentiation and aggregation, (Ronnov-Jessen 
et al, 1995; Lukas et al, 2009; Brenmoehl et al, 2009) and PDGF promotes 
myofibroblast differentiation indirectly via TGFß activity on stromal cells.   
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The communication between tumour and stroma cells has been shown to lead to the 
activation of the TGF-b/SMAD, HGF/MMP, Wnt and Hedgehog signalling pathways. 
The communication is primarily through autocrine and paracrine signalling believed 
to be responsible for the development of the prolific microenvironment that promotes 
tumourigenesis, (Mahadevan and Von Hoff, 2007), and supports the survival of the 
tumour.    
 
 
 
The dominant cell found in tumour stroma is the stellate CAF. It is said to represent 
almost 95% of the cell types found and is responsible for the dense desmoplastic 
reaction seen around the tumour in vivo. Apart from the histological differences seen 
in these CAFs on stromal activation, they proliferate and migrate more than their 
normal counterparts, (Schol et al 1985, 1988). There is evidence that these cells 
may differ phenotypically from fibroblasts associated with normal epithelium and they 
promote tumourigenesis, (Carpelan-Holmstrom, 2005; Direkze, et al, 2004; 
Dubernard, et al, 2008).  
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1.3 The Stellate Cancer-associated fibroblast 
 
1.3.1 The Cancer-associated fibroblasts (CAF) 
Desmoplasia is defined as fibrous connective tissue with an altered extracellular 
matrix. This change in the stroma is formed in response to an invasive epithelial 
carcinoma and is the hallmark of PDA. The mechanism behind this stromal change 
is yet to be fully defined. 
 
Normal fibroblasts are embedded within the fibrillar extracellular matrix (ECM) of 
connective tissue, which consists largely of type I collagen and fibronectin and plays 
a role in wound healing. Fibroblasts interact with their surrounding microenvironment 
through an integrin network including α1 β1 integrin. They typically, appear as 
fusiform cells with a prominent actin cytoskeleton and vimentin intermediate filament 
(Figure1.2). Fibroblast-specific protein 1 (FSP1), which is a member of the family of 
S100 Ca 2+ binding proteins, is specific for fibroblasts in normal tissues. 
 
Cancer-associated fibroblasts are activated fibroblasts within the desmoplasia. They 
are stellate cells that express α-smooth muscle actin, ECM proteins and growth 
factors that may act in an autocrine and paracrine fashion to potentiate and support 
the survival of a tumour and have also been referred to as myofibroblasts, tumour 
associated fibroblasts and stellate cells.  
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Fibroblasts that acquire an activated phenotype are associated with an increased 
proliferative activity and enhanced secretion of ECM proteins such as type I collagen 
and tenascin C. There is also an increased secretion of fibronectin that contains the 
extra domain, (EDA-fibronectin) and secreted protein acidic and rich in cysteine 
(SPARC) as shown in Figure1.2 below. 
 
The CAFs produce cytokines and components of the ECM that affect cancer cell 
growth and invasiveness. They have been reported to have the ability to induce 
epithelial oncogenesis, (Olumi et al 1999, Orimo et al 2006). Collagen types I and III 
and de novo expression of tenascin C induce an altered ECM, which potentially 
provides additional oncogenic signals such as stromal-cell-derived factor 1 (SDF1), 
Transforming growth factor- (TGF) and Hepatocyte growth factor (HGF) to resident 
epithelia, leading to cancer acceleration and invasion. Activated fibroblasts or CAFs, 
have been shown to be important promoters of tumour growth and progression. 
Despite this, however, the signals that mediate the transition from normal fibroblast 
to CAF are not fully understood and further studies are therefore required to 
determine whether CAFs do indeed have a unique fibroblast phenotype. 
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Figure 1.2 This figure shows the normal quiescent fibroblast with its fusiform shape. The 
extra cellular matrix (ECM) surrounding the fibroblast contains collagen 1. Within the cell the 
actin and vimentin fibres are seen and Fibroblast specific protein (FSP1).The figure on the 
right shows the stellate shaped  activated fibroblast .There is increased extracellular matrix 
production as shown by secretion of Tenascin C and Collagen I, EDA-fibronectin and 
specific protein acidic rich in cysteine (SPARC). The vimentin and alpha smooth muscle 
actin fibres are more prominent in the activated fibroblast suggesting greater activity. This 
activation is attributed to the effect of growth factors, ECM proteins and chemokines. 
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1.3.2 Origins of the Cancer-associated fibroblast 
Early assumptions concluded that the stellate CAF was merely an ‘activated 
fibroblast’ derived from the connective tissue around the tumour, since they are 
morphologically similar to their quiescent counterparts. The in vitro evidence for this 
originated from exogenous stimulation of fibroblasts with cytokines and TGFβ to 
induce expression of myofibroblast markers, (Ronnov Jessen et al, 1995; Tomasek 
et al, 1995). It is now known that additional factors are also required for this 
activation, including myeloid precursors and bone marrow derived mesenchymal 
cells, (Mishra et al,. 2008). Animal studies where the bone marrow has been 
transplanted with recombinantly tagged stem cells show a redistribution of these 
precursor cells within the tumour stroma bearing myofibroblast characteristics, 
(Direkze et al, 2004; Sangai et al, 2005).  
 
Intriguingly, human bone marrow-derived mesenchymal stem cells exposed to 
tumour-conditioned medium over a prolonged period of time assume a CAF-like 
myofibroblastic phenotype. These cells exhibit not only similar gene expression 
profiling but also functional properties of CAFs including sustained expression of 
SDF1, the ability to promote tumour cell growth both in vitro and in an in vivo co-
implantation model and expression of myofibroblast markers, including αSMA and 
FSP, (Franz et al, 2007). Other studies also suggest that mesenchymal stem cells 
selectively home to tumours, where they contribute to the formation of tumour-
associated stroma including CAFs ,(Franz et al, 2007; Hall et al, 2007;  Karnoub et 
al, 2007; Dubernard et al, 2008). 
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Another accepted source of the CAF includes the epithelial layer of tumours . In vitro 
studies have shown that induced cultures of epithelial cells undergo epithelial to 
mesenchymal transition (EMT), (Lee et al, 1999, Oldfield et al, 2001).  EMT is now a 
recognised mechanism of forming fibroblasts. Myofibroblasts from breast cancers, 
(Patterson et al, 2003, Monifar et al, 2000), as well as lung epithelia, were found to 
share genetic patterns with their respective epithelial compartments, (Kim et al, 
2006). 
 
As previously mentioned, fibroblasts are spindle shaped polarised cells and can be 
activated from their quiescent state. It has been proposed that there are three types 
of EMT. Type 1, involved in embryonic development, type 2, in the formation of 
fibroblasts from epithelial cells and type 3, which is linked to cancer progression, 
(Zeisburg et al, 2009). Although the mechanism of type 3 is not fully elucidated, it is 
believed to be the means by which metastatic cells form. (Kalluri et al., 2009, 
Zeisburg et al.,2009). Zeisburg and his group went further to identify criteria both in 
vitro and in vivo that confirm the presence of EMT.  
 
 Further evidence to demonstrate that CAFs are derived from organ specific cells 
has been seen in pancreatic cancers. Studies have shown that the main cell type 
that contributes to stroma formation is the activated pancreatic stellate cell (PSC), 
(Haber et al, 1999; Yen et al, 2002, Apte et al, 1998; Bachem et al, 2004). These 
cells are closely related to hepatic stellate cells, which are integral in the 
pathogenesis of liver fibrosis. Quiescent PSCs are found in the periacinar regions in 
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the pancreas and are characterised by the storage of fat droplets. They also express 
desmin and vimentin. In PDA, as well as in chronic pancreatitis, the PSCs become 
activated and develop features of myofibroblasts. Understanding the origins of CAF 
will help to highlight the genetic changes, if any, which may occur during its 
transformation.  
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1.3.3 Crosstalk between the CAF and tumour 
Cancer-associated fibroblasts are activated by a variety of cytokines produced by 
tumour cells, including interleukins, fibroblast growth factors (FGFs), TGFβ and 
PDGF. In turn, CAFs are found to produce cytokines and components of the ECM 
that affects cancer cell invasiveness and growth. They include FGFs, VEGF, 
connective tissue growth factor (CTGF), matrix metalloproteinases (MMPs), 
collagens and fibronectin. They are also known to produce ILGF-1 and II, the actions 
of which appear to predominantly impart tumour growth by conveying survival 
signals, (Hwang et al, 2008). 
 
Many in vitro studies of CAF activation have only focussed on individual cytokines. 
There is currently only one gene expression study examining the effects of activated 
CAF using co-culture experiments (Orimo et al, 2006). Research that used mouse 
models of genetically altered fibroblasts demonstrated a direct involvement of 
resident fibroblasts in the initiation of cancer (Olive et al., 2009). A further link 
between growth factors and stellate CAFs in tumour initiation was proposed by 
findings indicating that normal fibroblasts are required to maintain epithelial 
homeostasis, whereas CAFs probably initiate and promote tumorigenic alterations in 
epithelial cells, (Kalluri et al, 2006) 
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CAFs are also suspected to promote tumour progression through specific 
communications with cancer cells. They have been found to facilitate the 
invasiveness of otherwise non-invasive cancer when co-injected into mice but the 
details of this mechanism are still being investigated (Hu et al, 2008). Furthermore, 
animal models have been used to suggest that Sonic Hedgehog (SHH) signalling 
promotes the migration and invasion of human pancreatic myofibroblasts thereby 
increasing the desmoplastic and stromal reaction, (Madhevan, Von Hoff  et al 2007).  
 
 
Sonic Hedgehog (SHH) binds to the Patched-1 (PTCH1) receptor. In the absence of 
the SHH ligand, PTCH1 inhibits Smoothened (SMO), a downstream protein in the 
pathway. (Taipale et al, 2002). The binding of SHH relieves SMO inhibition, leading 
to activation of the GLI transcription factors Gli1 and Gli2 (activators) and the Gli3 
(repressor). Activated Gli accumulates in the nucleus and controls the transcription 
of hedgehog target genes, Figure 1.4. The sequence of molecular events that 
connect Smoothened to the Gli transcription factors is poorly understood and 
requires further investigation as this pathway can prove a useful target in the 
management of pancreatic cancer. PTCH1 has recently been reported to repress 
transcription of hedgehog target genes through a mechanism independent of 
Smoothened suggesting the existence of a non-canonical pathway, (Rahnama et al., 
2006). 
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The expression of Hh ligands and essential components of the pathway, including 
PTCH and SMO, have been reported in up to 70% of human pancreatic ductal 
adenocarcinoma specimens (Thayer et al., 2003). In addition, several studies have 
proposed that Hh ligands produced by tumour cells activate Hh signalling and 
tumour cell growth in an autocrine/ juxtacrine manner (Thayer et al., 2003, Pasca di 
Magliani et al., 2006).  
 
Previously, research focused heavily on the presence of hedgehog signalling in the 
pancreatic epithelium. Research performed by a Cambridge group led by Olive and 
Tuveson found that the hedgehog pathway is in fact effected within the stromal 
compartment, (Olive et al., 2009). Sauvage and his group also reported that for 
hedgehog–expressing tumours lacking mutations in the pathway, hedgehog 
signalling was indeed occurring in the stroma and not the cancer epithelial cells. 
They demonstrated that the hedgehog ligand from the cancer cell was activating the 
adjacent stroma. This data was corroborated with evidence by Olive and Tuveson 
who showed, using mouse models, that a hedgehog inhibitor could deplete the 
stroma and re-vascularise poorly perfused tumours, giving evidence that the stroma 
can be targeted by hedgehog antagonists.  
 
Part of the ability of tumour cells to evade programmed cell death is derived from 
survival signals supplied by the stromal compartment. Since there is increasing 
evidence that the tumour stroma may be crucial in determining the invasive and 
metastatic potential of many cancers, understanding the biology of the stellate 
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cancer associated fibroblast and its stroma has therapeutic potential. There may be 
benefit, for example, in reducing the cross-activation of the CAF and stromal cells by 
inhibitors of PDGF, VEGF and other mediators, many of which are becoming 
commercially available. Further therapeutic manipulations in the future may involve 
reversing the activation of CAF, which is an area that has not been studied. Thus far, 
the activated phenotype of CAF has been shown to be reversed by ligands of the 
peroxisome proliferator-activated receptor-gamma (PPARγ) pathway, as well as 
antioxidants, (Haber et al, 1999; Cat B et al, 2006). 
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Figure1.3. Factors involved in crosstalk between the CAF and the surrounding stroma. 
TGFβ and HGF promote proliferation and transformation. The Interleukins and Collagen I 
and III are responsible for angiogenesis, the inflammatory response, invasion and 
metastasis. Matrix metalloproteins and VEGF promote angiogenesis (Madhevan et al 2007). 
FGF: fibroblast growth factor, PDGF: platelet derived growth factor, HGF: hepatocyte growth 
factor, IL1: interleukin 1, MMP: matrix metalloproteinases, VEGF: vascular endothelial 
growth factor, ILGF: Insulin like growth factor. 
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1.3.4 Genetic changes 
Although the epithelial cancer cells of PDA have been studied extensively (Hartel et 
al, 2004;  Bhowmick et al, 2004; Hu et al, 2008), relatively less is known about the 
stroma, and in particular the CAF surrounding the tumour. However, evidence is 
emerging to suggest that stromal elements may harbour cancer associated 
mutations or chromosomal changes in a variety of different cancers. Cancer-
associated fibroblasts have been reported to carry a unique set of chromosomal 
aberrations, for example, the stromal cells of ovarian, breast and prostate cancers 
harbour loss of heterozygosity (LOH) and p53 mutations (Olumi et al,1999, Orimo et 
al, 2006).  
 
Significant aberrations between the CAFs’ LOH signature and both tumour grade 
and lymph node metastases have been reported in women diagnosed with sporadic 
breast tumours (Fukhino et al, 2007). Furthermore, in breast cancer, which has a 
very similar desmoplastic response to PDA, stellate CAFs are found to have 
defective p53/p21 pathways, reflecting neoplastic changes (Liotta et al, 2001) . Of 
clinical importance, genetic changes in the stroma correlated with tumour grade and 
nodal metastases more so than with epithelial genetic changes (Paget S, 1889;  
Kalluri et al, 2006). In contradiction to this, other studies using Single Nucleotide 
Polymorphism (SNP) arrays show no genetic changes in the stroma of breast 
cancers (Hanahan /Weinberg, 2000).  
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1.3.4.1 Somatic mutations 
It has been proposed that the stellate CAF may have acquired somatic genetic 
alterations similar to that seen in malignant epithelium. This was based on the ability 
of stellate CAFs to be propagated in vitro for prolonged periods and yet maintain 
their cancer-promoting phenotype (Olumi et al, 1999; Kuperwasswer et al, 2004). 
Several studies have shown that the somatic mutations acquired by stellate CAFs 
are associated with tumourigenesis (Patocs, et al, 2007; Weber et al, 2006; Weber 
/Zhang et al, 2007). For example, frequent somatic mutations in tumour suppressor 
genes such as     phosphatase and tensin homolog (PTEN) and P53 have been 
reported in fibroblasts associated with breast carcinomas (Weber et al, 2006;  
Kurose et al, 2002). The mutations were found to be distinct between cancer cells 
and stellate CAFs, ruling out the possibility of these mutations being due to 
contamination.  
 
Not all studies support the theory of somatic alterations in CAFs. Allinen and 
colleagues undertook array CGH and SNP array analysis of carcinoma cells and 
myofibroblasts from ductal breast carcinoma. Numerous alterations were noted in 
the epithelial cells but the myofibroblasts and other non epithelial tumour associated 
cells were found to be normal (Allinen et al, 2004). There is therefore a debate as to 
the presence or absence of stellate CAF somatic mutations. Campbell and 
colleagues have suggested that studies reporting frequent somatic mutations may be 
flawed. This is partly because previous studies have accredited the enhanced ability 
of individual fibroblasts to promote tumourigenesis to these somatic mutations 
(Campbell et al, 2009).These reports used limited numbers of cells derived from 
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micro-dissected formalin-fixed paraffin-embedded (FFPE) tissues and mutation 
assessment can be severely compromised when using the limited quantities of DNA, 
typical of FFPE tumours (Farrand et al, 2002; Sieben et al, 2000; Kern et a, 2006). 
 
1.3.4.2 Loss of heterozygosity and SNPs 
Currently there has only been one study on pancreatic cancer CAFs which showed 
no genomic changes using SNP arrays in cultured CAF or p53 mutations using 
immunohistochemistry (Walter et al., 2008). This study used cultured CAF from PDA 
resection specimens with an unknown proximity of the CAF to the tumour making the 
validity of the results questionable. In this study, fibroblasts were isolated from whole 
tumour biopsies rather than direct micro-dissection of tumour juxtaposed fibroblasts. 
The CAF alterations may therefore have been masked by the presence of normal 
fibroblasts. In light of the findings in other cancers, there is a need to study the 
possibility of chromosomal changes in PDA using more state-of-the-art technology, 
which would use both micro dissected stroma and CAF cell lines for validation. 
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Below is a table showing the studies of chromosomes and gene copy number 
alterations (CNA) reported in CAFs of different cancers including PDA. 
Authors 
Cancer 
Type 
Tissue 
Experiment 
methods 
Significant results 
Patocs Breast LCM 
LOH/AI 
(386 markers) 
19-25% LOH in stroma 7q, 10q, 15q, 
16p, 17q associated with prognosis 
Fukhino Breast LCM 
LOH/AI 
(386 markers) 
Chromosome changes associated 
with prognosis 1,2,5,11,18,20,22 
Tuhkanen Ovarian LCM 
LOH/AI 
(110 markers) 
10.8 changes (6.6gains, 4.2losses) 
6q, 7q, 11q, 12q, 16q 
Ellsworth Breast LCM 
LOH/AI 
(52 markers) 
10% changes in stroma alone 
Chromosomes 10,11 
Monifar Breast LCM 
LOH/AI 
(12 markers) 
20-75% changes 
Most frequent 11q, 16q, 17q 
Paterson Bladder LCM 
LOH/AI 
(3 markers) 
78% changes 
3p, 9q, 17p 
Kurose Breast LCM 
LOH/AI 
(13 markers) 
17-61% changes 
1,2,3,6,8,10,11,13,16,17,22 
Qi 
Breast/ 
Ovarian 
LCM/ 
culture 
SNP (250K) 
1 LCM change Ch 22 
1 cell line change Ch7, 10 
Allinen Breast Cell sorting SNP (250K) No genetic changes 
Walter Pancreas Culture SNP (250K) No genetic changes 
Campbell Breast 
LCM/ 
culture 
SNP (500K) No genetic changes 
Table1.1. Studies of chromosomes/gene copy number changes in CAFs. There has only 
been one study on pancreatic cancer CAFs. This study showed no genomic changes using 
SNP arrays in cultured CAF or in p53 mutations using immunohistochemistry.   
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1.3.4.3 Gene expression 
 
To date our knowledge of the gene expression profile specific to pancreatic cancer is 
still scarce. The few studies that have been performed on the stroma from tumour 
blocks are proving to be controversial (Sato et al, 2004; Pilarsky et al, 2008). In one 
study using micro dissected PDA stroma, the expression of more than 200 genes 
was shown to be altered in the stroma of PDA as compared with chronic pancreatitis 
samples. However, in another similar study, no such alterations were observed but 
instead at least 100 common stromal gene expression profiles were seen in both 
PDA and chronic pancreatitis samples (Binkley et al., 2004). The latter study used 
subtraction of gene expression patterns to obtain their data, which is inherently less 
reliable. There is therefore a need to perform more detailed cross-platform studies of 
PDA stroma and stellate CAF, both using gene expression arrays and chromosomal 
analysis. Table 1.2 shows the results of gene expression arrays performed on CAFs. 
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Authors Cancer Tissue Comparison Microarray Genes expressed in common 
Pilarsky  Pancreas Histology CaS vs. CP Affymetrix COL10A1, COL11A1, MATN3, CXCL14, TNFSF4 
Binkley Pancreas Histology* CaS/CP vs. CaE Affymetrix  
Sato Pancreas Cell lines AcPSC vs. NonPSC Affymetrix 
MCP1, COX2, CXCL8, CXCL1, 
CXCL2 
Iacobuzio Pancreas Cell lines CaS vs. CaE SAGE  
Buchholz Pancreas Cell lines PSC(nonCAF) vs. NF Operon  
Glass Pancreas Cell lines (rat) 
AcPSC vs. 
NonPSC Affymetrix  
Micke Skin (BCC) Histology CAF vs. NF Sanger SPARC, MGP, CILP, COL5A2, MMP11, PDGFRL 
Nagakaw
a 
Colorectal 
(liver mets) Cell lines CAF vs. NF Affymetrix 
FGF1, MCP1, COX2, COL4A1, 
COL6A2, PDGFA, IGFBP7, 
IGFBP5, CTGF, VEGF, TGFB2 
Mellick Breast Histology CaS vs. CaE Incyte,  
Singer Breast Cell lines CAF vs. NF Micromax TGFB1 
Finak Breast Histology CAF vs. NF (prognosis) Agilent  
Casey Breast Histology CaS vs. NS Affymetrix 
COL10A1, COL11A1, TGFB1, 
FGF1, SPARC, MATN3, MGP, 
CILP, MMP7, MMP1, MMP13, 
TIMP3 
Boersma Breast Histology CAF vs. CAF (inflam) Affymetrix  
Richards
on Prostate Histology CaS vs. NS Affymetrix  
Allinen Breast Histology CsS vs. CaE SAGE  
 
Table1.2. Studies using gene expression microarrays on CAFs. Gene expression obtained 
by subtraction of signals between specimen, and other histology samples obtained by laser-
capture micro dissection. X – Studies comparing Cancer-associated stroma/fibroblasts 
against non-cancer stroma/fibroblasts with genes which are up- or down regulated in at least 
two different studies, X – Genes which are in the same family (or similar) to others described 
in at least two different studies, CaS – cancer stroma, CP – chronic pancreatitis, CaE – 
cancer epithelium, NS – normal stroma,  PSC – pancreatic stellate cells, AcPSC – 
activated/stimulated PSC, NonPSC - non-stimulated PSC,   CAF – cancer stromal fibroblast, 
NF – normal fibroblast, CAF (inflam) – CAF from inflammatory breast cancer.                              
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1.3.4.4 Pluripotency in the CAF 
As mentioned previously, in section 1.3.3, the cancer-associated fibroblast is 
stimulated to its activated stellate phenotype from a quiescent state with the aid of 
cytokines from the tumour epithelial cells. As described, this happens in an autocrine 
and paracrine fashion along with the signalling pathways such as Wnt, Notch, 
Hedgehog and receptor tyrosine kinase. These pathways have been linked to cancer 
stem cell status and reprogramming mechanisms. They are also involved in the 
activation and stimulation of quiescent fibroblasts to their active state and support 
their proliferation. 
 
 The ability of the CAF to develop into or from different mature cells, based on 
environmental stimulants, is open for discussion. Kadera et al showed that primary 
CAFs were not derived from tumour epithelial cells with the use of KRAS sequencing 
and in situ immunofluorescence staining for epithelial and mesenchymal markers. 
These included SMA, pancytokeratin, Vimentin and GFAP, (Kadera et al., 2013). 
Their research also showed that co-injecting CAFs with tumour cells into genetically 
modified mice, enhanced tumour growth but no tumour was produced when CAFs 
were injected alone.  This would suggest that these cells are unable to act as an 
autonomous clone and unable, on their own, to produce a separate lesion from the 
tumour. 
 
With respect to the stem cell like qualities of the CAF, it has been demonstrated that 
the transcription factors Klf4 and Sox2, downstream of the microRNA-200 family 
promote a stem cell like, tumour initiating phenotype in pancreatic cancer, (Li and 
Laterra, 2012). Zinc finger E-box binding homeobox protein (ZEB1) inhibits the miR-
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200 family, which induce epithelial cell differentiation. These transcription factors 
(Oct-3/4, Sox2, KLF4 and c-Myc) have been shown to induce an embryonic like 
pluripotent stem cell from fibroblasts cultured from mice, (Takahashi et al.,2007). 
However, the stem cell like behaviour in human pancreatic stellate cancer 
associated fibroblasts is yet to be elucidated. This data may provide further insight  
into the understanding of the aggressive nature of this disease.  
 
 
1.4 Chemoresistance in pancreatic ductal adenocarcinomas 
Chemo-resistance in pancreatic ductal adenocarcinoma has been a limiting factor to 
disease management.  Many forms of the cancer develop resistance soon after a 
fleeting initial response to Gemcitabine but Gemcitabine as yet remains the gold 
standard of adjuvant therapy. This Chemo-resistance is multifactorial and has been 
attributed to several factors including poor drug accumulation, altered targets and 
increased repair of drug induced DNA damage, (Sebens et al, 2011). This is 
compounded by the paucity of a suitable screening tool or biomarkers to help identify 
the presence of the disease at an early and less aggressive stage.  
 
Currently, patients tend to present at a locally advanced stage of disease. At this 
stage it is more difficult to achieve a satisfactory response to the current 
chemotherapeutic regimes used. The key factors at a molecular level include cancer 
cell genetic mutations, poor drug delivery to the tumour site, activated tumour-
stromal cell interactions with promote tumourigenesis and cross-talk of signalling 
pathways within the stroma that promote tumour development and resistance. These 
are discussed in further detail below.  
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1.4.1 Genetic mutations 
Pancreatic cancer is characterised by a unique molecular fingerprint with activating 
point mutations at codon 12 of the K-ras gene found in more than 90 % of cases, 
(Moore et al., 2001). The tumour suppressor gene p53 has been found to be 
inactivated in 60% and DPC4/Smad4 altered in 50%, of xenografted cancers, (Hahn 
et al., 1996). These factors undoubtedly play a role in tumour development and the 
changes are believed to contribute toward chemoresistance.  See table 1.3 
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Table 1.3 The common genetic changes found in pancreatic cancer cell lines. “-----“refers to No 
genetic alteration; blank is undetermined; HD homozygous deletion, the gene is not present and 
mutations Mut cannot be assayed; Del intragenic deletions; bp base pairs; R rearrangement of 
one of the alleles of p53 and the other has a deletion resulting in inactivity of the p53 gene; WT 
wild type sequence. For K-ras, p53 and DPC4 the codon and amino acid change is shown. Blank 
spaces indicate no published data. These cell lines showed no MKK4 mutations or BRCA2 
mutations, not shown in this table. 
 
 
 
 
Cell line K-Ras 
AKT2 
19q 
9p 
LOH 
P16 
HD 
13q 
LOH 
17P 
LOH 
P53 
Mut 
MKK4 
HD 
18q 
LOH 
DPC4 
HD 
DPC4 
Mut 
AsPc1 12 Asp Ampl LOH 2bp del LOH LOH 
1bp 
del HD LOH ----- 
100 
Thr 
BxPc3 ----- Poss Ampl LOH ? LOH LOH 
220 
Cys ----- LOH HD ----- 
MiaPaCa2 12 Cys ----- LOH HD ----- LOH 248 Trp ----- LOH ----- ----- 
Panc1 12 Asp Ampl LOH HD LOH LOH 273 His ----- LOH ----- ----- 
Su86.86 12 Asp Ampl LOH HD LOH LOH 245 Ser ----- LOH ----- ----- 
HPAC 12 Asp      WT   ----- WT 
Hs776T 61 His ----- LOH ----- ----- ----- R ---- LOH HD ? 
PL5            
PL45            
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1.4.1.1 Micro RNA gene expression profiling 
 
Recent interest has been on Micro RNAs and their role in cancer development and 
progression. These are a small class of non-coding RNAs between 19 to 25 
nucleotides long, (Bartel et al.,2004),  believed to have important roles in 
uncontrolled cell division and poor cell differentiation. (Ambros et al.,1984, Reinhart 
et al., 2000). MicroRNAs have therefore been linked to cancer as this is the endpoint 
of poor cell differentiation. In human tissues micro RNAs are believed to inhibit 
tumour suppressor genes.  They do this by targeting messenger RNA and are 
sometimes referred to as Oncomirs. They are believed to affect post-transcriptional 
gene expression by inhibiting the translational process. The mechanisms suggested 
include direct cleaving of the target messenger RNA and well as possibly reducing 
the rate of the initiation step in mRNA translation. A non cleaving pathway has also 
been postulated but the mechanism is not yet elucidated, (Valencia –Sanchez et 
al.,2006). 
 
Bloomston and his colleagues used miRNA microarray to identify 30 upregulated 
and 4 downregulated miRNAs that were present in pancreatic cancer and of 
importance miR- 21 and 155 were uniquely expressed in pancreatic cancer. Granted 
there was some overlap, none of those overexpressed were found to be present 
simultaneously in either cancer, normal and acute pancreatitis tissue. They 
suggested miR-21, miR-155, miR-221 and miR-222 as key players, with miR-221 
being particularly highly expressed in pancreatic cancer compared to the benign 
tissue groups but its role or mechanism is unclear, (Bloomston et al.,2007). See 
table 1.4. 
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Szafranzka et al used miRNA arrays to profile those miRNAs differentially expressed 
in PDAC compared to benign tissue. They identified 11 microRNAs that were 
strongly downregulated by up to 5 fold in PDAC and a further 11 that were 
upregulated. In their 8 PDAC samples, miRNA- 222 was again found to be 
upregulated as was seen by Bloomston et al, See table 1.4. 
 
 
Xue and colleagues showed upregulation of miR-196 and downregulation of miR-
148a and miR-217 in PDAC and its precursors compared to regular parenchyma. 
They reported a significant overexpression of miR-21 in PDAC and high expression 
of miR10b in its precursors, PaIN II and III, (Xue et al., 2013). Their findings have 
suggested that these Oncomirs may be markers to discern between normal tissue 
and cancer precursors. Du Rieu et al also showed its expression to increase in the 
early stages of PDA development, particularly in the low grade pre-malignant PanIN 
lesions, (Du Rieu et al.,2009).     
 
 
Micro RNA-21 has been the focus of many recent publications in PDA and has 
shown to be more cancer cell specific than mRNA (Lu et al., 2005). Dillhoff and 
colleagues used Fluorescent in situ hybridization to show that miRNA-21 is highly 
overexpressed in pancreatic cancer tissues compared to benign tissue. They found 
no correlation with tumour size, node status, T-stage or differentiation but correlated 
strong expression with poor outcome in patients with node negative disease. (Dillhoff 
et al., 2008)  
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A Japanese group showed an increase in proliferation and resistance to 
Gemcitabine in cells infected with miR-21 precursor. The converse was seen when 
miR-21 was inhibited. They correlated the mRNA expression of MMP2, MMP9 and 
VEGF with miR-21 expression, linking miR-21 to cell proliferation and invasion, 
(Moriyama et al., 2009). 
 
In 2013 Kadera and his group published their findings in which tumour associated 
fibroblasts were induced by epithelial tumour cells to express miR-21. They proved 
miRNA expression in these CAFs using Fluorescent in situ hybridization and 
inhibition of this miRNA in epithelial cells and CAFs gave an additive effect in 
reducing tumour invasion. (Kadera et al., 2013). This oncomir may soon become 
another key in the chemoresistant nature of PDA. 
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Table 1.4 MicroRNA changes in PDA. Highlighted are the MicroRNA and the     
significant genes found to be influenced by them 
Author Platform 
used 
Tissue Upregulated 
microRNAs in 
PDAC   
Downregulated 
microRNAs in 
PDAC 
Genes affected 
Bloomston  
Microarray 
 
1100 
miRNA 
probes 
 221, 222,  
 21, 155,  
196a-2 
375 KIT (stem cell 
factor) 
Predictor of 
survival 
Szafranzka  Microarray  
377 miRNA 
probes 
 cell lines 93, 196a,  
196b, 203,  
205, 210, 224 
 
 
  
221, 222 
 
 
29c, 30a,  
 3p, 96, 
130b, 141,  
148a, 216, 217, 
375, 494, 148b, 
 
 
 
 
 
CDKi (1b/1c) 
 
Szafranzka 
 
Primary 
neoplastic 
tissue  
18a, 31, 93,  
221, 205,  
224 * 
 
216, 217 
 
Xue  
 Primary 
neoplastic 
tissue 
21, 196 148a, 217  
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1.4.2 Chemoresistance due to alterations in gene products involved in 
Gemcitabine uptake 
Genetic and epigenetic alterations found in the gene products involved in 
Gemcitabine transport and metabolisms have been associated with resistance. The 
nucleoside transporter hENT1 is important for cellular uptake of Gemcitabine. 
Genetic alterations leading to decreased levels of hENT-1 appear to be associated 
with Gemcitabine resistance, (Giovannetti E et al, 2006) The changes in the levels of 
gene products associated with Gemcitabine uptake also appear to play a significant 
role in resistance. Decreased levels of Deoxycytidine kinase (dCK), up-regulation of 
Deoxycytidine deaminase (CDA catalyses and deaminates GEM) and the up-
regulation of ribonucleoside reductase M1 and M2, (Duxbury et al, 2004), all appear 
to affect Gemcitabine resistance. Aberrant expression of genes associated with 
apoptosis and cell survival have also been implicated, specifically S100A4. Up-
regulation of this S100 family gene may increase resistance to Gemcitabine by 
regulation of BNIP3, a hypoxia induced pro-apoptotic gene. (Mahon et al, 2007; 
Erkan et al, 2005). 
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1.4.3. Up-regulated survival pathways /down-regulated apoptosis and protein 
secretion 
An alteration in survival pathways in combination with the downregulation of 
apoptosis is believed to play a significant role in chemoresistance as discussed by 
Kim and Gallick. Upregulation of the Phosphatidylinositol 3-kinase, protein kinase B 
(PI3 kinase/AKT) pathway has been shown in pancreatic cancers, (Asano et al, 
2004), and this has been implicated in Gemcitabine resistance, (Asano et al, 2004). 
Decreased C-SRC and C-Met activation have also been shown to play a role in 
Gemcitabine resistance, (Duxbury2 et al, 2004; Bondar et al, 2002; Ng et al 2000; Ng 
SS, et al 2001). Increased HMGA1, which induces a stem cell like state has been 
implicated in Gemcitabine resistance, (Liau SS et al, 2006). Activated MAPK/ERK, 
although dose dependent, (Zhao et al, 2006) and the activation of focal adhesion 
kinase, (Duxbury et al, 2004); have also been implicated in Gemcitabine resistance 
in pancreatic cancer. Finally, upregulation of Heat shock protein 27 (HSP27) in 
resistant pancreatic cell lines suggests an anti-apoptotic response thus conferring 
relative resistance to therapy (Sayaka Mori-Iwamoto et al, 2008). 
 
 Zavoral and colleagues have summarised the many oncogenes and tumour 
suppressor genes involved in the signalling pathways implicated in pancreatic cancer 
tumourigenesis and progression. The RAS, AKT and Wnt signalling pathways have 
all been implicated due to their roles in transcription and proliferation as well as the 
cell cycle regulators SMAD/DPC, CDKN2A/P16 and Tp53, which are all integral 
players in cell apoptosis. (Zavoral et al, 2011). These elements, although functional 
in tumour initiation and progression, due to the aggressive nature of pancreatic 
cancer, may be contributors to the resistant nature of the disease.  
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1.4.4 Pancreatic Stellate cells and chemoresistance  
The stellate cell has been implicated in the chemoresistance of pancreatic cancer; 
however, the exact mechanism by which this occurs has not been fully identified.  
Hwang and associates showed that in the presence of human pancreatic stellate 
cells, cancer cells, in particular BXPC3 show no significant change in cell number 
when exposed to Gemcitabine or irradiation, (Hwang et al, 2008). They also found 
an increase in the anti apoptotic signalling pathway expression whereby the cancer 
cell lines responded to stellate conditioned media with a multiple fold increase in 
AKT and ERK expression after several minutes when co-cultured with human 
stellate cells. They showed that stellate cells were necessary for tumour initiation 
and growth and without them tumours failed to develop on their own. Co-injection of 
stellate with BxPc3 in orthotopic mice resulted in metastases in a dose dependent 
manner.   
 
 
 
Stellate cancer associated fibroblasts themselves have already been implicated in 
the pro-genesis of several cancers including breast, pancreas, lung, (Pageau et al, 
2011), cutaneous squamous cell carcinoma, (Commandeur et al, 2011), as well as 
the aggressiveness of others such as oral squamous cell carcinoma, (Sobral et al, 
2011), making them viable targets when considering options for chemotherapy in the 
fight against pancreatic cancer.  
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1.4.5 The hedgehog signalling pathway  
 
Hedgehog signaling pathway
Smoothened
Patched
Sufu
Gli
-­‐Hh+Hh
Gli	  repressionGli	  activation
Hh
 
Figure 1.4 The Hedgehog signalling pathway 
 
Patched, is a twelve-pass membrane protein that inhibits Smoothened, a seven-pass 
membrane protein, in the absence of hedgehog binding. In the presence of 
hedgehog binding, the inhibitory function of Patched on Smoothened is reversed and 
a Gli complex is formed which promotes the activation of Gli transcription factors. In 
the absence of the hedgehog ligand binding to patched, Gli acts as a repressor of 
protein transcription. 
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The hedgehog signalling pathway has proved to be a key player in the development 
and proliferation of PDA. This pathway was previously thought to stimulate the 
epithelial cells of tumours, resulting in tumour progression. It has since been shown 
that this pathway is activated in the activated stromal compartment (Yauch et al, 
2008; Olive/Tuveson et al, 2009). Hedgehog stimulates stromal proliferation via 
paracrine signalling and inhibition of this pathway has shown to have therapeutic 
potential. 
 
 
Smoothened is a membrane protein in the hedgehog pathway. A smoothened 
inhibitor when used in combination with Gemcitabine to treat genetically modified 
mice was found to increase the median survival by more than 2 fold, (Olive/Tuveson 
et al, 2009). These KPC mice (KrasLSL.G12D/+; p53R172H/+; PdxCretg/+) have 
pancreas-specific KrasG12D and Trp53R172H mutations, (Olive/Tuveson et al, 2009). 
 
 
Olive and colleagues have shown that the use of hedgehog inhibitors can alter 
communication between the tumour and stroma via the hedgehog pathway, 
interrupting the feedback loop necessary for stromal activation and development and 
resulting is stromal depletion. This depleted stroma becomes less of a barrier to 
chemotherapeutic intervention as drug delivery to the tumour is somewhat 
enhanced. Hedgehog signalling has also been shown to be directly responsible for 
tumour cell growth in other cancers such as prostate cancer, (Domenech et al, 
2012). 
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1.4.6 Stromal density and chemoresistance 
The density of stroma is also believed to be chemoprotective in that it hinders 
adequate drug delivery to an already resistant cancer. Notably PDA has a 
particularly prolific desmoplastic reaction making it comparable to breast cancer 
where greater than 90 percent of cells are pancreatic stellate cells. Studies have 
attempted to perforate this dense barrier in order to access the tumour thereby 
facilitating better drug delivery. They showed a 60% increase in Gemcitabine 
concentration in the tumours if preceded by a hedgehog inhibitor, and the 
combination of this inhibitor with Gemciabine more than doubled mouse survival 
compared with Gemcitabine alone, (Olive/Tuveson et al, 2009). 
 
Several compounds have been identified as potential key players in the 
chemoresistant nature of pancreatic cancer. Fibroblast activating protein, which is 
seen in the activated fibroblast, is one of the factors implicated with the development 
of the stromal compartment and has recently been identified as a possible prognostic 
indicator for PDA, (Min et al, 2012). It alters the extracellular matrix, making it a more 
favourable environment for tumour invasion. Disruption of this fibroblast activating 
protein effect has been found to hinder tumour invasion, (Lee, Mullins et al, 2011; 
Santos et al, 2009), making it a potentially useful chemotherapeutic target.  
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1.5 Aims 
To rule out genetic changes in the stellate cancer associated fibroblast believed to 
be responsible for tumour development and progression. 
To elucidate any changes and behaviour of the stellate cancer associated fibroblast 
that may play a role in tumour progression and chemoresistance. 
To profile PDA cell lines and stellate cancer associated fibroblasts with the use of 
high throughput screening which will look at the drug response of these cells to 
known chemotherapeutic compounds and help identify potential targets or drug 
combinations that may be further examined 
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Chapter 2 
Materials and Methods 
2.1 Materials 
2.1.1 General Materials 
Dry ice,  
Glass pipettes,  
100% alcohol, 
Multiwell plates 
13mm cover slips 
Water bath @ 37°C, 
Vortex and Centrifuge,  
 0.22 and 0.45 µm filters,  
Falcon tubes, 15 and 50ml, 
PCR gel cast and equipment 
5, 10 and 25ml plastic pipettes, 
5, 10 and 15 ml Luer lock syringes,  
Tissue culture flask (25cm²) 0.2µ vented blue seal cap,  
Tissue culture flask (175cm²) with vented blue seal cap 
Tissue culture flask (75cm²) with vented orange seal cap 
 50ml, 100ml and 1000ml beakers and measuring cylinders, 
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2.1.2 Materials for cell culture 
                
 
Reagent Recipe Source 
 
Store 
 
DMEM Dulbecco’s modified Eagles medium 1X + Glucose 4.5g/ 
Invitrogen (Gibco) 
Cat#11960 4°C 
Pen/Strep 
Penicillin G sodium salt 5000 units. 
Streptomycin Sulphate in 0.85% saline 
5000µg/ml 
 
Invitrogen (Gibco) -20ºC 
FCS Fetal Bovine Serum, 50ml aliquots Invitrogen (Gibco) Lot 07F1753K -20ºC 
L-
Glutamine 100X liquid 29.8mg/ml in .85% saline, 100ml 
Invitrogen (Gibco) 
Cat#25030081 -20ºC 
Trypsin 
10X Trypsin EDTA solution 100mls 
Invitrogen (Gibco) Cat# 
35400-27 
-20ºC 
 
Versene 
1X 100 ml solution 
Invitrogen (Gibco) Cat# 
15040 
Lot 3048582 
 
-20ºC 
Panc1 PANC1 cell line ATCC number CRL-1469 
Liquid 
Nitrogen 
PBS Phosphate buffered saline 
Invitrogen (Gibco) 
Cat# 10010-023 
RT 
DMSO Dimethy sulfoxide  
Sigma 
D4540-100ml 
RT 
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2.1.3 Materials for Immunohistochemistry 
 
 
Reagent Recipe Source Store 
 
PBS pH 7.4 Phosphate buffered saline Invitrogen (Gibco) 
Cat# 10010-023 
RT 
IFF PBS+ 1%BSA +2% Fetal 
Calf Serum 
Made up prior to use 4°C 
BSA Biotinylated secondary 
antibody 
Sigma Aldrich 4°C 
Alexa conjugate 2mls IFF+ 2µl mouse 488+ 
2µl Rab555 for 1 in 1000 
solution 
Invitrogen 
Cat# A-21370 
4°C 
Vecta shield No counter stain Vector labs 
Cat# H-1000 
4°C 
Triton –X 100 Triton X100 in PBS Sigma Aldrich 
CAT #: 9002-93-1 
25°C 
Clear nail varnish As per protocol Any retailer RT 
Primary antibody  
Alpha SMA mouse 488 
Vimentin goat IgG 
R and D systems 
CAT #IC1420G 
CAT #AF2105 
4°C 
Paraformaldehyde 4% Paraformaldehyde Sigma Aldrich 
Cat# P6148 
RT 
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2.1.4 Materials for Protein gel analysis 
 
 
 
 
 
 
 
 
Reagent Recipe Source Store 
 
15ml tube Acetone resistant conical 
tube 17x120mm, 
BD 
Cat# 352096 
RT 
 
50 ml tube Acetone - resistant Falcon 
tubes 
BD  
Cat#352098 
RT 
 
Filter Devices Amicon-Ultra 4ml 
Centrifugal Filter devices 
3KD 
Amicon RT 
 
Tris- HCL Tris hydroxymethyl 
methylamine  
1M pH 7.60  
Sigma 
#T-2788 
Lot 072k8417 
RT 
 
Gradient Gel Novex Tris-Glycine 4-20% 
gradient gel 
Novex 
 
4°C 
 
Cyber safe DNA 
gel stain 
10µl of 10000X concentrate 
in DMSO 
Invitrogen  
Cat#S33102 
Lot 489224 
RT 
RNase free 
DNase set 
As per protocol Qiagen 
Mat#1023460 
RT 
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2.1.5 Materials for Laser capture micro-dissection 
 
 
 
 
 
 
 
 
 
Reagent Recipe Source Store 
 
Adhesive cap Adhesive cap 500 
opaque 
Carl Zeiss 
Cat#415101-4400-250 
Lot 000732-09 
RT 
Picopure® DNA extraction Kit Life Technologies 
Arcturus 
Cat# Kit 0103. 
Lot 137842 
RT 
Zymo 
research 
DNA clean and 
concentrate™-5 kit 
Zymo research 
cat#d4013 
 Lot ZRC163134 
RT 
Ambion Recover All Total Nucleic 
acid Isolation 
Ambion Cat#AM1975 
 Lot 0905032 
RT 
Qiagen QiAmp DNA mini Kit (50) Qiagen 
Cat# 51304 
 Lot 133192112 
RT 
Sterile water DNase-RNase free 
Sterile water 
Sigma 
 Lot 019k2374 
RT 
NaSCN 8.1g of NaSCN in 100ml 
nuclease free water 
Sigma Aldrich 
Cat#251410 
            RT 
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2.1.6 Reagents for PicoGreen assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagent Recipe Source Store 
 
Quant-iT™ 
PicoGreen® 
dsDNA Assay 
Kits 
Pico green reagent 
TE Buffer-10 mM Tris-HCl, 
1 mM EDTA, pH 7.5 
Lambda DNA standard 
Invitrogen 4°C 
RT 
4°C 
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2.1.7 Reagents for Multiplex PCR 
 
 
 
 
 
 
Reagent Recipe Source Store 
 
10X Buffer Gene amp 10X pcr buffer Qiagen Multiplex PCR Kit  
Cat# 206143 
-20ºC 
MgCl2 25mM MgCl2 Qiagen Multiplex PCR Kit 
Cat# 206143 
-20ºC 
dNTP mix 10 mmol each Qiagen Multiplex PCR Kit 
Cat# 206143 
-20ºC 
TAE Buffer 20mls TAE in 1L of H20 
1:50 
Sigma Aldrich 
Cat# T9285 
RT 
Agarose 0.8g Agarose in 100mls of 
TAE 1:50 Sigma Aldrich 
Cat# G4510 
-20ºC 
Primer mix 1.25µM each Qiagen Multiplex PCR Kit 
Cat# 206143 
-20ºC 
Taq 5U/µl Qiagen Multiplex PCR Kit 
Cat# 206143 
-20ºC 
Female and 
male DNA 
100ng each  4°C 
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2.1.8 Reagents for Array CGH 
 
 
                 
Reagent Recipe Source Store 
 
Bioprime 
labelling kit 
Random primers 
Cy3, Cy5 
Klenow 
Invitrogen 
Cat#18095011 
RT 
dNTP stock 12µl dATP, dGTP, dTTP 
and 6µl of dCTP 
100mM stocks in 1ml TE 
Qiagen Kit C – 28004 
 
-20ºC 
Qiagen Mini 
Elute purification 
kit 
 
Buffer PB- Binding buffer 
Buffer EB- Elution buffer 
Buffer PE 
Qiagen Kit C – 28004 
Lot 133206093 
Lot 130161242 
Lot 133203411 
RT 
SSC Saline-sodium citrate 
   
Breakthrough lab 
Code66 
Batch 49 
RT 
SDS Sodium dodecyl sulphate 
 
USB 
Lot 115185 
RT 
Formamide Deionised Formamide MP 
Lot R26530 
-20ºC 
BSA filter 1g of BSA dissolved in 
49.5mls H20  
Sigma 
Lot 08/16291 
RT 
Yeast tRNA As per protocol 
Invitrogen 
Cat#15401-029 
 
-20ºC 
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2.1.9 Reagents for Fluorescent in- Situ Hybridisation 
 
 
 
 
 
 
Reagent Recipe Source Store 
 
NaOAc Sodium Thiocyanate 
As per protocol 
Sigma Aldrich RT 
Salmon sperm As per protocol Invitrogen 
Cat#15632-011 
 
-20ºC 
 
Colcemide As per protocol Invitrogen 
Cat#15210-040 
4°C 
Alcohol 70%, 90% and 100% Sigma Aldrich RT 
PBS 
Phosphate buffered saline 
Invitrogen (Gibco) 
Cat# 10010-023 
RT 
Trypsin Trypsin EDTA solution 
100mls 
Invitrogen (Gibco) Cat# 
35400-27 
-20ºC 
 
Methanol Mixed with acetate to form 
fixative solution 
Sigma Aldrich RT 
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2.1.11 Reagents for Cell titre-Glo Luminescence 
 
 
2.1.12 Reagents for Plasmid DNA transfection 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Reagent Recipe Source Store 
 
384 well plates As per protocol Corning RT 
Cell titre-Glo one 
solution assay 
reagent 
1:4 dilution with PBS Promega 
Cat#G8461 
-20ºC 
PBS Phosphate buffered saline Invitrogen (Gibco) 
Cat# 10010-023 
RT 
Reagent Recipe Source 
 
Store 
 
Trans-IT-
2020 
reagent 
2.5mg/ml in 80% ethanol 
Mirus 
Cat# MIR5410 
Lot# KLN04315 
-20°C 
Opti-MEM 
reduced 
serum 
Medium 
As per protocol 
Invitrogen 
Cat# 11058-021 
 
4°C 
6 well plates As per protocol Cat#3335 RT 
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  2.2 Methods 
2.2.1 Ethics approval 
Ethics approval was obtained from the research ethics committee via the tissue bank 
at the Hammersmith hospital prior to the acquisition of samples.  
 
2.2.2 Tissue collection 
For primary fibroblasts, fresh tissue samples of Pancreatic Ductal Adenocarcinoma 
(PDA) were collected, with informed patient consent, in collaboration with the 
hepatopancreatobiliary (HPB) unit at the Hammersmith Hospital. Tissue samples 
were immediately taken for primary culture under aseptic conditions.  
 
2.2.3 Cell culture 
Primary cultures of stromal fibroblasts were established from surgically resected 
pancreatic cancer specimens from patients with moderate to poorly differentiated 
PDAs. Immediately post resection, tissue from the tumour edge was removed under 
aseptic conditions. The fresh tissue was cut into 1mm³ fragments and mounted on a 
culture dish. The tissue was then cultured in DMEM (Dulbecco’s Modified Eagles 
Medium) supplemented with 10% Fetal Calf Serum (FCS), L-Glutamine, Penicillin 
and Streptomycin. Once plated, the cells were allowed to adhere by incubation at 
37˚C in a humidified atmosphere containing 5% CO2. A successful culture was 
evident by an outgrowth and proliferation of a monolayer of spindle-shaped cells 
from the tissue blocks. This usually occurred after 10 days. The explants were 
observed every 2 days at which time they were fed with new media as necessary.  
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Fibroblasts were sub-cultured by trypsinisation into T25 flasks. Once confluent, the 
fibroblasts were subcultured into T75 flasks following which they were either frozen 
in liquid nitrogen in DMSO or passaged to a secondary culture. In order to remove 
cells from the primary explants, 1 ml of 1:4 Trypsin and Versene was introduced into 
the Petri dishes containing outgrown fibroblasts. This was then incubated at 37°C in 
5% CO2 for 5 minutes or until disaggregated. Gentle tapping was used to help 
detach the ‘sticky’ fibroblasts from the base of the Petri dish used. Once detached, 
the cells were suspended in culture medium (DMEM) and centrifuged at 1000rpm for 
5 minutes at room temperature. The supernatant was removed and the remaining 
pellet re-suspended in fresh culture media and transferred into a filtered T25 flask. 
Isolation and growth of CAFs were performed using the outgrowth method. This 
involved 2 or 3 passages until a sufficient monolayer (a confluent T75 ≥70% 
coverage) was acquired. Secondary cultures were incubated under the same 
conditions as primary cultures as described above.  
 
The pancreatic ductal cell lines were purchased from American Type Culture 
Collection, (ATCC). The pancreatic cancer lines purchased were PANC-1, AsPC-1, 
MiaPaCa-2, HPAC, HS776T, BxPc3, PL45 and SU86.86.  Dr Claus Jorgensen of the 
Institute of Cancer Research donated PL5. These cell lines were expanded and 
cultured as described above in DMEM or RPMI according to ATCC instructions. See 
table 2.1. 
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Dr. Ralf Jesnowski of the University of Heidelberg, Germany kindly donated the 
immortalised stellate cell line. The cells were isolated by the outgrowth method and 
were immortalized by transfection with SV40 large T antigen and human telomerase 
(hTERT), (Jesnowski et al, 2005). 
Cell line Source Cell type Gender Media used 
AsPC-1 ATCC Epithelial Female RPMI-1640 
BxPc3-3 ATCC Epithelial Female RPMI-1640 
HPAC ATCC Epithelial Female DMEM 
Hs776T ATCC Epithelial Male DMEM 
MiaPaCa-2 ATCC Epithelial Male DMEM 
PANC-1 ATCC Epithelial Female DMEM 
PL5 
Dr Claus   
Jorgensen Epithelial 
Male DMEM 
PL45 ATCC Epithelial Male DMEM 
SU86.86 ATCC Epithelial Female RPMI-1640 
RLT-PSC 
STELLATE 
CELLS 
Dr Ralf 
Jesnowski 
Stellate 
     Fibroblasts 
Unknown DMEM 
 
Table 2.1 Cell lines. According to ATCC, ASPC-1 was derived from the ascitic fluid of a 
female patient with a poorly differentiated pancreatic cancer. HPAC is a pancreatic 
adenocarcinoma epithelial cell line explanted from a female pancreas with a moderate to 
well differentiated pancreatic adenocarcinoma of ductal origin. Hs776T was originally derived 
from a lymph node metastasis of a male patient with an undefined differentiated pancreatic 
tumour. Panc-1 cells were originally derived from a female patient with a poorly differentiated 
pancreatic tumour. MiaPaCa-2 was explanted from a male patient with a poorly 
differentiated pancreatic cancer. Su86.86 cell line was derived from the liver metastases of a 
female patient with a moderate to poorly differentiated pancreatic lesion. 
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Passage was performed by firstly adding 1: 4 Trypsin and Versene solution to the 
monolayer and incubating for 5 minutes under usual culture atmospheric conditions. 
The cells were then washed in culture media (DMEM or RPMI containing FCS) in 
order to neutralise trypsin activity and this solution was centrifuged to obtain a cell 
pellet. The supernatant was removed and the pellet re-dissolved in fresh media 
before being transferred to a T75 or T150 flask or frozen in liquid nitrogen. Figure 2.1 
below shows primary fibroblasts at different stages of passage. 
 
      
     
Figure 2.1 Electron microscopy of primary fibroblasts at x10 magnification, the cells appear 
spindle shaped. Pictures were taken at 60% confluence, a) PF3 fibroblasts at passage 5, b) 
PF7 fibroblasts at passage 7, c) PF16 at passage 1, d) PF18 at passage 4. 
 
PF3 PF7 
PF16 PF18 
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For the purpose of cell storage the pellets that were not passaged following 
trypsinisation, as described above, were re-suspended in a freezing solution of 10% 
Dimethylsulfoxide (DMSO) and 90% culture media before being placed into 1.8ml 
screw cap freezing tubes and kept in -80˚C for 24 hours. This was done to introduce 
slow freezing and prevent crystallisation prior to cryostorage in liquid nitrogen. To 
thaw frozen cells, the freezing tubes were warmed to 37°C and culture media was 
added. The suspension was centrifuged at 1000rpm for 5 minutes at room 
temperature and re-suspended in fresh culture media before being transferred to a 
culture flask T25 for incubation. 
 
2.2.4 Immunoflourescent labelling of cells on cover slips 
 
Cells were cultured on 13mm cover slips in multiwell plates and allowed to grow to 
70% confluence. Once confluent the cells were fixed with 4% Paraformaldehyde in 
phosphate buffered saline (PBS) at pH 7.4 for 1 hour. This was rinsed in PBS and 
stored in 0.5mls of PBS at 4°C to prevent the fixed cells from desiccation. The PBS 
was then removed and the cells permealised with 0.5% TritonX-100 in PBS over 10 
minutes.  The cells were then rinsed in PBS twice followed by a protein carrier IFF. 
IFF was made up of PBS, 1% BSA and 2% FCS.  The primary antibodies were 
appropriately diluted in IFF and the cells were incubated with this for 40 minutes on a 
shaking incubator. They were then washed in PBS three times at 5 minutes each 
and incubated with the Alexa conjuagte1 in 1000 in IFF for a further 40 minutes. 
They were then washed in PBS plus DAPI 1 in 10000 three times at 5 minutes each, 
rinsed in PBS and dipped in water. The cover slips with adhered cells were carefully 
drained and mounted in 4µl vectashield on slides. Excess vectashield was carefully 
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blotted and the cover slips sealed with nail varnish onto the slides. These were either 
stored at 4°C prior to viewing or stored for longer at 20°C. 
 
 
 
       
             
 
Figure 2.2. Immunohistochemistry of primary fibroblasts, A) Negative stain for αSMA (no red 
seen), B) Pancreatic CAFs immunostained for αSMA (red) and counterstained with DAPI 
(blue), C) FAP (Fibroblast activating protein, green stain), D) unstained fibroblasts as seen 
under a light microscope 10X magnification. 
 
 
 
 
 
 
 
A B 
C D 
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2.2.5 Laser-capture microdissection (LCM) of FFPE 
Deciphering the cellular and molecular interactions that drive disease within the 
tissue microenvironment holds promise for discovering drug targets in the future. 
Laser-capture micro-dissection is a method used to procure pure sub-populations of 
tissue cells, such as stroma, under direct microscopic visualisation. LCM technology 
can harvest the cells of interest directly, to give a histologically pure enriched cell 
population.  
 
    
 
 
Figure 2.3 Zeiss PALM Laser Capture Micro-dissection station. This photo shows the exact 
set up used to obtain micro-dissected tissues fro Formalin Fixed Paraffin embedded 
samples. 
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This system was initially developed for the analysis of solid tumours, in particular, 
prostate cancer. The system, based on an inverted bright-field light microscope, has 
been previously described by Emmert-Buck et al and has since been improved.  In 
PALM systems, separation of the specimen occurs with a laser beam focused so 
precisely that a beam accuracy of less than 1µm can be achieved. The selected 
specimen is removed with a software controlled laser beam and catapulted by a 
laser pulse into a collection device. This procedure ensures that no unwanted 
elements reach the specimen. Because the laser is only directed at the sample for 
less than 1 nano second, it does not transfer any heat. The process is completely 
contamination free and guarantees the best possible preservation of the material.  
 
Archived samples of formalin fixed paraffin embedded (FFPE) blocks of PDA were 
retrieved, including 1 block of chronic pancreatitis. Each slide was micro-dissected to 
isolate the tumour and stromal components using the PALM Microbeam micro 
dissection system (Carl Zeiss) according to published methods. In order to obtain 
sufficient quantities of DNA for downstream applications (≥ 1500ng), 12 slides of 
each block were required.  
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Ten-micrometre sections were cut from FFPE tissue blocks and placed onto glass 
membrane slides. One slide of each sample was stained with Haematoxylin and 
Eosin in order to correctly identify regions of stroma and glandular tissue and to 
guide the sections to be cut by LCM. A consultant Histopathologist identified suitable 
areas of stroma and glandular tissue.  The same areas were identified and outlined 
on methylene green stained slides. This process consisted of immersion in Xylene 
(deparaffinisation step) for 5 minutes followed by hydration in graded alcohol 
concentrations, (100% and 70% alcohol respectively) and de-ionised water. The 
slides were then immersed in methyl green dye for a further 5 to 10 minutes to 
achieve a light stain. Twelve serial sections were cut out from the laser capture 
slides and catapulted into adhesive caps of 500µl tubes using the PALM Laser micro 
dissection system.  
 
     
Figure 2.4 H and E stained and LCM methyl green cut sample of FFPE Haematoxylin and 
Eosin staining of FFPE samples and LCM of the area as seen on the P.A.L.M system. A) A 
magnified area of stromal fibroblasts with H and E staining, B) A methyl green stained slide 
with an area of micro-dissected stroma using the PALM laser system  
 
A B 
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DNA was isolated using the Arcturus – Pico Pure® DNA Extraction Kit- KIT0103. An 
initial fragmentation step was used with 1ml of 1M sodium thiocyanate (NASCN). For 
this step the tissue was transferred to a 1.5ml tube. The samples were incubated 
overnight at 38ºC then centrifuged at maximum 10,000g and the Sodium 
Thiocyanate (NASCN) removed. The samples were washed with sterile PBS 1ml 
and centrifuged for 5 minutes. This step was repeated and the PBS removed.  A 
proteinase K solution was made up by adding 155µl of reconstruction buffer provided 
to a vial of proteinase K mix. This was placed on ice immediately. Samples were 
immersed in 50µl to 155µl of proteinase K solution dependent on volume in the tube 
and tubes were incubated overnight at 65°C (minimum 16 hours) followed by a 10 
minute incubation at 95˚C in order to inactivate the proteinase K. The samples were 
allowed to cool to room temperature.  
The DNA obtained was then subjected to a clean and concentrate step using Zymo 
research DNA Clean and Concentrate ™-5. A DNA binding buffer double the volume 
of the current concentration in each microcentrifuge tube was added to each double 
stranded (ds) DNA sample, i.e. 100µl. The new mixture was loaded onto a Zymo 
spin column and this was mounted onto a 2ml collection tube. This was centrifuged 
at full speed (≥ 10,000g) for 30 seconds and the subsequent flow through was 
discarded. Two hundred microlitres of the wash buffer provided was then added to 
each Zymo column and centrifuged for 30 seconds at maximum sped of 10,000g and 
the flow-through discarded. This step was repeated in order to thoroughly wash the 
DNA. The Zymo spin column was then placed onto a new 1.5ml collection tube and 
10-15µl of water added for DNA elution. This was centrifuged at maximum speed of 
10,000g for 30 seconds. The DNA concentration was then quantitated using a 
Nanodrop® 1000 spectrophotometer. 
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Pico green Assay for double stranded DNA (dsDNA) quantification 
PicoGreen is a fluorochrome that selectively binds dsDNA and has characteristics 
similar to that of SYBR-Green I. It has an excitation maximum at 480 nm and an 
emission peak at 520 nm. When bound to dsDNA, very little background interference 
occurs since the unbound dye does not fluorescence. Fluorescence enhancement 
of PicoGreen is greater than 1000 fold; Pico Green is 10,000-fold more sensitive 
than Ultra Violet (UV) absorbance methods and highly selective for dsDNA over 
single stranded (ss) DNA and RNA.  
 
The samples to be assayed were processed in duplicate. Each sample was placed 
on a plate as a ‘neat’ and a, 1:10 dilution. The samples were diluted in 1 x 
hydroxymethylaminomethane (tris) and ethylenediaminetetraacetic acid (EDTA), 
(TE) buffer. The DNA standards were prepared based on a low range standard 
curve, (Table 2.1). Ninety nine microlitres of 1 x TE was added to all test sample 
wells and 100µl to the blank wells. A calculated volume of 1 x TE was added to the 
standard wells based on the low range standard curve. The standard DNA was 
added to the appropriate wells, followed by 100µl of PicoGreen to all wells excluding 
the empty ones. This was left at room temperature for 2-5 minutes and the samples 
were read on the Perkin Elber VictorX5 scanner using Perkin Elber 2030 Manager 
software. 
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Table 2.1 The low range standard curve used for Pico Green quantification. A low range 
curve was chosen as a predictor as the values that were expected should fall within these 
ranges. This was used as a scale to quantify the DNA concentrations.  
 
 
 
 
2.2.6 Array CGH of primary cells and FFPE 
 
Bacterial artificial chromosomes (BACs) are large insert genomic clones that have 
been widely used in aCGH studies (Tan et al., 2007). Bacterial artificial chromosome 
probes vary in length from 100 to 200 kb and the resolution (i.e. the distance 
between each DNA target represented on the array) of each BAC array is defined by 
the number of unique probes it contains. The probe content of genome-wide BAC 
arrays range from 2,400 to 32,000 unique elements, (the tiling path array). Tiling 
path arrays (i.e. arrays where each BAC overlaps with its contiguous BACs) provide 
a resolution of up to 50 kb, given that a genomic change can only be detected if it is 
sufficiently big to significantly change the hybridization intensity in one of the 
channels (i.e. change the red: green ratios).  The ratio of fluorescent intensities (red 
and green) is proportional to the ratio of the copy numbers of the DNA sequences in 
the test and reference genomes.  
 
 
50ng/ml control 
DNA stock (µl) 
Volume of TE 
(µl) 
Diluted 
PicoGreen 
reagent (µl) 
Final DNA 
concentration 
DNA in 200µl 
assay 
100 0 100 25ng/ml 5ng 
40 60 100 10ng/ml 2ng 
10 90 100 2.5ng/ml 500pg 
4 96 100 1ng/ml 200pg 
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Equal intensities of the fluorescent dyes on a probe are interpreted as this region of 
the genome having an equal quantity of DNA in the sample and reference DNA. If, 
however, there is an altered Cyanine3 (Cy3) to Cyanine 5(Cy5) ratio, this is 
interpreted as a loss or a gain of the sample DNA at that specific region on the 
genome, (lee et al, 2007). Any genomic imbalances found would be validated with 
metaphase fluorescent in situ hybridization. These platforms provide sufficiently 
intense signals for the detection of single-copy number alterations, accurately define 
the boundaries of genomic aberrations, and, importantly, can be applied to archival 
FFPE tissue as well (Little et al, 2006; Johnson et al, 2006). 
 
 
DNA was purified from cell pellets using the Qiagen DNeasy Extraction Kit according 
to the manufacturers’ protocol. Equal amounts of labelled genomic DNA from a test 
and a reference sample were co-hybridized to an area representative of the genome. 
Pooled DNA can be used as controls (Shinawi et al, 2008) and a pooled female DNA 
obtained from the Institute of cancer research was used in this methodology. 
Genomic DNA of the samples and the control were differentially labelled with dCTP- 
(Cy3) and (Cy5). Hybridization of repetitive sequences was blocked using human 
Cot-1 DNA. The slides were scanned into image files using an Axon 4000B scanner 
(Axon instruments, Burlington, CA, USA). 
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The spot intensities were measured and the gpr image files quantified using Genepix 
Pro6 image analysis software (Axon instruments).  These gpr files were analysed to 
produce the copy number analysis. Smoothed Log2 ratio values less than 0.12 were 
categorised as losses, >0.12 as gains and in between as unchanged. Amplifications 
were defined as smoothed log2 ratios values greater than 0.4. 
 
 
Figure 2.5 below is a schematic representation of the principle of array CGH. This 
figure shows the steps in BAC array CGH. (1) BAC clones are selected from a 
physical map of the genome, see figure 2.6. (2) DNA samples are extracted from 
selected BAC clones and their identity is confirmed by DNA fingerprinting or 
sequence analysis. (3) A multi-step amplification process generates sufficient 
material from each clone for array spotting. Each clone is spotted in replicate onto a 
solid support. Reference DNA and test DNA are differentially labelled with cyanine 3 
and cyanine 5 respectively. (4) The two labelled products are combined and 
hybridized onto the spotted slide. (5) Images from hybridized slides are obtained by 
scanning in two channels. Signal intensity ratios from individual spots can be 
displayed as a simple plot (6) or by using more complex software such as SeeGH, 
which can display copy number alterations (CNA) throughout the whole genome.  
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                                                     Figure 2.5 Principle of arrayCGH.   
 
Region 
1. Genome map 
2. Selection of BAC  
   clones from library 
4. Co- Hybridization onto slides 
Test DNA Cy5 labelled Reference DNA Cy3 
labelled 
3. DNA labelling 
BAC DNA prep  
5. Image analysis, using 
Axon 4000B scanner 
6. Genome plot showing 
log2 intensity ratios 
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The array CGH platform used for this study was constructed at the Breakthrough 
Breast Cancer research centre and comprised about 32000 BAC clones tiled across 
the genome and spotted onto corning GAPS11 coated glass slides (Corning, NY, 
USA). Six hundred nanograms of the sample DNA and same sex, all Female DNA, 
(Breakthrough Breast Cancer research centre) were placed into a 0.5ml thin tube 
and appropriately labelled. The volumes required based on the starting concentration 
are represented in the Table 2.2. Ultra filtrated water was added to a total 
concentration of 21µl.  
DNA Sample Concentration needed Volume H20 added 
PF3 80ng/µl 8µl 13µl 
PF7 100ng/µl 6µl 15µl 
PF9 100ng/µl 6µl 15µl 
PF16 100ng/µl 6µl 15µl 
Panc1 100ng/µl 6µl 15µl 
Female DNA 75ng/µl 8µl 13µl 
Table 2.2 DNA concentrations and volumes added for initial labelling step  
 
A pooled Female DNA, from 24 individuals, was used as the control for all 
experiments. Twenty microlitres of random primers was added to each tube and 
denatured for 5 minutes at 95˚C. This was placed immediately on ice for 10 mins and 
5µl of deoxribonucleotide triphosphate (dNTP) stock, 3µl of Cy3 or Cy5 and 1µl of 
Klenow was added to each tube and the mixture incubated overnight in the thermo 
cycler. The dNTP stock was made up of 12µl dATP, dGTP, dTTP and 6µl of dCTP at 
100mM stock in I ml Tris/EDTA, (TE) buffer. 
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Purification of the labelling reaction (Qiagen MinElute Purification Kit) 
For each sample, five volumes of binding buffer (PB) were added to each labelled 
material, vortexed and transferred to a mini elute column. This was centrifuged for 1 
minute at 13,000 rpm and the flow through discarded. Subsequently 700µl of Wash 
Buffer was added and centrifuged at the above speed and the flow through 
discarded. To avoid any residue of ethanol in the samples they were centrifuged 
again at 13,000 rpm. Twelve microlitres of elution buffer (EB) was added to the 
middle of the filters within their columns and then centrifuged at 13,000 rpm for 1 
minute. 
 
Sample precipitation  
Tumour and reference DNA were combined in a thick 0.5ml tube and 100µl (1µg/µl) 
of Cot-1 DNA, 2µl of NaOAc pH 7.0 and 300µl of ice-cold 100% ethanol was added 
to each sample. The mixed reagents were precipitated at 20°C for 1-2 hours and 
then centrifuged at 13,000 rpm for 30 minutes. The supernatant was removed and 
the samples air dried.  
 
Slide preparation: 
The pre- hybridization buffer was heated and filtered. Slide pre-Hybridisation buffer 
was made up of 49.5mls of UF water, 25mls of 20x SCC, 25mls of deionised 
formamide and 0.5mls of 20% SDS per 100 ml solution. The slides were placed into 
the pre-hybridisation blocking buffer (in a 50ml falcon tube) and incubated for a 
minimum of 45 minutes at 42˚C (optimally 2hrs). Following this the slides were rinsed 
in de-ionised water and spun at 2000rpm for 2 minutes to dry.  
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Hybridisation 
Forty five microlitres of hybridization buffer was added to each of the sample pellets. 
Hybridisation buffer was made up with 250µl of Deionised formamide, 50mg of 
Dextran Sulphate, 50µl 20x SCC, 50µl of 20%SDS, 20 µl of 100µg/µl yeast tRNA 
and 130 µl of ultrafiltrated water per 500µl solution. The samples were left at room 
temperature in the dark for 30-45 minutes. They were then vortexed and centrifuged 
to ensure that the pellet reconstituted completely in the hybridisation buffer. They 
were denatured for 15 minutes at 70˚C and re-annealed for 30 minutes at 37˚C 
(using PCR machine). Each sample was applied to the cover slip (24x60mm) and 
the slide was carefully lowered onto the cover slip. The slides were then placed in a 
moist Hybridisation chamber and incubated at 42˚C overnight.  
 
 
Wash solutions 
Wash 1, 0.1% Sodium dodecyl sulphate (SDS), consisted of 10mls of 20x Saline-
sodium citrate (SSC), 0.5mls of 20%SDS and 89.5mls of Ultra-filtrated water per 100 
mls of solution. Wash 2, 50% formamide was made up of 10mls of 20x SCC, 50mls 
of formamide and 40mls of ultrafiltrated (UF) water per 100 mls of solution and wash 
3 was made using 1ml of 20 times SCC and 99mls of UF. 
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Stringency wash  
The slides were washed in Wash1 (20x SCC, 0.1% SDS) for 15 minutes at 45˚C and 
then the cover slip removed slowly by allowing it to gently slip off the slide. This was 
followed by wash 2 (20x SCC, 50% formamide, pH 7.0) for 15 minutes at 45˚C, 
Wash 1 (20x SCC, 0.1% SDS) for 30 minutes at 45˚C, Wash 3 (0.2x SCC) for 15 
minutes at room temperature and finally Wash 3 (0.2x SCC) for 15 minutes at room 
temperature. They were then centrifuged at 2000rpm for 2 minutes. The slides were 
scanned using an Axon 4000B scanner (Axon instruments) and images were 
processed using Genepix Pro 5.1 image analysis software.                   
 
2.2.7 Fluorescent in Situ Hybridisation (FISH) 
Fluorescent in Situ Hybridisation mapping was used to map the clones of any 
possible deletions. The cells were mounted onto slides and labelled with BAC clones 
representative of the areas suspected to have genomic changes. These clones were 
hybridized and a fluorescent probe added prior to inspection under microscopy. Cells 
were viewed in metaphase. 
 
Mapping of BAC clones 
Clones were chosen from an available 32K clone library at the Institute of cancer 
research. They were mapped based on the array CGH location of possible genomic 
changes as shown below. See figure 2.6. 
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Figure 2.6 Region overview of Chromosome 19P 13.2 showing a possible gain  
 
 
 
 
 
 
 
 
Region overview of CH19p13.2 
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The clones used from the Library were as follows: 
1) RP11- 743O10                  
2) RP11- 361O08                   
3) RP11- 282G19                  
4) RP11- 367L15                   
5) RP11- 598E05                  
6) RP11- 680A23                  
 
 
The DNA concentration of each BAC clone was measured via Nanodrop 
BAC clone DNA concentration 260/280 260/230 
1 1393.1 1.58 1.81 
2 813.5 1.71 2.01 
3 1272.8 1.61 1.85 
4 1050.1 1.65 1.88 
5 1147.7 1.57 1.78 
6 926.7 1.69 1.96 
Table 2.3 DNA concentrations of the BAC clones chosen. Each sample was made up to 
20µl in 200 µl. These were vortexed well and 5µl of the 1 in 10 diluted solutions was used for 
Biotin labelling.  
 
Biotin Labelling 
Bacterial artificial chromosomes DNA was labelled with Biotin in a 45µl reaction. 5µl 
of amplified BAC DNA diluted to 1 in 10 as described previously was mixed with 20µl 
of random primers and 23µl of H2O. This mixture was denatured at 95ºC for 5 
minutes and placed on ice immediately for 10 minutes. Five microlitres of dNTP and 
1µl of Klenow DNA polymerase was added to this mixture. After quickly vortexing 
and spinning the solution was incubated for 3 hours at 37 ºC via PCR. 
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Purification 
Preparation of G50 columns prior to purification 
These columns are vortexed for one minute and the ends snapped off and placed 
into an empty 1.5ml eppindorf. This is spun at 48rpm for 1.5 minutes and the column 
transferred to a new tube. 
Purification step 
One hundred microlitres of amplified biotin labelled BAC DNA was added to each 
column and this was centrifuged. Each sample was then transferred to a 0.5ml thick 
tube. 
 
 
Precipitation  
To 44µl of each sample 50µl of H2O, 60µl of COT1, 2µl of salmon sperm, 16.4µl of 
NaOAc and 360µl of 100% ethanol was added. After Vortexing the samples were 
precipitated at -80 ºC for 1 hour. Following precipitation the samples were 
centrifuged at 13.2K rpm, the supernatant discarded and the precipitate dried for 5 to 
7 minutes at 37 ºC. This process of centrifugation and removal of supernatant was 
repeated and the samples dried again for 5 minutes at 45 ºC. Twelve microlitres of 
hybridization buffer was added to each dried pellet and incubated at 37 ºC for 10 
minutes.  
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Slide preparation 
The slides were placed in 70% acetic acid for 10 minutes followed by repeated 
washes in PBS. The slides were then dehydrated in 70%, 90% and 100% alcohol 
consecutively for 2 minutes each. The slides were dried on a warmer at 45 ºC for 1 
minute then at room temperature for a further 10 minutes. 
 
Generating a metaphase from growing cells 
The cells were exposed to 2µl of Colcemide per ml of media and incubated for 2.5 
hours in humidified air at 37°C and 5% CO2. Following this, the culture media was 
removed and 7mls of trypsin was added to each T75 flask and cells were allowed to 
detach for 7 minutes under the same conditions. Once the cells were fully detached, 
15mls of pre-warmed distilled water or KCL0.0075M was added and left to incubate 
for a further 15 minutes. Fixative solution, (200mls of 3:1 methanol to acetate) was 
then added to the cells and this was quickly vortexed and centrifuged at 1500rpm for 
5 minutes. The resulting supernatant was poured out and the cells re-suspended in 
another 15mls of fixative solution. This was again centrifuged at 1500rpm for 5 
minutes. The latter step was repeated and the cells were stored in 5mls of fixative 
solution at -20ºC. For use the cells were centrifuged for 5 minutes and resuspended 
in 1 ml of fixative solution prior to mounting onto slides. The pictures are taken of the 
probes in metaphase spread  
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2.2.8 Drug screening and Cell titre Glo (CTG) measurement 
 
 
2.2.8.1 Cell titration for Gemcitabine curves 
Prior to performing the Ashworth plate 10 compound library screen on the PDA cell 
lines, an initial simple cell titration was performed in order to ascertain the growth 
pattern of the pancreatic cancer cell lines obtained from ATCC. Cells were plated in 
a reducing number from 1x 104 cells per well to 7.8x10-2 cells per well on day 1, in 96 
well plates and allowed to expand. Cell Titre Glo (CTG) read at Day 6 determined 
that 1000 cells per well was the suitable cell count to be used for further 
experiments. With this cell number plated there were 20,000 to 25,000 cells per well 
after a 72 hour period. These cells expanded suitably into a monolayer without 
overcrowding or cell death. 
 
 
2.2.8.1.1 Gemcitabine resistance after 72 hours of treatment 
Once the cell count to be used had been established, it was then necessary to 
review the response of these cells to Gemcitabine. A simple experiment to establish 
the response to Gemcitabine was performed. This was done firstly after 72 hours of 
exposure to a reducing dose of Gemcitabine. PDA cell lines PANC-1 and BxPc3 
were plated on 96 well plates at 1x103, 2x 103, 3x103 and 4x103 cells per well. 
Twenty four hours post plating; the cells were fed with Gemcitabine ranging from -5M 
to-11M and a 0M control. As per protocol, CTG readings were done seventy two 
hours post treatment with Gemcitabine and the data analysed for cell survival.   
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The four concentrations of 1000, 2000, 3000 and 4000 cells per well were used to 
see if there wound be a difference in the pattern of sensitivity or resistance based on 
cell number.        
 
2.2.8.1.2 Gemcitabine resistance after 6 days of treatment 
After 4 days of exposure to Gemcitabine the cells were washed and fed with 
Gemcitabine free media. The CTG reading was performed after 72 hours as per 
protocol.  The same experiment was repeated; however, on day 4 the media was 
changed to Gemcitabine free media and CTG readings done on day 6. This was to 
observe the true effect of the drug already taken up by the PDA cells. The results of 
these experiments are discussed in further detail in chapter 4.  
 
 
 
2.2.8.2 Cell titre Glo (CTG) survival readings 
 
The liquid from each plate was removed by tipping and the plates spun to dryness 
for a few seconds via centrifuge at 1000rpm. Cell titre Glo solution was made in a 
ratio of 1 in 4 with PBS. This bioluminescent marker quantifies the ATP in cells which 
is a representative of those that are metabolically active.  Using the Multidrop Combi 
Reagent Dispenser 25 µl of CTG solution was applied to each well. This was 
incubated in darkness on a rotating platform for ten minutes before being read on a 
plate reader. The data collected was collated and analysed using R’ and Cell HTS 
software programming in order to find compounds to which the pancreatic cancer 
cell lines were sensitive to.  Graph pad Prism (version 5.0) was used to carry out 
statistical analysis. 
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2.2.8.3 High throughput screening  
For the Ashworth plate 10 compound library drug screen, cells were cultured as 
previously described in order to obtain a greater than 70% confluent monolayer in a 
T75 flask. These cells were trypsinised and re-suspended in fresh media. A 10µl 
sample of cell suspension was mixed with 10µl of tryptan blue staining dye and read 
using the Countess® Automated Cell Counter. The number of live cells only, was 
used to calculate the volume of cell suspension required to give 1000 cells per well 
per 384 well plate.  On average about 40,000 cells were necessary for each 384 well 
plate or 1.2x106 for triplicate plates of each sample at a volume of 25µl per well. The 
cells were plated using the Multidrop Combi Reagent Dispenser from Thermo 
Scientific. These plates were incubated for 24 hours at 37ºC and 5% humidified CO2.  
The cells were then exposed to the Plate 10 compound library by serial dilutions of a 
previously prepared plate of chemotherapeutic compounds. Each drug was 
administered in volumes that would represent four concentrations, 1µM, 10µM, 100 
µM and 1000 µM respectively and these were administered using the Hamilton 
automated liquid handler robot. Following application of the drug library to each cell 
line, the triplicate samples were again incubated for 72 hours at 37ºC and 5% 
humidified CO2. On day 4 the plates were read for cell viability. 
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2.2.9 Luciferase marking of PDA and stellate cell lines 
Prior to coculture experiments, it is necessary to mark both PDA cell lines and 
stellate cells with distinct bioluminescent markers that can be differentiated when 
read using CTG.  
 
2.2.9.1 Generating Renilla and Firefly luciferase plasmid 
The vector chosen was pcDNA3 (Invitrogen, Life technologies) for Renilla and 
pIRESpuro3 for Firefly. The vector with the synthetic Renilla insert was 
pCMV5C/chRluc or chFluc respectively, see figure 2.7. 
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Figure 2.7 Luciferase plasmid containing the synthetic Renilla and Firefly insert. The vector 
is 5.4 kilo bases in length, resistant to ampicillin and containing the cloning site XhoI/XbaI for 
Renilla luciferase. In Firefly luciferase XhoI disappears from the cloning site but XbaI is still 
present. The ligation sites for each luciferase are shown in green for Firefly and blue for 
luciferase. 
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The steps to cloning involved firstly purification of the plasmid (using mini prep and 
nanodrop) followed by digestion and purification of the insert, ligation, 
transformation, amplification of he clones and finally, sequencing. The end result 
being that of a purified insert placed into a plasmid vector and cloned to be used in 
coculture. 
 
 
Lucifrase cloning
Plasmid Gene Plasmid
Purification
Digestion Digestion
Purification
Amplification
Transformation 
Ligation
Sequencing 
 
Figure 2.8 Steps in Luciferase cloning 
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2.2.9.2 Plasmid purification using Gen-EluteTM HP plasmid miniprep kit and 
protocol  
Harvesting, lysis and preparation of the cleared lysate 
Each sample was processed in duplicate. One millilitre of plasmid was pelleted at ≥ 
12,000xg for one minute and the supernatant discarded. The plasmids were 
resuspended in 200µl of resuspension solution and pipetted up and down to mix. 
Two hundred microlitres of lysis buffer was added and the solution gently inverted 6 -
8 times to mix. This was allowed to clear for 3-5 to minutes. Three hundred and fifty 
millilitres of neutralizing or binding buffer was added and the mixture gently inverted 
4 to 6 times. The debris was pelleted at ≥ 12,000xg for 10 minutes via centrifuge. 
 
Column preparation 
The miniprep binding column was inserted into a microcentrifuge tube and 500µl of 
column preparation solution was added to the column. This was centrifuged at ≥ 
12,000xg for 30 seconds to one minute and the flow through was discarded. 
 
Binding, washing and elution of Plasmid DNA 
The cleared lysate obtained earlier was transferred to the prepared column and 
centrifuged at ≥ 12,000xg for 30 to 60 seconds to bind the DNA to the column. The 
flow through was discarded. To wash away contaminants, 500µl of wash solution1 
was added to the column and centrifuged at ≥ 12,000xg for 30 to 60 seconds and the 
flow through discarded. This was followed by a second wash with 750µl of wash 
solution 2 which was centrifuged at the same speed for 30 o 60 seconds. This flow 
through was also discarded and the column was centrifuged for an additional 1 
minute at ≥ 12,000xg to remove any excess ethanol.  The binding column was then 
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transferred to a fresh collection tube and 100µl of elution solution added to the 
column. This was centrifuged at ≥ 12,000xg for 60 seconds. The concentration of 
each sample was quantified by nanodrop, see table 2.4 below. 
 
Sample DNA concentration ng / µl 
Firefly 1 141.83 ng / µl 
Firefly 2 
176.25 ng                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
/ µl 
Renilla 1 148.01 ng               / µl 
Renilla 2 161.42 ng               / µl 
 
Table 2.4 Nanodrop quantification of Plasmid DNA 
 
 
 
2.2.9.3 Digestion 
This step was necessary to digest the gene from the PCR product and the plasmid 
prior to insertion into pCDNA3 and pIRESpuro3. The enzymes needed, their 
respective buffers and plasmids are shown in table 2.5 
 
 
Table 2.5 Enzymes and buffers needed for luciferase digestion 
Insert Enzymes needed Buffer Plasmid 
Firefly1 EcorV, BamH1 3 pIRESpuro3 
Renilla 1 Xho1, Xba1  4 pcDNA3 
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Each sample was made up with a mixture of enzyme, DNA, Buffer10X, BSA 10X and 
H2O to a volume of 50 µl. The solutions were incubated for 1 hour at 37ºC and the 
enzymes inactivated by incubation at 80 ºC. To prevent re-ligation the samples were 
treated with phosphatase 10,000U/ml. for this, 0.5 µl of phosphatase was added and 
the mixture incubated for one hour at 37ºC then stored at -20 ºC. 
 
 
Reagent Firefly1 Renilla 1 pcDNA3 pIRESpuro3 
Enzyme 0.5 +0.5 0.5 +0.5 0.5 +0.5 0.5 +0.5 
DNA (1µg) 7µl 6.7µl 0.5µl 1.5µl 
Buffer 10X 5µl 5µl 5µl 5µl 
BSA 10X 5µl 5µl 5µl 5µl 
H2O 32µl 32.25µl 38.5µl 37.5µl 
 
Table 2.6 Reagent mix for digestion step 
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2.2.9.4 Agarose gel purification and DNA extraction 
A 1% agarose gel was made using 1.2g of agarose 120mls volume. Twelve 
microlitres (1X) of 10000X gel green nucleic acid was added and mixed to a yellow 
orange solution and the gel poured into the mould. Once the gel was set the Tae 
buffer was added to the mould. Gel loading dye was added at 10µl per sample 
making each sample a total of 50µl plus 10µl of dye. Thirty microlitres of each 
sample was loaded in duplicate along with a quick load 1kb ladder. The gel was run 
a 100V, 0.13 Amp for 1 to 1.25 hours. The gel in Figure 2.9 shows the ligated Renilla 
with very strong bands and a very weak Firefly bands. This may have been due to 
the need for longer ligation time, multiple ligation sites and the cut fragment (insert 
alone).  
 
Agarose gel purification
 
Figure 2.9 Agarose Gel purification and extraction of Renilla and Firefly luciferase  
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The bands from the gel in figure 2.9 were cut out with a clean sharp scalpel and their 
molecular weight measured as below prior to DNA extraction. 
                 
Sample Weight of gel sample 
pIRESpuro3 0.41g 
pcDNA3 0.40g 
Firefly luciferase 0.32g 
Renilla luciferase 
0.24 g 
 
 
Table 2.7 Molecular weights of Gel bands 
     
Using the QIAquick Gel extraction protocol (Qiagen) the DNA was extracted. Buffer 
GQ was added to the gel, in a 3:1 ratio (100mg to 100µl), to obtain a yellow colour 
indicating a pH of ≤7.5. This was incubated at 50ºC for 10 minutes to completely 
dissolve the gel. This was aided by vortex of the tube every 2 to 3 minutes during 
incubation. One hundred microlitres of isopropanol was added to the sample and 
mixed. Using a spin column within a collection tube each sample was applied to the 
column and centrifuged for one minute at 13000 rpm in order to bind the DNA to the 
column. The flow though was discarded. For DNA that was to be used for direct 
sequencing and in vitro transcription, 0.5mls of buffer GQ was added to the column 
and centrifuged for one minute at 13000 rpm. Following this, the column was washed 
with 0.75mls of buffer PE and centrifuged for one minute at 13000 rpm and the flow 
through discarded.  
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On completion of the washing steps the column was centrifuged in a 2ml collection 
tube for 1 minute at 13000 rpm. The DNA was eluted in a clean 1.5 ml 
microcentrifuge tube using 50 µl of buffer EB (10nM Tris-Cl, pH8.5). The DNA was 
quantified using nanodrop as shown in table 2.6. 
 
Sample ID 
DNA 
concentration 
260/280 260/230 
Firefly1 3.09 1.65 0.01 
Firefly1 2.65 2.71 0.01 
Renilla 1 3.73 2.73 0.01 
Renilla 1 3.31 2.43 0.01 
pcDNA3 7.82 2.33 0.02 
pIRESpuro 11.74 1.82 0.04 
 
Table 2.8 Nanodrop quantification of DNA extracted from the Agarose gel 
 
 
2.2.9.5 Ligation of luciferase insert into vector 
For the insertion of the luciferase marker into the vector the same procedure was 
used for both Renilla and Firefly luciferase. The ligation ration calculator used was a 
3:1 ratio of 3 inserts to 1 bacterium. A 20µl reaction was made up of 2µl of 10X 
buffer, 1µl of Enzyme, 10µl of Vector, 5µl of insert (Renilla or Firefly) and 2µl of H2O. 
This mixture was incubated at room temperature for 2 hours. The following is a 
description of the procedure using Renilla Luciferase. 
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2.2.9.6 Transformation of the DNA 
The DNA was transformed into DH5αTM competent cells, (Invitrogen), onto an agar 
plate fed with penicillin. For the negative control no plasmid was used and the 
positive control was pUC19 control DNA (Invitrogen). One micro litre of ligated DNA 
(1-10ng) was added to the competent cells and 2.5µl to the control. This was mixed 
gently by hand and incubated on ice for 30 minutes. Without shaking, the cells were 
then heat shocked for 20 seconds in a 42ºC water bath and then placed on ice for 2 
minutes.  Five hundred micro litres of pre warmed medium was added to each 
sample and the tubes were incubated at 37ºC for 20 minutes at 225rpm.  Twenty 
microlitres to 200µl of  each transformation was spread onto pre-warmed agar plates 
ensuing well spaced colonies. For the positive control pUC19, 100µl was spread 
onto a plate containing 100µg/ml of Ampicillin. The agar plates wee incubated 
overnight at 37 ºC. 
 
 
Transformation results 
Twenty four hours later the results were as follows. There were no colony formations 
on the negative control, multiple colonies over the entire plate of the positive control 
and 5 colonies seen for Renilla luciferase. 
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2.2.9.7 Amplification of colonies 
The 5 colonies were amplified in 1X Ampicillin and 2.5ml of LB media (broth). This 
was placed in a shaking incubator at 37 ºC overnight. The Amplified DNA was 
prepared using Gen-EluteTM HP plasmid miniprep kit and protocol as previously 
described.  Each sample was prepared in duplicate and the results were tabulated 
below. 
 
Colony 
Concentration ng                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
/ µl 
For 1ug of DNA 
C1 166.80 5.9µl 
C2 126.78 7.88µl 
C3 172.96 5.78µl 
C4 168.71 5.93µl 
C5 141.97 7.04µl 
 
Table 2.9 Average concentrations of colonies formed. 
 
The DNA of the formed colonies was digested and run on a gel in order to ascertain 
the presence of the Renilla insert. A 50 µl mixture was made up of the reagents 
necessary for the digestion of the DNA. This consisted of 0.5µl of each enzyme Xho1 
and Xba1, 5µl each of buffer 10X and BSA, 1 microgram of DNA and the rest made 
up with H2O, table 2.10. The mixture was incubated for 15 minutes at 37ºC.   
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Reagent C1 C2 C3 C4 C5 Negative 
Enzyme 0.5 +0.5 0.5 +0.5 0.5 +0.5 0.5 +0.5 0.5 +0.5 0.5 +0.5 
DNA 5.9 µl 7.88 µl 5.78 µl 5.93 µl 7.04 µl 0.5 µl  
Buffer 10X 5µl 5µl 5µl 5µl 5µl 5µl 
BSA 5µl 5µl 5µl 5µl 5µl 5µl 
H2O 33µl 31µl 31µl 33µl 33µl 32µl 
Table 2.10 Reagent mix for digestion of colonised DNA and negative control. BSA 
was made from 100X BSA (Biolabs) by adding 10µl of BSA to 90µl of H2O.  The 
negative control used was pcDNA3. 
 
Ten micro litres of 6X loading dye was added to each sample and they were loaded 
onto a gel. The results are displayed in figure 2.10. All 5 colonies showed the Renilla 
insert present and there was none present in the negative control. 
Agarose Gel of Colonies containing Renilla luciferase insert
 
Figure 2.10 Agarose gel showing the 5 colonies with the Renilla insert. 
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Chapter 3 
Array Comparative Genomic Hybridization of stellate cells (From 
cultured primary pancreatic specimens and formalin fixed paraffin 
embedded laser capture microdissected tissue stroma)  
 
3.1 Introduction 
Cancer associated fibroblasts are activated stellate cells believed to be integral to 
the communication between tumours and stroma thereby promoting tumourigenesis. 
It has not yet been elucidated whether their tumour promoting ability is due to 
crosstalk via secretory products from the tumour itself or its stroma or via genetic 
changes to activated fibroblasts. Normal fibroblasts are involved in the fibrotic 
reaction leading to scarring but they are also involved in the desmoplastic reaction 
surrounding the tumour. 
 
 Stellate cells display a change in morphology in their activated state and maintain 
this phenotype for prolonged periods whilst being propagated in culture. It has 
therefore been suggested that genetic changes are responsible for this behaviour, 
(Orimo et al 1999). Allinen and colleagues performed Array CGH and single 
nucleotide polymorphism array (SNP) analysis of myofibroblasts from ductal breast 
carcinoma. The myofibroblasts and other non epithelial tumour associated cells were 
found to be normal (Allinen et al, 2004).  
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Further studies have suggested that there are no genetic changes in these cells 
(Walter K Omura et al 2008). This study, the only one to date performed on 
pancreatic ductal adenocarcinoma, used a SNP array platform (250k) on cultured 
cells. It was then proposed that the absence of changes found was due to the 
possibility of normal fibroblasts being cultivated, (Campbell et al., 2009). There is 
therefore a debate as to the presence or absence of somatic mutations in stellate 
cells and a need to ensure that results obtained are indeed from tumour associated 
fibroblasts.  
 
 
The following experiments aim to characterise these changes, using the array CGH 
platform,  on cultured tumour juxtaposed cells as well as formalin fixed paraffin 
embedded tissue. This platform is sufficient to detect any copy number alterations 
that may be present, (Kallioniemi, 2008). Copy number alterations have been 
implicated in cancer initiation and progression. The loss or gain of function seen at 
specific gene loci tends to affect cellular pathways that control cell behaviour such as 
proliferation and apoptosis. These mechanisms are used by transformed cells to 
alter cell proliferation, growth and metastasis, (Kallioniemi, 2008). 
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3.2 Cell culture 
 
Primary stellate cancer associated fibroblasts were cultured as described in 
Materials and Methods section 2.2.2. They were not immortalised. As previously 
explained these stellate cells originated from primary wedge resections obtained with 
consent via the histopathology department at the Hammersmith Hospital. Stellate 
fibroblast explants were labelled in order of their acquisition, e.g. PF1, was the first 
explant obtained, PF2, the second and PF 20 was the 20th sample. These cells were 
cultured from tissue within 5mm from the tumour margin. 
 
For the experiments described, cells were used at passage 3 or 4 to obtain a less 
differentiated group of cells and 70% confluence. Table 3.1 below, shows all 
samples obtained and those that were found to be suitable for array CGH and 
fluorescent in situ hybridisation. Suitability was determined by the histological 
appearance of pancreatic ductal adenocarcinomas and good cell expansion in 
culture. The cells that were used were found to be healthy and growing up to 
approximately passage 9 after which growth slowed dramatically.  
 
Of the primary sections obtained 8 primary samples were successfully explanted, 
primary fibroblasts (PF), PF3, PF7, PF8, PF9, PF16, PF18 and PF20. Of these PF3, 
8 and 9 were extremely slow growing and PF7, PF16, PF18 and PF20 were more 
successful in culture without immortalisation. Non stellate cells were excluded from 
further experiments; however, PF10 and PF11 were expanded and stored in liquid 
nitrogen as they showed good proliferation. Those cells with no growth or expansion 
were discarded, see Table 3.1. 
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Cell culture library from primary wedge resections 
 
NAME HISTOLOGY CELL TYPE 
PF1 Pancreatic Ductal Adenocarcinoma Fibroblasts 
PF2 Pancreatic Ductal Adenocarcinoma No growth 
PF3 Pancreatic Ductal Adenocarcinoma Fibroblasts 
PF4 Pancreatic Ductal Adenocarcinoma No growth 
PF5 Pancreatic Ductal Adenocarcinoma No growth 
PF6 Pancreatic Ductal Adenocarcinoma No growth 
PF7 Pancreatic Ductal Adenocarcinoma Fibroblasts 
PF8 Pancreatic Ductal Adenocarcinoma Fibroblasts 
PF9 Pancreatic Ductal Adenocarcinoma Fibroblasts 
PF10 Ampullary Carcinoma Epithelial cells 
PF11 Ampullary Carcinoma Epithelial cells 
PF12 Pancreatic Ductal Adenocarcinoma Infected , No growth 
PF13 Chronic Pancreatitis No growth 
PF14 Pancreatic Ductal Adenocarcinoma No growth 
PF15 Pancreatic Ductal Adenocarcinoma No growth 
PF16 Pancreatic Ductal Adenocarcinoma Fibroblasts 
PF17 Ampullary Carcinoma Epithelial cells 
PF18 Pancreatic Ductal Adenocarcinoma Fibroblasts 
PF19 Chronic Pancreatitis No growth 
PF20 Pancreatic Ductal Adenocarcinoma Fibroblasts 
   
Table 3.1 Primary explants cultured from pancreatic wedge resections, their histology 
and growth pattern. Primary fibroblasts PF3, PF7, PF8, PF9, PF16, PF18 and PF20 
were successfully explanted. 
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3.3 DNA yield and quality 
For the archived samples of FFPE tissue that were micro-dissected, DNA was 
extracted using Arcturus® Picopure DNA extraction kit KIT0103, Life Technologies, 
UK. Formalin Fixed Paraffin Embedded tissue is known to have poor DNA yields 
following micro-dissection and therefore only suitable samples with sufficient DNA, 
(600ngs), for array CGH were used from this archive. DNA concentrations were 
determined by nanodrop spectrophotometry from which only higher concentrations of 
DNA were used and a 260/280 reading of 1.7 and greater was considered good 
quality DNA, see table 3.2. Low DNA concentrations were not taken to the next step. 
These samples underwent the thiocyanate defragmentation step prior to Proteinase 
K dissolution which proved to acquire greater quantities of DNA on nanodrop 
spectrophotometry. 
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Archival FFPE specimens obtained for LCM Initial specimen blocks 
Sample No of LCM slides Stromal DNA Concentration 260/ 280 260/230 
A15 5 6 
16.8ng/µl 
13.7ng/µl 
1.24 
1.26 
0.64 
0.82 
C16 
1 
4 
6 
6 
3.6ng/µl 
12.9ngµl 
33.7ng/µl 
11.2ng/µl 
2.08 
1.48 
1.69 
1.49 
1.67 
0.58 
1.22 
0.22 
3J 4 4 
11.0ng/µl 
15.0ng/µl 
2.34 
1.39 
-0.70 
0.65 
C33 
1 
5 
6 
7.1ng/µl 
23.1ng/µl 
43.1ng/µl 
1.41 
1.95 
1.83 
0.58 
1.75 
1.93 
A17 
4 
4 
6 
10.8ng/µl 
6.1ng/µl 
36.1ng/µl 
1.47 
1.79 
1.54 
0.74 
2.56 
1.03 
A22 
4 
4 
6 
6 
6 
12.7ng/µl 
19.5ng/µl 
37.86ng/µl 
23.9ng/µl 
65.1ng/µl 
1.43 
1.30 
1.93 
1.86 
1.88 
0.78 
0.87 
1.33 
1.28 
1.87 
8F 4 5 
13.4ng/µl 
12.1ng/µl 
1.33 
1.74 
0.63 
2.03 
F17 2 49.7ng/µl 1.76 1.77 
10T 1 6 
8.7ng/µl 
33.8ng/µl 
1.98 
1.55 
0.73 
1.24 
EB4 4 6 
11.8ng/µl 
58.3ng/µl 
1.42 
1.93 
0.77 
1.18 
ROT4 3 12.9ng/µl 2.35 1.93 
EB1 3 14.2ng/µl 1.99 1.05 
3K 
1 
3 
6 
6 
7.5ng/µl 
45.6ng/µl 
36.18ng/µl 
25.0ng/µl 
1.47 
1.96 
1.87 
1.79 
0.51 
1.61 
0.72 
1.55 
76H 4 20.3ng/µl 1.19 0.64 
 
 
Table 3.2 This table shows the full list of all the archival samples obtained and the nanodrop 
spectrophotometry of the DNA of the microdissected stromal tissue.  
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3.3.1 Pico Green assay of DNA from LCM samples 
 
DNA from FFPE tissues may sometimes be contaminated with proteinaceous 
material and single stranded DNA which may give a falsely high reading of DNA 
concentration. Double stranded DNA is needed for arrayCGH and in order to 
establish the true concentration of dsDNA in these samples, Pico-green assay, 
specific for dsDNA, was performed. 
Pico Green, as discussed in the methodology, selectively binds dsDNA. It has an 
excitation maximum at 480 nm and an emission peak at 520 nm. When bound to 
dsDNA, fluorescence enhancement of Pico Green is greater than 1000 fold. The 
background interference that is seen with nanodrop spectrophotometry is eliminated 
as unbound dye does not fluorescence. Pico Green is 10,000-fold more sensitive 
than Ultra Violet (UV) absorbance methods and highly selective for dsDNA over 
single stranded (ss) DNA and RNA.  
In table 3.4 column 3 shows the true dsDNA concentration obtained via Pico Green 
assay. When expressed as a percentage, it was found that 10 to 20 percent of the 
DNA concentration obtained via nanodrop was true double stranded DNA.  
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Pico green quantification of double stranded DNA in LCM tissues 
 
 
 
Sample Nanodrop concentration Pico Green ds DNA concentration 
%of dsDNA Pico 
Greene vs. nanodrop 
A22 stroma 65.1ng/µl 6.6ng/µl 10.2% 
C33 stroma 141.08ng/µl 31.9ng/µl 22.6% 
EB4 stroma 49.14ng/µl 4.5ng/µl 9.2% 
3K  stroma 96.29ng/µl 9.8ng/µl 10.2% 
 
Table 3.3 This table shows that using Pico green assay, between 10 to >20% of the 
nanodrop concentration was dsDNA. These samples were freshly cut and the DNA 
extraction process was started on the same day.  
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3.4 Array CGH analysis results 
Array CGH as described in methodology was performed on primary cells and FFPE 
DNA.  The array CGH protocol has been described in chapter 2 section 2.2.6. The 
platform used for this study was constructed by the Breakthrough Microarray 
Laboratory and comprises a fluorescence in situ hybridization (FISH) mapped tiling 
path array set of 32,000 bacterial artificial chromosome (BAC) clones from Children’s 
Hospital Oakland Research Institute (http://bacpac.chori.org/) spaced at 
approximately 50 kb intervals throughout the genome. All 32,000 BAC clones were 
spotted onto single Corning GAPSII-coated glass slides (Corning). 
 
 
Six hundred nanograms of reference (normal DNA extracted from blood lymphocytes 
pooled from 24 females) and tumour DNA were labelled with Cy3- or Cy5-conjugated 
dCTP (Amersham Biosciences) using random primed BioPrime DNA labelling 
(Invitrogen Life Technologies) according to the manufacturer’s protocol, modified to 
incorporate 1.0 mmol/L Cy dye, 0.6 mmol/L dCTP, and 1.2 mmol/L dATP, dGTP, and 
dTTP. After labelling at 37ºC for 18 hours, non-incorporated reaction constituents 
were removed by MinElute Reaction Cleanup (Qiagen Ltd). Labelled reference and 
tumour DNA were co-precipitated with 100mg human Cot-1 DNA (Invitrogen Life 
Technologies) at 20ºC for 1-2 hours followed by re-suspension in 50mls hybridization 
buffer (50% deionized formamide, 10% w/v dextran sulphate, 2x SSC, 2% SDS, 20 
mg yeast tRNA). 
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Denaturation of labelled DNA was performed at 70°C for 15 minutes, followed by 
incubation at 37ºC for 30 minutes to allow blocking of repetitive sequences by 
human Cot-1 DNA. Denatured DNA samples were hybridized to the microarray at 
37ºC overnight. Following hybridization, slides were washed in 2x SSC/0.1% SDS for 
15 minutes at 45ºC to remove the coverslips, followed by 50% deionized 
formamide/2º SSC wash for 15 minutes at 45ºC. Finally, slides were washed in 2x 
SSC/ 1% SDS for 30 minutes at 45ºC and twice in 0.2x SSC for 15 minutes at room 
temperature. After post hybridization washing, slides were dried by centrifugation at 
2,000 rpm for 2 minutes. Following hybridization and washes, slides were scanned 
using an Axon 4000B scanner (Axon Instruments) and images were processed using 
Genepix Pro 5.1 image analysis software (Axon Instruments).  
 
 
Data were smoothed using a local polynomial adaptive weights smoothing (aws) 
procedure for regression problems with additive errors (Hupe et al, 2004). The red, 
green fluorescent intensities represented on the array were analysed using R 
statistic software to generate a genome plot for each sample. A change in intensities 
represented as an unequal Cy3:Cy5 ratio is interpreted as a loss or gain in the DNA 
of that sample at that locus on the genome. The aws log2 ratio of each BAC clone is 
plotted on the y-axis and according to its genomic location on the x-axis. BAC clones 
that are gained (aws log2 ratio > 0.12) or amplified (aws log2 ratio > 0.4) are 
represented as green dots, clones with no change in copy number (aws log2 ratio 
0.12 to -0.12) are represented by black dots and clones which are lost, (aws log2 
ratio < - 0.12) are represented as red dots. 
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3.4.1 Genome plots for primary cultured fibroblast samples 
Figure 3.1 below, displays the genome plot representation for the primary cancer 
associated fibroblasts of PF3, PF7, PF9 and PF16 respectively. The raw data shows 
a relatively clean signal with a low level of experimental noise, demonstrating the 
high quality of DNA. 
 
3.4.2 Genome plots for FFPE samples 
Laser capture micro-dissected tissue of FFPE stromal fibroblasts also showed 
consistent results when compared to the cultured primary cancer associated 
fibroblasts. The deletion seen on 19p was noted in the fibroblasts cultured from 
primary cells. This region examined, using the same R statistical software as for the 
cultured cells, showed expected normal variants as opposed to a new deletion, 
leading to the conclusion that these samples also show no copy number alterations 
in this region. 
 
In Figure 3.2, both Laser capture micro-dissected  samples show a flat line signal 
apart from the signal loss seen in chromosome 19p in sample C33 and the possible 
gain at chromosome 18 in sample 3KS. Notably the signal loss of chromosome 19 is 
not present in the latter.  
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   Genome plots for primary cultured fibroblasts PF3, PF7, PF9 and PF16 
                    Figure 3.1 All four primary stellate fibroblasts show a deletion at chromosome 19p13.2. 
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       Genome plot of Formalin Fixed Paraffin Embedded stroma C33 and 3KS 
 
 
Figure 3.2 a. Genome plot of FFPE stroma C33 and 3KS. This genome plot of C33 displays no significant 
genomic gains or losses seen apart from a signal in the short arm of chromosome 19 below the threshold of 
-0.4. b. Genome plot of FFPE stroma 3KS. This figure shows a signal at chromosome 18 but none at 
chromosome 19 as seen in the previous samples. 
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All amplifications and deletions seen were reviewed in a database of genomic 
variants, (Http://projects.tcag.ca/variation/). This database contains the full 
chromosome list, their associated genes and the variations that have been found 
and documented at their loci. This includes normal variants. An MTable was 
generated from the array CGH spot diagram and from this the values seen at 
chromosome 19p13.2, corresponding to that of the deletion seen on the genome 
plots, were reviewed. The ranges obtained from the MTable for the common possible 
deletions found, not shown, were entered into genetic profile software to review the 
gene profile within the locus chr19:8665706-8955628, see table 3.4. This data was 
used to generate the region overview as below, see figure 3.3. 
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Table3.4. Variation locus showing the variation types found at 19p13.2 and the genes 
known in this locus, chr19:8665706-8955628. 
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Figure 3.3 Region overview of Ch19p13.2. (www.ensembl.org). Above is the region overview of the 
short arm of chromosome 19p where a possible genomic deletion was noted in all four cultured 
primary stellate CAFs and FFPE tissue DNA. The genes highlighted, ACTL9 and OR2ZL were both 
common, normal variant, copy number alterations on the Http://projects.tcag.ca/variation/ 
database provided, suggesting that there are no true genomic changes in the above fibroblast cell 
lines.   
 
 
 
 
Region overview of CH19p13.2 
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3.5 Fluorescent in situ hybridisation (FISH) analysis of Copy Number 
alterations 
In order to validate that the deletions seen on Array CGH were indeed normal 
variants and to rule out the presence of homozygous deletions or a true loss at 
chromosome 19, the tissues from the cultured cells were subject to fluorescent in 
situ hybridisation, (FISH). Bacterial Artificial Chromosome clones RP11- 282G19, 
RP11- 367L15, RP11-680A23 were mapped based on the location of genomic 
deletions seen on chromosome 19p13.2. The clones were chosen from a library 
provided by the Institute of Cancer Research. The clones were hybridized and a 
fluorescent probe was added. The cells with these probes were mounted onto slides 
and viewed in metaphase. A normal lymphocyte cell was used as a control to show 
the presence of the clones. Both alleles were seen on fluorescent microscopy of 
these cells in metaphase, see figure 3.4 below. 
The same validation experiment was conducted on cultured primary fibroblasts PF3, 
PF7, PF9 and PF16 in order to confirm the findings of the array CGH on these 
fibroblasts. See figure 3.5. Clearly visible are the control probes in red as well as 
both alleles a chromosome 19p13.2 as both alleles are clearly demonstrated I 
suggests the absence of any homozygous deletions at this locus and therefore no 
true loss, see figure 3.5. 
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Figure 3.4 FISH analysis of Copy Number Variations in a normal lymphocyte cell as seen in 
metaphase showing presence of 19p13.2 BAC clones. This normal human metaphase 
spread shows the presence of both BAC clone alleles at 19p13.2 in an unaltered 
lymphocyte.  
 
 
 
 
 
 
 
 
 
 
 
BAC clones 
at 19p13.2 
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   FISH Probes 
a.  b.   
 
c.  d.  
 
 
 
Figure3.5 This figure shows the metaphase spread of a nucleus of a PF3, PF7, PF9 
and PF16 stellate CAFs. FISH probe analysis of the primary fibroblast shows the presence 
of both alleles at chromosome 19p13.2 labeled in green. The absence of homozygous 
deletions confirms no true loss at this locus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PF9 
PF3 PF7 
PF16 
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3.6 Discussion 
Cell cultures established from fresh tissue ensures that a pure sample is obtained 
and allows for control of the number of passages at which the cells are used. Cell 
lines were obtained from primary explants of PDA tissue. On average about 27 to 30 
cases of surgery for Pancreatic cancer are performed each year at the Hammersmith 
hospital Hepatobiliary unit. This figure includes Whipple and other pancreatic 
procedures. All samples were taken with informed consent from patients admitted to 
this department.  
 
As shown in the results, (Table 3.1), 8 cell lines were successfully explanted, 
Primary fibroblasts (PF), PF3, PF7, PF8, PF9, PF16, PF18 and PF20. Of these PF3, 
8 and 9 were extremely slow growing and PF7, PF16, PF18 and PF20 were more 
successful in culture without immortalisation. These were the samples out of 20 
initial specimens that produced a pure fibroblast culture, and did not become 
infected. In the initial stages of cell culture positive outgrowth was the limiting factor 
to the successful establishment of cell lines. Other limiting factors were the 
acquisition of the fresh samples and infection. Along with sterile conditions the 
growth media used was supplemented with antibiotics in order to discourage 
infection and the culture conditions were consistent throughout at 37°C and 5%CO2.  
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The primary fibroblast cultures were tested for mycoplasma infection with each 
passage. ‘No outgrowth’ was determined after a minimum of one week and 
maximum of 10 days. The cell lines that were established were shown by 
immunohistochemistry to be free of epithelial cells. This analysis on PDA fibroblasts 
closely mimics these studies with the use of fibroblasts cultured from whole tumour 
biopsies. For this reason laser capture microdissection was performed to obtain a 
pure population of tumour-juxtaposed fibroblasts.  
 
In this study we show that there are no homozygous copy number alterations seen in 
the either stromal cancer associated cultured fibroblasts or the FFPE stromal 
fibroblasts from PDA specimen.  The recurrent deletion seen at the 19p13.2 locus 
harboring the ACTL9 and OR2ZL genes were found to be normal variants. The 
arrayCGH findings were supported by FISH, which confirmed that there were no 
homozygous deletions at this gene locus. 
 
 
The evidence presented thus far has not been consistent and not all studies support 
the theory of somatic alterations in stellate cells. The scepticism arose where the 
quality of DNA was put into question as well as the type of fibroblast explanted, i.e., 
normal vs. tumour associated. For this reason it was necessary to use tumour 
juxtaposed, stellate cells for the experiments performed and ensure that sufficient 
and good quality DNA was obtained for array CGH studies and fluorescent in situ 
hybridisation. 
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 Previous evidence has accredited the enhanced ability of individual fibroblasts to 
promote tumourigenesis to somatic mutations found in them, (Patocs et al., 2007, 
Weber et al., 2006, 2007). These studies used paraffin embedded tissue for their 
experiments. FFPE is known to produce a limited number of cells and therefore a 
low yield of DNA. Poor quantity, as seen with FFPE tissue, will reduce the likelihood 
of acquiring good quality of DNA. Therefore, the finding of frequent somatic 
mutations reported in these studies, may have been technically flawed. As seen from 
the results in PDA stromal tissue, (Table 3.4) only up to 20% of the DNA yield 
measured via nanodrop is indeed dsDNA. In order to eliminate doubt as to the 
validity of results obtained only dsDNA, as confirmed by Pico Green assay, was 
used for arrayCGH of the FFPE samples obtained.  
 
 
In 2004, Allinen and colleagues found that non-epithelial tumour associated cells 
showed no copy number variations, (Allinen et al, 2004). A further study, 4 years 
later, using SNP arrays on cultured stellate CAFs from PDA resection specimens 
also showed similar findings with no genomic changes in the stromal tissue, (Omura 
et al June, 2008). Of Importance, the latter study is unclear as to whether the 
fibroblasts used in were extracted from the immediate tumour juxtaposed region. 
Fibroblasts that are furthest from the tumour may be normal, and this has put the 
validity of the findings into question. All stromal tissue used in this study of PDA 
stromal cells were tumour juxtaposed to within 5mm from the tumour margin. 
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In keeping with recent publications in which no evidence was found for DNA 
aneuploidy, somatic genetic alterations or CNA in a set of 57 stromal cell fractions 
used, (Corver et al, 2011), this study using arrayCGH has also found a lack of CNA 
in the stromal tissue of pancreatic ductal adenocarcinoma. Corver and colleagues 
used flow cytometry and 6K SNP arrays to study DNA aneuploidy, percentage of S 
phase (synthesis phase of DNA) loss of heterozygosity and CNA in cervical cancer 
from both stromal cell fractions and FFPE samples. They showed that the stromal 
cell fractions from this cancer group was DNA diploid and was found to have the 
same genotype as those of the patient-matched normal tissue and are therefore 
genetically stable. The findings in this study using PDA are in agreement with the 
conclusion that these cells are genetically stable. 
 
 
The presence of tumour stimulates a change in morphology of the stellate cells 
through crosstalk between the tumour cells and the stroma. This communication 
results in an activated phenotype of the stellate cells and they lose their quiescent 
elliptical shape. The smooth muscle actin and vimentin fibres become elongated and 
more prominent and there is increased extracellular matrix production as seen by the 
increased tenascin C, collagen I, EDA fibronectin and SPARC (specific protein acidic 
rich in cysteine). 
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This study has found no homozygous genetic changes in these activated stellate 
cells, It therefore puts even more emphasis on the theories that suggest the cytokine 
mediated activation and signalling pathways, upregulated during cancer progression 
and metastases, play a significant role in the tumour growth and development that 
occurs in the presence of stellate cells, (Olive/Tuveson et al, 2009). These findings 
have not ruled out the presence of heterogeneous or epigenetic changes in either 
group of fibroblasts and further investigations are warranted into these profiles in 
order to gain more insight into the genetic changes undergone in this cell group.  
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                                    Chapter 4 
Pancreatic cancer cells and chemoresistance 
4.1  Introduction 
4.1.1 Chemoresistance in pancreatic ductal adenocarcinoma (PDA) is a limiting 
factor to disease management 
Chemoresistance in pancreatic ductal adenocarcinoma has been a limiting factor in 
disease management, resulting in the poor prognosis of 6.4 months median survival, 
despite multiple clinical trials involving combination drug therapy. Many forms of 
PDAC develop resistance soon after a fleeting initial response to Gemcitabine. 
However, Gemcitabine remains the gold standard of adjuvant and neo-adjuvant 
therapy in the absence of more efficient therapies.  It is a cytotoxic pyrimidine 
deoxynucleoside analogue with fluorine for hydrogen atom substitutions on the 
number 2 carbon atom of deoxycytidine.  
 
 
4.1.2 Chemoresistance is multifactorial 
This chemoresistance is multifactorial. It has been attributed to several factors, 
including the paucity of a suitable screening tool or biomarkers. Because of this, 
patients tend to present at a locally advanced stage of disease and tumours may be 
metastatic and resistant to the chemotherapeutic regimes used at the time of 
presentation. The key factors that play a role in resistance, at a molecular level, 
include cancer cell mutations, poor drug delivery and activated tumour-stromal cell 
interactions and signalling pathways within the stroma.  
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4.1.2.1 Cancer cell mutations, poor drug delivery, anti apoptotic factors, 
activated tumour-stromal cell interactions and signalling pathways.  
 
4.1.2.1.1 Cancer cell mutations 
Cancer cell mutations found in pancreatic cancer cells include K-RAS proto-
oncogene substitutions, AKT2 19q amplifications, Loss of heterozygosity at 9p, 13q, 
17p and 18q gene loci, homozygous deletions at p16 and DPC/Smad4 and p53 
mutations, (http://pathology.jhu.edu/pancreas/geneticsweb/Profiles). Pancreatic 
cancer is characterized by a unique molecular fingerprint with activating point 
mutations at codon 12 of the K-RAS gene found in more than 90 to 95% of cases, 
(Moore et al, 2001). The tumour suppressor gene p53 has been found to be 
inactivated in 60% and DPC4/SMAD4 has been reported as altered in 50% of 
xenografted cancers, (Hahn et al, 1996). Although the mechanism of action is 
unclear, these factors undoubtedly play a role in tumour development and are also 
believed to contribute towards chemoresistance. 
 
In a recent paper by Biankin and colleagues, they defined 16 significantly mutated 
genes, confirmed the known significant mutations seen in pancreatic cancer (KRAS, 
TP53, CDKN2A, SMAD4, MLL3, TGFBR2, ARID1A and SF3B1), uncovered novel 
mutated genes including additional genes involved in chromatin modification such as 
(EPC1), enhancer of polycomb homologue1 involved in histone acetylation and 
(ARID2), AT rich interactive domain containing protein 2, needed in chromatin 
modification as well as  genes involved in DNA damage repair (ATM)-ataxia 
telangiectasia mutated.(Biankin et al., 2012). 
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They identified novel genes involved in other mechanisms (ZIM2, MAP2K4, NALCN, 
SLC16A4 and MAGEA6). Zinc finger imprinted 2 (ZIM2) is involved in regulation of 
transcription, Dual specificity mitogen activated protein kinase 4 (MAP2K4) is a toll 
like receptor signalling pathway, Sodium leak channel non-selective protein (NALCN) 
has a specific role in sodium channel activity, Solute carrier family 16 member 4 
(SLC16A4) is a monocarboxylate transporter and Melanoma-assisted antigen 
6(MAGEA6) is involved in protein binding. 
 
Axon guidance pathway genes, recently implicated in cancer cell growth, survival, 
invasion and angiogenesis, (Mehlen et al., 2011), are regulators of neuronal 
migration and positioning during embryonic development. Biankin and his group also 
identified recurrent mutations and copy number variations in these genes in their 
cohort of samples. They found CNV losses in ROBO1 and SLIT2 in 5% of their 
patients suggesting aberrant signalling in this pathway as a common feature of 
PDAC, (Biankin et al, .2012). 
 
4.1.2.1.2 Drug delivery: Gemcitabine transport, uptake and metabolism 
4.1.2.1.2.1 Gemcitabine transport and uptake  
Genetic and epigenetic alterations in the gene products involved in Gemcitabine 
transport and metabolism have been shown to affect resistance to chemotherapy in 
pancreatic cancer, (Giovannetti et al, 2006). The human equilibrative nucleoside 
transporter-1 (hENT-1) transports Gemcitabine into cells, (Mackey et al, 1998). 
Those cells with low levels or lacking hENT-1 are highly resistant to Gemcitabine, 
(Spratlin et al, 2004; Mackey et al, 1998). The study, led by Mackey, suggested that 
passive uptake of Gemcitabine into cells was a minor component of Gemcitabine 
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uptake and in some cell lines used, the lack of mediated uptake, via hENT-1, 
conferred resistance to the anti proliferative activity of Gemcitabine by greater than 
1000 fold.  
 
4.1.2.1.2.2 Gemcitabine Metabolism 
The changes in the levels of gene products associated with Gemcitabine metabolism 
also play a significant role in resistance.  Gemcitabine, 2’2’-Difluoro-2’deoxycytidine, 
must first be phosphorylated, to the active diphosphates and triphosphates which 
inhibit ribonucleotide reductase (RR). This inhibition reduces the deoxynucleoside 
triphosphate production that is required for DNA repair and synthesis, figure 4.1. The 
active metabolite also inhibits DNA polymerase which catalyses DNA synthesis. 
 
Deoxycytidine kinase (dCK) is a rate limiting enzyme in the biotransformation of 
nucleoside analogues. It activates Gemcitabine and an increase in its activity has 
been shown to improve the efficacy of Gemcitabine, (Blackstock et al, 2001; Kroep 
et al, 2002). This effect was best seen in pancreatic cancer cell lines when used in 
combination with an inhibitor of Deoxycytidine deaminase (CDA). Deoxycytidine 
deaminase, catalyses and deaminates Gemcitabine to its inactive metabolite, figure 
4.1. Increased levels of this enzyme would confer a degree of resistance to the cells 
involved, (Neff et al, 1996). 
 
Duxbury and colleagues used small interfering RNA (siRNA) to show that the 
suppression of the ribonucleoside reductase M2 (RRM2) subunits enhanced 
Gemcitabine induced cytotoxicity in vitro. Gemcitabine together with RRM2 inhibition 
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was seen to significantly reduce tumour growth, increase tumour apoptosis and 
inhibit metastases in mouse xenograft models, (Duxbury et al, 2004). 
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Gemcitabine metabolism, activation and excretion 
Figure 4.1 Human equilibrative nucleoside transporter-1 (hENT-1) transports Gemcitabine 
across the cell membrane into the cytoplasm. Deoxycytidine kinase (dCK) catalyses the 
phosphorylation of Gemcitabine (2’2’-Difluoro-2’deoxycytidine) to difluorodeoxycytidine 
monophosphate, (dFdCMP). Nucleoside kinases (NK) convert the monophosphate form to 
difluorodeoxycytidine 5'diphosphate (dFdCDP), and difluorodeoxycytidine 5'triphosphate 
(dFdCTP). Ribonucleoside reductase (RR) reduces Cytidine Diphosphate (CDP) to 
deoxycytidine Triphosphate (dCTP). The enzyme dCMP deaminase (dCMPDA) converts the 
monophosphate to an inactive metabolite, difluorodeoxyuridine monophosphate (dFdUMP), 
which is excreted. Cytoplasmic 5' nucleotidase (C5’N) reverses the action of dCK.  
Gemcitabine is deactivated by Deoxycytidine deaminase (CDA). 
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4.1.2.1.3 Acquired chemoresistance due to downregulation of proapoptotic 
genes and upregulation of antiapoptotic genes  
 
An alteration in survival pathways is believed to play a significant role in 
chemoresistance as discussed by Kim and Gallick, (Kim et al, 2008). The abnormal 
expression of genes associated with apoptosis and cell survival has been implicated 
in chemoresistance, specifically S100A4. This S100 family gene enhances 
chemoresistance in pancreatic cancer by suppression of apoptosis, (Mahon et al., 
2007). 
 
Up-regulation of S100A4 is suspected to increase resistance to Gemcitabine by 
modulating BNIP3, a hypoxia induced pro-apoptotic gene in the Bcl-2 family of 
apoptosis-regulating molecules. BNIP3 activity normally induces a necrotic like cell 
death. It’s silencing through the upregulation of S100A4 results in chemoresistance 
and correlates with poor survival in patients with pancreatic cancer. (Mahon et al., 
2007; Erkan et al., 2005). 
 
Heat shock protein 27(HSP27), which is responsible for mediating the cells response 
to injury, was found to be expressed to a greater degree in resistant pancreatic cell 
lines.  It acts as an anti-apoptotic factor and thereby confers a relative resistance to 
cells, (Mori-Iwamoto et al., 2008). 
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4.1.2.1.4 Activated tumour-stromal cell interactions and signalling pathways 
Upregulation of the PI3 kinase/ AKT pathway has been shown in pancreatic cancers 
and this has been implicated in Gemcitabine resistance, (Asano et al, 2004). PI3 
kinase phosphorylates the serine/threonine kinase PKB/AKT which then regulates 
the transcription of genes involved in cell survival within the nucleus, (Ng SS et al., 
2000). It has been reported that PKB/AKT can phosphorylate and inactivate BAD, a 
proapoptotic member of the Bcl-2 family, (Dragovich et al., 1998). This suppression 
of apoptosis reduces the sensitivity of cells to the apoptotic effects of Gemcitabine. 
 
Increased SRC kinase activity has been linked with inherent Gemcitabine resistance 
in pancreatic adenocarcinoma cells. Duxbury and colleagues used small interfering 
RNA to inhibit SRC tyrosine kinase. They found that the inhibition of C-SRC led to an 
increase Gemcitabine cytotoxicity via caspase mediated apoptosis, (Duxbury et al, 
2004).  This same group has linked the activation of focal adhesion kinase to 
Gemcitabine resistance in pancreatic cancer.   
 
Increased HMGA1 induces a stem cell like state. It is activated by the MAPK/ERK 
pathway in a dose dependent fashion, (Zhao et al., 2006). In a study by Liau and 
colleagues they showed that a decrease in the HMGA1 expression in xenograft 
mouse models resulted in an increase in apoptosis and promoted sensitivity to 
Gemcitabine in vitro, (Liau et al., 2006). Shah and colleagues have implicated C-
MET as a factor that may contribute to Gemcitabine resistance. They found that C-
MET, a tyrosine kinase believed to have a role in EMT transition, was upregulated in 
cells resistant to Gemcitabine, (Shah et al, .2007). 
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4.2 Compound library High throughput screening (HTS) of PDA cell lines   
It seems reasonable to suggest that one approach to improving the PDAC response 
to chemotherapy is to take a combination strategy, as proven in other cancer types. 
As a first step towards identifying evidence based combination approaches for 
PDAC, I generated drug sensitivity profiles for a panel of commonly-used PDAC 
tumour cell models. These profiles were generated using a high-throughput 
screening platform in which cells can be exposed to a large panel of 
chemotherapeutics and targeted agents.  
 
4.2.1 Ashworth plate 10 compound library  
The Ashworth plate 10 compound library consists of 80 compounds. These include 
approved agents currently in clinical use as well as agents in early and late stages of 
development in the treatment of pancreatic cancer, see table 4.1.For the Ashworth 
plate 10 compound library drug screen, shown in figure 4.3, cells were cultured as 
previously described in order to obtain a greater than 70% confluent monolayer in a 
T75 flask, (A). These cells were trypsinised and re-suspended in fresh media. A 10µl 
sample of cell suspension was mixed with 10µl of tryptan blue staining dye and live 
cell numbers estimated using the Countess® Automated Cell Counter, Invitrogen, 
and (B). The number of live cells only, was used to calculate the volume of cell 
suspension required to give 1000 cells per well per 384 well plate.  On average 
about 40,000 cells were necessary for each 384 well plate or 1.2x106 for triplicate 
plates of each sample at a volume of 25µl per well. The cells were plated using the 
Multidrop Combi Reagent Dispenser, Thermo Scientific, (C). These plates were 
incubated for 24 hours at 37ºC and 5% humidified CO2.  The cells were then 
exposed to the Plate 10 compound library by serial dilutions of a previously prepared 
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plate of chemotherapeutic compounds. Each drug was administered in volumes that 
would represent four concentrations, 1nM, 10nM, 100nM and 1000nM respectively 
and these were administered using the Hamilton automated liquid handler robot, (D). 
Following application of the drug library to each cell line, the triplicate samples were 
again incubated for 72 hours at 37ºC and 5% humidified CO2, (E). On day 4 the 
plates were read for cell viability using Cell titre Glo bioluminescent marker as 
described below, (F). 
 
4.2.1.1 Map of the sample layout for HTS 
 
Figure 4.2 below shows the layout of the 384 well plates into which the compounds 
were administered.  The wells in column 2 labelled N were negative controls which 
contained DMSO only and the wells labelled P were the positive controls in which 
cells were treated with cytotoxic puromycin. Each quadrant of wells, for example, A3, 
B3, A4 and B4 was filled with one of four concentrations, 1nM, 10nM, 100nM and 
1000nM respectively, of the compound being administered to the cells.  All wells 
contained an equal volume at the end of drug administration. 
 
Figure4.2 Heat map of the 384 well High Throughput Screen. This heat map shows the 
plate 10 compound configuration of all 384 wells. The wells marked N (A2 to F2, K2 to P2, 
A23 to F23 and K23 to P23) are negative controls containing only DMSO. The cells marked 
P (2G to 2J and 23G to 23J) are positive controls of Puromycin. All other wells contained test 
samples to be treated. 
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Ashworth plate 10 compound library of agents 
 
 
S)(1000nM)-+- camptothecin (TOPOIpoison) Lapatinib (1000nM)(Her2i) 
17-AAG (HSP90i) Lestaurtinib (1mM)-(JAK2/FLT3/TrkAi) 
2-methoxyestradiol (anti-angiogenesis) MDV-3100 (CRPCi) 
4-OH-tamoxifen (Eri) MK-1175 (WEE1i) 
5-FU (anti-metabolite) MK-2512 (PARPi) 
6-thioguanine (anti-metabolite) MK-4827 (PARPi) 
ABT-737 (Bcl2i) Nilotinib (BCR-ABLi) 
AG-14699 (PfizerPARPi) Nutlin3 (MDM2i) 
AZ4547 (FGFRi) Olaparib (PARP1/2i) 
BEZ-235 (PI3K/mTORi) OL-PIX-A17A (LeadTh, PARPi) 
BI-2536 (PLKi) OL-PIX-F3-B (LeadTh, PARPi) 
BIBW2992 (EGFR/HER2i) Paclitaxel (microtubule poison) 
Bleomycinsulfate (DNA breaks) PBS-1086 (NfkBi) 
BSI-201 (SanofiPARPi) PBS-1169 (NfkBi) 
Canertinib (pan-ErbBi) PD-0332991 (CDK4/6i) 
Carboplatin (DNA alkylation) PD173074 (FGFRi) 
Celecoxib (COX2i) PD-184352 (Mbeki) 
CT241533 (CHK2i) PF-00299804 (pan-ErbBi) 
Curcumin (NSAID) PF-00477736 (CHK1i) 
CyclophosphamideH20 (DNAalkylation) PF-02341066 (MET/ALKi) 
149Indomethacin (BCR-ABL/Srci) PF-03758309 (PAKi) 
Decitabine (DNAmeth) PF-03814735 (Aurora) 
DMX50-1281 (IKKEi) PF-04691502 (PI3K/mTORi) 
DMX501331-2 (IKKEi) PF-04929113 (HSP90i) 
DMX50-1338-2 (IKKEi) PF-332991 (CDK4/6i) 
DoxorubicinHCl (DNAintercalator) Piroxicam (NSAID) 
EB-47 (25mM)(1000nM) PARPi PLX-4720 (Braid) 
Erlotinib (EGFRi) PRIMA1 (mut-p53activator) 
Etoposide (TOPOIIi) Resveratrol (NSAID) 
Everolimus (mTORi) Salinomycin (microtubule poison) 
Flavopiridol (CDKi) Sapacitabine (CNDAC) 
GDC-0449 (SMOi) SAR-20106 (CHK1, Sutton) 
Gefitinib (EGFRi) Sorafenib (inhibits RAF, PDGF, VEGF1&2) 
Gemcitabine HCL (DNArepinhib) Sunitinib (VEGFR1-3i, PDGFRi, Kiti, CSF1Ri) 
GSK1904529A (IGFRi) Sutent (Pfizer=sunitinib) 
GSK2194069A (Faso) Temozolomide (DNAalkylation) 
GSK-2334470A (PDKi) Vinorelbine (anti-mitotic) 
Imatinibmesylate (Bcr-ABLi) Voronostat (classI&IIHDACi) 
Indomethacin (NSAID) XAV-939 (TNKSi/Wnti) 
KU0057788 (DNA-Pki)  
KU-59652 (ATMi)  
 
 
Table 4.1 Ashworth plate 10 compound library. This library consists of currently used 
chemotherapeutic agents such as Gemcitabine, 5-FU, Doxorubicin, and Oxaliplatin, agents 
in late stages of development such as Paclitaxel, pathway inhibitors such as GDC-0449, 
Pi3K/mTOR inhibitors and other compounds such as Non steroidal anti-inflammatory drugs 
which have been shown to have an anti-cancer effect. 
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Figure 4.3 Schematic of High throughput screening  
 
 
 
 
+
A. Cell expanded to 70% confluence
B. Live cells counted  with 10 µl tryptan blue on 
Countess  automated cell counter
C. Cells plated 1x103 per well on a 384 well plate and 
incubated for 24 hours at 37ºC and 5% humidified CO2.
D. Drugs administered in volumes of 1nM, 10nM, 
100nM and 1000nM using the Hamilton automated 
liquid handler robot
E. Negative (N) and positive (P) controls were plated 
in column 2 and 23 and column 1 and 24 were left 
empty. Treated cells were incubated for a further 72 
hours at 37ºC and 5% humidified CO2.
F. Bioluminescent  CTG was added and cell survival 
readings taken on plate reader
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4.2.1.2 Cell titre Glo (CTG) survival readings 
 
The liquid from each plate was removed by tipping and the plates were spun to 
dryness for a few seconds via centrifuge at 1000rpm. Cell titre Glo solution was 
made in a ratio of 1 in 4 with PBS. This bioluminescent marker quantifies the ATP in 
cells, which is a representative of those that are metabolically active.  Using the 
Multidrop Combi Reagent Dispenser, 25µl of CTG solution was applied to each well. 
This was incubated in darkness on a rotating platform for ten minutes before being 
read on a plate reader at 550nM wavelength. The data collected was collated and 
analysed using R’ and Cell HTS software programming in order to identify 
compounds to which the pancreatic cancer cell lines were sensitive.  Graph pad 
Prism (version 5.0) was used to carry out statistical analysis. Cell survival was 
represented as a fraction of 1 in which 1 was equivalent to no cell death and 0.5 is 
the equivalent of 50 percent cell death. 
 
 
4.2.6 Cell titration for PDA cell lines 
Prior to screening the PDA cell lines, an initial simple cell titration was performed in 
order to ascertain the growth pattern of the pancreatic cancer cell lines. On day one 
of the experiment, cells were plated in a reducing number from 1x105 to 7.8x10-2 per 
well in 96 well plates and allowed to expand. Cell titre Glo cell viability readings were 
taken at Day 6 and it was determined that 1x103 cells per well were the suitable cell 
count to be used for further experiments. These cells expanded suitably into a 
monolayer without overcrowding or cell death, in the time period needed for the 
duration of the experiment. 
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In figure 4.4, cells plated at 1K per well were found to be in the linear phase of the 
curve. In order to avoid plateau of the CTG signal, it was necessary to do 
experiments with cell numbers that lie in the linear range of the curve in which the 
cells are in the growth phase.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure4.4 Simple cell titration of epithelial cell lines. The X axis shows the number of cells, 
plated on day one, in thousands. This figure shows the duplication rate of the pancreatic 
cancer cell lines used. 1x103 cells per well or 1K showed a suitable doubling time for these 
cell lines and was used as the plating number of choice for further experiments. 
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4.2.3 Baseline Gemcitabine resistance curves for PDA cell lines 
 
Once the cell count to be used, 1x103 cells per well, had been established, it was 
then necessary to review the response of these PDA cell lines to Gemcitabine. Prior 
to high throughput screening, a simple experiment to establish the response to 
Gemcitabine was performed. 
 
4.2.3.1 Gemcitabine resistance after 72 hours of treatment 
Pancreatic ductal adenocarcinoma cell lines PANC-1 and BxPc3 were plated on 96 
well plates. Cells were plated at 1x103, 2x103, 3x103 and 4x103 cells per well for 
comparison of the patterns of sensitivity or resistance based on cell number, see 
figure 4.5. The cells were allowed to adhere for 24 hours post plating. They were fed 
with differing doses of Gemcitabine ranging from 1x10-5M (10µM) to 1x10-11M 
(0.01nM) and a 0M control was included. Seventy two hours post treatment with 
Gemcitabine, Cell titre Glo readings were done and the data analysed for cell 
survival. Initial resistance appeared higher in the cell lines that were plated in larger 
numbers on day one, (2K to 4K). This may be due to cell load. 
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Figure 4.5 Gemcitabine survival curves 72 hours. On day one of this experiment, cells 
were plated at 1x103(1K), 2x103 (2K), 3x103 (3K), and 4x103(4K). The Gemcitabine 
concentrations used are represented on the X axis. These values represent times 10 
increments of Gemcitabine from 0.01nM (1x10-11) to 10µM (1x10-5). 
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4.2.3.2 Gemcitabine resistance after 6 days of treatment 
 
The same experiment was repeated; however, on day 4 the media was changed to 
Gemcitabine free media and CTG readings done on day 6. Figure 4.5 shows the 
resistance curves after this length of exposure. The survival curves obtained after 6 
days were more pronounced than after 72 hours of exposure to Gemcitabine.  Again, 
the greatest sensitivity was noted in the 1K (1x103) cells per well group at 1x10-9M 
(1nM) and 1x10 -8 (10nM) concentration of Gemcitabine. There was only 50% cell 
survival in this group compared to almost no response in the 2K to 4K group at this 
low dose. At 10nM (1x10-8) there was only 40% cell survival in the 1K group.  
 
Figure 4.5 shows sensitivity to Gemcitabine to occur between 1x10-8M (10nM) and 
1x10-9M (1nM) of Gemcitabine. All cell lines displayed a survival fraction less than 
0.20 at (1x10-7M) 100nM and (1x10-6M) 1000nM. BxPc3 appeared more sensitive 
when compared to PANC-1. Asorza and colleagues performed similar experiments 
in which they looked at the resistance to Gemcitabine with and without CHk point 
silencing in the pancreatic cell lines. In their CHk point silenced cells there was an 
increase in sensitivity to Gemcitabine as seen by a shift in the curve. In their non 
silenced group however, both BxPc3 and MiaPaCa2 PDA cell lines showed 
sensitivity at log-8 (10nM) of Gemcitabine, (Asorza et al, 2009).   
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Figure 4.6 Gemcitabine survival curves day 6. The X axis shows the log values of 
Gemcitabine concentration. The value, log-9, represents 1x10-9(1nM) and log-6 represent 
1x10-6(1000nM) concentrations of Gemcitabine. Each curve is representative of a triplicate 
experiment. Cell number was assessed and data normalised to the negative control and 
results plotted. 
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4.2.4 HTS Screen results of all PDA models 
Having established the response of the cell lines to one of the plate 10 compounds, 
the screen was then expanded to profile all the PDA cell lines performed and include 
the full Ashworth library of chemotherapeutic agents. The results obtained were 
represented as heat maps, bar graphs and histograms which confirmed quality 
control of the HTS screens. Below are the results of the screens for each pancreatic 
cell line 
 
For quality control, the z prime factor is an indication of the signal to noise ratio of the 
CTG reading (assay output quantification) between the untreated cells (DMSO only, 
0.2% volume to volume ratio (v/v)) and the cell death control. The z prime factor for 
all screens ranged form 0.5 to 0.78. It is essentially the ratio between the blue dots 
(positive control) and red dots as seen on the histograms). A screen with a value of 
>0.5 or higher was considered an excellent quality. The spearman rank correlation is 
another indication of the quality control of the screen. A value of greater than 0.5 is 
considered an acceptable screen. See appendix 1. 
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4.2.4.1 Cell Survival HTS results for AsPC-1 
 A.
ASPC	  QC:OK
 
B.
ASPC
ASPC
ASPC
 
Figure4.7. Quality control for AsPC-1. A) AsPC-1 cell line screen results plate configuration 
and histograms with good quality control and output of the screen for this cell line. In b, the 
bar graphs have a normal distribution for positive and negative controls indicating a 
successful screen throughout replicates 1, 2 and 3.  
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Figure4.8. This survival curve shows the screening results for compounds to which there 
was some sensitivity. The X axis shows the drug concentration used as a log value, where (-
6) represents 1x10-6 or the equivalent of 1000nM, -7 (100nM), -8 (10nM) and -9 (1nM) 
respectively. Compounds that produced a cell death of 50% (survival ≤ 0.5) or more were 
considered to produce significant cell death.   
 
 
 
This survival curve shows a survival fraction of less than 0.5 in AsPC-1 cells in 
response to Paclitaxel and Bi-2536 (PLK) inhibitor at (-8)10nM concentrations of 
either drug. At (-7) 100nM, compounds that induced cell survival fraction of 0.7 or 
less includes Vinorelbine (anti-mitotic), BEZ-235 (PI3K/mTOR inhibitor), and 17 AAG 
(HSP90 inhibitor). Of note, there was no response to the smoothened inhibitor GDC-
0449 in this epithelial cell line and the response to Gemcitabine was at the higher 
100nM concentration where the survival fraction was still a high 0.7. 
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4.2.4.2 Cell Survival HTS results for HPAC 
A.  
B.  
 
Figure 4.9 Quality control for HPAC. This z prime factor for this screen is 0.75 and 
spearment rank is within 0.86 to 0.9, indicating a successful screen. 
HPAC%QC:OK%
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Figure4.10 Cell Survival High Throughput Screen results for HPAC. This survival curve 
shows the screening results for compounds to which there was some sensitivity including 
those that produced a cell death of 50% or more on HPAC cells. Compounds that produced 
a cell death of 50% (survival ≤ 0.5) or more were considered as having a significant effect 
 
 
 
HPAC cells have shown significant sensitivity to Paclitaxel and HSP90 inhibitor 
compound BEZ-235 at 100nM of either compound with a survival fraction of 0.5. 
There was a limited response to Gemcitabine with a survival fraction of 0.8 at the 
highest concentration of 1000nM and no response to the smoothened inhibitor GDC-
0449, (result not plotted). 
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4.2.4.3 Cell Survival HTS results for Hs776T 
 
A.
HS776T	  QC
 
B.
HS776T	  QC HS776T	  QC
HS776T	  QC
 
Figure 4.11 Quality control heat map, bar graph and box plot for Hs776T. A shows Hs776T 
cell line screen results plate configuration and histograms with quality control and output of 
the screen for this cell line. In B the bar graphs distribution accounts for errors in plating 
which were normalized during data analysis. 
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Figure4.12 Cell Survival HTS results for Hs776T.  
 
 
 
Hs776T appears to be resistant to most of the common drugs including Gemcitabine 
and Paclitaxel. A survival fraction of < 0.5 is seen at 100nM of Flavopiridol (a cyclin 
dependent kinase inhibitor) and HSP90 inhibitors. In a similar fashion to that of the 
other cell lines thus far, Hs776T showed no response to GDC-0449 smoothened 
inhibitor.  
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4.2.4.4 Cell Survival HTS results for PANC-1 
 
A.
PANC-­‐1	  QC:	  OK
 
B.
PANC-­‐1	  QC:	  OK PANC-­‐1	  QC:	  OK
PANC-­‐1	  QC:	  OK
 
Figure 4.13 Quality control heat map, bar graph and box plot for PANC-1. Figure A shows 
PANC-1 cell line screen results plate configuration and histograms with good quality control 
and output of the screen for this cell line. In B, the bar graphs have a normal distribution for 
positive and negative controls indicating a successful screen throughout replicates 1, 2 and 
3.  
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Figure4.14 Cell Survival HTS results for PANC-1.  
 
 
 
PANC-1 cells displayed a marked response to Paclitaxel with a survival fraction of 
only 0.25 at 10nM concentrations of the drug. Treatment with 100nM of Gemcitabine, 
Vinorelbine and Doxorubicin produced a survival fraction of 0.5 in these cells. Of 
note there is no response to the smoothened inhibitor GDC-0449 in this PDA cell line 
as demonstrated in the survival curve, with 100 percent survival in cells that were 
exposed to this compound at all concentrations of the drug used. The response to 
BEZ-235 (PI3K/mTOR inhibitor), 17 AAG (HSP90 inhibitor) and Flavopiridol was 
moderate with a cell survival of 0.7 at 100nM concentrations and little or no response 
was seen at 10nM concentrations of these compounds. 
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4.2.4.5 Cell Survival HTS results for PL5 
A.
QC : PL5 OK
 
B.
PL5 PL5 PL5
 
 
Figure4.15 Quality control heat map, bar graph and box plot for PL5. Figure A shows PL5 
cell line screen results plate configuration and histograms with good quality control and 
output of the screen for this cell line. In B, the bar graphs have a normal distribution for 
positive and negative controls indicating a successful screen throughout replicates 1, 2 and 
3.  
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Figure4.16 Cell Survival HTS results for PL5.  
 
PL5 cells responded significantly to Paclitaxel with a mere 0.25 survival after 
exposure to the 10nM. There was some sensitivity seen with (-7M) 100nM 
concentrations of Vinorelbine, 17 AAG (HSP90 inhibitor) in which cell survival was ≤ 
0.5. A moderate response was seen to the DNA intercalator, Doxorubicin, at this 
same concentration of 100nM. There was no response to Gemcitabine at lower 
concentrations and there was no response to GDC-0449 smoothened inhibitor, (not 
shown). 
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4.2.4.6 Cell Survival HTS results for PL45 
 A. 
QC:PL45 OK
 
B.
PL45 PL45 PL45
 
 
Figure4.17 Quality control heat map, bar graph and box plot for PL45. Figure a shows PL45 
cell line screen results plate configuration and histograms with good quality control and 
output of the screen for this cell line. In b, the bar graphs have a normal distribution for 
positive and negative controls indicating a successful screen throughout replicates 1, 2 and 
3.  
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Figure4.18 Cell Survival HTS results for PL45.  
 
 
Similar to what was seen in previous cell lines, PL45 showed a significant response 
to Paclitaxel with only a 0.25 survival fraction following treatment with as low as 
10nM concentrations of the drug.  There was also a significant cell death seen at 
100nM concentrations of Vinorelbine, 17 AAG (HSP90 inhibitor) and BEZ-235 
PI3K/mTOR inhibitor with a cell survival < 0.5.  Flavopiridol and Doxorubicin had a 
moderate response in this PDA cell line with survival as high as 0.7. There was 
however, a good response to Gemcitabine with cell survival being a mere 0.25 at 
100nM concentrations. 
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4.2.4.7 Cell Survival HTS results for MiaPaCa-2 
 
 
A.
MiaPaCa-­‐2
 
B.
MiaPaCa2 MiaPaCa2 MiaPaCa2
 
 
Figure4.19 Quality control heat map, bar graph and box plot for MiaPaca2. Figure A shows 
MiaPaCa2 cell line screen results plate configuration and histograms with good quality 
control and output of the screen for this cell line. In B, the bar graphs have a normal 
distribution for positive and negative controls indicating a successful screen throughout 
replicates 1, 2 and 3.  
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Figure4.20 Cell Survival HTS results for MiaPaca2.  
 
 
MiaPaCa-2 cells showed a significant response to three compounds, a Bcl2 inhibitor, 
a PARP inhibitor and a non steroidal anti inflammatory drug (NSAID). The survival 
fraction of this cell line after exposure to these compounds was less than 0.15 even 
at low concentrations of 1nM. These cells were particularly sensitive to the PARP 
inhibitor and Bcl2 inhibitor with a less than 0.02 survival fraction. These cells showed 
no sensitivity to Gemcitabine, Paclitaxel or HSP inhibitors as seen by the previous 
PDA cell lines. 
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4.2.4.7.1 Cell Survival HTS results for clone 2 of luciferase marked MiaPaCa-2 
 
 
A. 
miapacaRluc2	  QC:	  OK
 
B.
MiaPaCaRluc2 MiaPaCaRluc2 MiaPaCaRluc2
 
 
 
Figure4.21 Quality control heat map, bar graph and box plot for clone 2 of luciferase marked 
MiaPaca2.  
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Figure4.22 Cell Survival HTS results for clone 2 of luciferase marked MiaPaca2.  
 
 
This is a clone of a luciferase marked MiaPaCa-2 cell line. Cell survival was seen as 
less than 0.2 for all concentrations used suggesting significant cell death and 
sensitivity to these compounds. 
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4.2.4.7.2 Cell Survival HTS results for clone 3 of luciferase marked MiaPaCa-2 
 
A.
miapacaRluc3	  QC:	  OK
 
B.
MiaPaCaRluc3
MiaPaCaRluc3 MiaPaCaRluc3
 
 
Figure4.23 Quality control heat map, bar graph and box plot for clone 3 of Renilla luciferase 
marked MiaPaca2 
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Figure4.24 Cell Survival HTS results for clone 3 of Renilla luciferase marked MiaPaca2.  
 
This clone of a Renilla luciferase marked MiaPaCa-2 cell line showed the similar 
pattern of sensitivity to the parent cell line in which there was significant sensitivity to 
three compounds ABT-737 (Bcl-2 inhibitor), AG-14699 (PARP inhibitor) and 
Indomethacin (NSAID). The survival fraction of was less than 0.8 across all 
concentrations of these drugs with almost 100 cell death after treatment with the Bcl-
2 and PARP inhibitors. 
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Figure4.25 Cell Survival HTS results for clone MiaPaca2 and its luciferase marked clones 
 
 
 
 
Both clones and parent cell line responded in a similar fashion as discussed above. 
There was a significant response to three compounds, a Bcl2 inhibitor, Ag-14699 (a 
PARP inhibitor from Pfizer) and an NSAID, Indomethacin. Although clone 3 of the 
luciferase marked cells appeared most sensitive, both clones responded in a similar 
pattern to the parent cell line with almost total cell death from both the PARP inhibitor 
and the NSAID.  
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4.2.4.8 Cell Survival HTS results for Su86.86 
A.
Su86.86
 
 B.
Su86.86 Su86.86 Su86.86
 
 
Figure4.26 Quality control heat map, bar graph and box plot for Su86.86. Figure A shows 
Su86.86 cell line screen results plate configuration and histograms with good quality control 
and output of the screen for this cell line. In B, the bar graphs have a normal distribution for 
positive and negative controls indicating a successful screen throughout replicates 1, 2 and 
3.  
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Figure4.27 Cell Survival HTS results for Su86.86.  
 
The survival fraction of SU86.86 was 0.7 on exposure to Gemcitabine and Paclitaxel 
at 10nM concentrations. There was little response to any of the other compounds at 
this concentration. At the higher concentration of 100nM, survival fraction was 0.7 in 
response to Gemcitabine, Vinorelbine, Flavopiridol and HSP inhibitors. The greatest 
sensitivity was seen with Paclitaxel, with a survival fraction of 0.5 at 100nM of the 
compound.  
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4.2.5 Comparison of cell survival at low concentrations 10nM 
Table 4.2 below, shows a list of the survival fractions of each cell line and the 
compounds to which they have shown sensitivity. A score of 1 indicates no cell death 
and 100% survival.  A cell survival reading from 0.6 to 0.8 was considered a 
moderate response and 0.5 or less was considered a significant response to the 
drug. All cell lines with the exception of MiaPaCa-2 responded to Paclitaxel at this 
low concentration, with PL5, PL45 and PANC-1 having the greatest response to 
Paclitaxel with a survival fraction of 0.3 and ASPC-1 having a survival fraction of 0.5. 
HPAC, Hs766T and Su86.86 appeared more resistant to Paclitaxel. There was a 
poor response to Gemcitabine across all 8 cell lines with Aspc-1, HPAC,  Hs766T, 
PL5 and MiaPaCa-2 having limited or no response at all and PANC-1, PL45 and 
Su86.86 having only a mild response with high survival fractions of 0.8 . None of the 
cell lines responded to the smoothened inhibitor GDC-0449 and there was a limited 
or no response to all of the other compounds at 10nM. 
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Cell survival for common hits seen from Ashworth HTS compound library 
screen at 10nM concentrations 
Plate 10 
compound 
hits 
AsPC-
1 HPAC Hs776T 
Panc-
1 PL45 PL5 
MiaPaCa-
2 Su86.86 
17 AAG 
HSP 
inhibitor 
0.7 0.9 1 1 1 1 1 1 
BEZ-235 
PI3K/mTOR 
Inhibitors 
1 1 1 1 0.8 1 1 1 
BI-2536 
PLKi 
0.9 1 1 1 1 1 1 1 
Doxorubicin 
DNA 
Intercalator 
1 1 0.8 0.9 0.9 1 1 1 
Flavopiridol] 
CDKi 
1 1 0.8 1 1 1 1 1 
Gemcitabine 
DNA repair 
inhibitor 
1 0.9 1 0.8 0.8 1 1 0.8 
Paclitaxel 
Microtubule 
suppressor 
0.5 0.7 0.8 0.3 0.3 0.3 1 0.8 
Vinorelbine 
Anti mitotic 
1 1 0.9 1 0.8 1 1 1 
GDC-0449 
Smoothened 
inhibitor 
1 1 1 1 1 1 1 1 
 
Table 4.2 Cell Survival for PDA cell lines at (1x10-8)10nM concentrations .  
This table compares cell survival fractions following treatment with 10nM concentrations of 
each compound via high throughput screening.  No colour = no response,    = very 
significant response,  ,    = significant response,     = minimal response,        = moderate 
response 
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4.2.6 Comparison of cell survival at higher concentration 100nM 
As seen from table 4.3 below, 6 out of 8 PDA cell lines displayed a response to the 
microtubule suppressor Paclitaxel, particularly PL45, PL5 and PANC-1 (highlighted 
in red) which showed the lowest cell survival after treatment. ASPC-1, HPAC and 
SU86.86 displayed a 50% cell survival and Hs776T and MiaPaCa-2 had limited and 
no sensitivity to this compound. At this concentration there was also limited or no 
response to Gemcitabine from PDA cell lines HPAC, Hs776T, PL5 and MiaPaCa-2. 
PL45 and PANC-1 appeared more sensitive with very low cell survival fractions, 
PL45 being the most sensitive with a survival fraction of 0.3. None of the PDA cell 
lines showed any response to the smoothened inhibitor GDC-0449. 
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Cell survival for common hits seen from Ashworth HTS compound library 
screen at (1x10-7)100nM concentrations 
Plate 10 
compound 
hits 
AsPC-
1 HPAC Hs776T 
Panc-
1 PL45 PL5 
MiaPaCa-
2 Su86.86 
17 AAG 
HSP 
inhibitor 
0.7 0.5 1 0.7 0.3 0.4 1 0.7 
BEZ-235 
PI3K/mTOR 
inhibitors 
0.6 0.9 0.4 0.7 0.5 0.9 1 1 
BI-2536 
PLKi 
0.6 1 1 1 1 1 1 1 
Doxorubicin 
DNA 
Intercalator 
0.8 1 0.8 0.5 0.7 0.6 1 0.8 
Flavopiridol 
CDKi 
0.7 1 0.4 0.7 0.7 1 1 0.7 
Gemcitabine 
DNA repair 
inhibitor 
0.7 0.9 1 0.5 0.3 1 1 0.7 
Paclitaxel 
Microtubule 
suppressor 
0.5 0.5 0.9 0.3 0.2 0.3 1 0.5 
Vinorelbine 
Anti mitotic 
0.6 1 0.9 0.5 0.4 0.4 1 0.6 
GDC-0449 
Smoothened 
inhibitor 
1 1 1 1 1 1 1 1 
 
Table 4.3 Cell survivals for PDA cell lines at (1x10-7)100nM concentrations. This table 
compares cell survival fractions following exposure to 100nM concentrations of each 
compound via high throughput screening. A score of 1 indicates no cell death and 100% 
survival. A low score indicated a better sensitivity to the drug, indicated in red. 
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4.3 Discussion 
 
Several methods have been used to predict in vitro chemosensitivity of tumour cells 
to cytotoxic agents and different assays; clonogenic, which first expand tumour cells 
prior to treatment with cytotoxic agents and non-clonogenic assays in which primary 
tumour cells are exposed to chemotherapeutic drugs, have been employed. 
Chemosensitivity profiles have been reported for breast, stomach and liver cell lines 
(Nakatsu et al,.2005). This study reviewed genes that determine the 
chemosensitivity of these pancreatic ductal adenocarcinoma cell lines to a library of 
anti-cancer drugs.  
 
 
For pancreatic cancer, studies have profiled the expression of individual genes 
implicated in chemoresistance, such as BNIP3, (Erkan et al, 2005), as well as those 
involved in Gemcitabine uptake and metabolism, (Nakahira et al, 2007; Nakano et al, 
2007). Michalski and colleagues used the ATP-based tumour chemosensitivity assay 
(ATP-TCA) on primary resected pancreatic cells and used real time PCR to 
determine the RNA expression of specific genes associated with chemoresistance, 
(Michalski et al. , 2008). Sanger and broad have performed genomic and gene 
expression analyses, (www.cancerrxgene.org). They correlated the sensitivity 
patterns of their large library of cell lines with genomic and expression data in order 
to identify features that may predict sensitivity.  
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 High throughput screening is a method that allows large volume screening of 
several compounds in the hope of new drug delivery. It is a drug screen compared to 
the genetic screens described above. From the compounds screened in this library, 
those that produced at least 50% cell death or a cell survival fraction of 0.5 or less 
included heat shock protein inhibitors, Pi3K/mTOR inhibitors, DNA intercalators,  
microtubule suppressors, anti-mitotics and cyclin dependent kinase inhibitors. Of the 
8 PDA cell lines screened, none of these responded to treatment with the 
smoothened inhibitor GDC-0449, even at the highest concentration of 1µM. 
 
 
The PDA cell lines above appear to be resistant to Gemcitabine at lower 
concentrations of the drug (10nM), and only PANC-1 and PL45 have displayed a 
50% cell death or less than 0.5 cell survival fractions when exposed to higher 
concentrations of Gemcitabine. All the cell lines appeared resistant even at 1µM of 
Gemcitabine with the exception of PANC-1, PL5 and PL45. These PDA cell lines all 
had a low cell survival count at this concentration whilst all other cell lines showed 
minimal or no response. 
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With the exception of MiaPaCa-2 and Hs776T, all the other epithelial cell lines 
showed sensitivity to the lower 10µM concentration of Paclitaxel. PL45, PL5 and 
AsPC-1 had survival fractions ≤ 0.5, equivalent to 50% or more cell death. A similar 
pattern was seen at higher concentrations. Of note, MiaPaCa2 was resistant to 
Gemcitabine and Paclitaxel and showed no response to smoothened inhibitor 
compound GDC-0449. Although this is not appreciated at 10nM, the more sensitive 
cell lines in this group PANC-1, PL5 and PL45 also showed significant response 
(survival fraction ≤ 0.5) to the anti-mitotic, Vinorelbine and the heat shock protein 
inhibitor compound 17 AAG at 100nM concentrations of these compounds. 
 
 
As mentioned before Sanger and Broad have compiled a database, from several 
sources, that correlated drug response with genetic alterations that may affect 
sensitivity of the cancer cell lines screened. They have screened over 1000 
genetically characterised human cancer cell lines with a wide range of anti-cancer 
drugs, (www.cancerrxgene.org).  The Sanger and Broad drug library did not include 
some of the hits obtained from drugs in the Ashworth compound library such as 
BEZ-235 the Pi3K/mTOR inhibitor and Flavopiridol and therefore these could not be 
compared. They did however have data on 17-AAG (HSP inhibitor), Doxorubicin, 
Dasantinib, Gemcitabine, Paclitaxel and Vinorelbine. Of their collection of PDAC cell 
lines, only ASPC-1 and MiaPaCa-2 were included. 
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The known genetic mutations in PDAC include mutations of KRAS, AKT2, CDKN2A 
(p16), DPC/SMAD4 and P53. The number of mutations in these genes and their 
effect on sensitivity were correlated in the Sanger and Broad database. From their 
data, the gene mutation having any effect on sensitivity of pancreatic cell lines was 
CDKN2A (p16).  Its effect on sensitivity was however limited with a maximum 55 fold 
increase in sensitivity to 17 AAG and minimum of 16 fold increase in sensitivity to 
Paclitaxel. There was a 100 fold increase in resistance to Doxorubicin with this 
genetic mutation. The other mutations commonly seen in PDAC were not found to 
have any notable effect on sensitivity or resistance. There were no genetic 
correlations found that affect sensitivity of PDAC lines to Vinorelbine and the genetic 
changes seen in CDKN2A and SMAD4 had little correlation or affect on sensitivity of 
the PDAC cell lines to GDC-0449.  
 
AsPC-1, HPAC, PANC-1, PL5, PL45 and Su86.86 appear to be the more sensitive 
cell lines when compared to MiaPaCa2 and Hs776T, with PL5, PL45 and PANC-1 
displaying a comparatively larger amount of cell death on high throughput screening. 
Although there are no specific similarities in these two apparently resistant cell lines, 
the amplification in AKT2/ch 19q is absent in both MiaPaCa-2 and Hs776T and 
neither of them have the LOH at 13q, seen in the other cell lines. Based on the data 
from Sanger and broad neither AKT2 nor 13q LOH confer any degree of sensitivity 
or resistance in the cell lines screened. Of the two cell lines with the least response 
to drugs, only MiaPaCa2 has a homozygous deletion at CDKN2A (p16). Hs776T has 
no genetic alteration in this gene and p16 homozygous deletions can also be found 
in ASPC-1, PANC-1 and SU86.86. 
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Currently in the clinical setting, the drugs that have been used include Gemcitabine, 
Oxaliplatin, Capecitabine, Cisplatin and Irinotecan, with varying and limited 
outcomes, Gemcitabine being the gold standard of treatment. The results of the High 
throughput screen showed little cell death in response to Gemcitabine at lower 
concentrations (10nM) and a  response in only 2 cell lines (PANC-1 and PL45) at the 
higher concentration of 100nM. Combination therapy has included some of the other 
compounds in the screen including, Gemcitabine/GDC-0449(Anti smoothened) and 
Gemcitabine/Nab- Paclitaxel.  None of the PDAC models used in this study 
responded to the smoothened inhibitor however, there was significant cell death, up 
to 70%, in response to the microtubule suppressor Paclitaxel even at lower 
concentrations of the compound (10nM).  
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Chapter 5 
Pancreatic stellate cells and chemoresistance 
5.1 Introduction 
The pancreatic stellate cell has been shown to be necessary for the development of 
tumours in KPC mouse xenograft models (Olive/Tuveson et al., 2009). Stellate 
cancer associated fibroblasts themselves have already been implicated in the 
aggressiveness of others cancers such as oral squamous cell carcinoma, (Sobral et 
al., 2011). This suggests a role for pancreatic stellate cell in tumour development 
and progression.  
 
Due to the dense desmoplastic reaction particular to pancreatic cancer and the 
majority of cells in these tumours being pancreatic stellate cells, these cells may be 
intimately involved in the chemoresistant nature of these tumours, making them 
viable targets when considering options for chemotherapy in the fight against 
pancreatic cancer 
 
Hwang and associates showed that in the presence of human pancreatic stellate 
cells, cancer cells, in particular BxPc3, show no significant change in cell number 
when exposed to Gemcitabine or irradiation, (Hwang et al, 2008). They also found 
an increase in the anti apoptotic signalling pathway expression whereby the cancer 
cell lines responded to stellate conditioned media with a multiple fold increase in 
AKT and ERK expression after several minutes when co-cultured with human 
stellate cells.  
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They showed that stellate cells were necessary for tumour initiation and growth and 
without them tumours failed to develop on their own. Co-injection of stellate with 
BxPc3 in orthotopic mice resulted in metastases in a dose dependent manner. 
(Hwang et al., 2008). The mechanism of this effect has not yet been elucidated but 
may be multi-factorial. These factors may include crosstalk between the stellate cells 
and the tumour and the related feedback mechanisms. Other contributing factors are 
that of increased signalling pathways involved in tumour development such as the 
hedgehog signalling pathway and the dense stroma which may act as a physical 
barrier to drug delivery, (Olive et al., 2009). 
 
 
5.1.1 Crosstalk and chemoresistance 
Pancreatic stellate cells are activated by a variety of cytokines produced by tumour 
cells, including interleukins, fibroblast growth factors (FGFs), TGFβ and PDGF. In 
turn, pancreatic stellate cells are found to produce cytokines and components of the 
ECM that affect cancer cell invasiveness and growth. They include FGFs, VEGF, 
connective tissue growth factor (CTGF), matrix metalloproteinases (MMPs), 
collagens and fibronectin. They are also known to produce insulin like growth factor 
IGF-1 and II, the actions of which appear to predominantly impart tumour growth by 
conveying survival signals, (Hwang et al., 2008).  Ueda and colleagues reported 
IGF-1 receptor (IGF1R) and epidermal growth factor receptor (EGFR) 
overexpression in the pancreatic ductal specimen resected, (Ueda et al., 2006). 
Their data suggests that EGFR family member signalling through IGF1R is important 
in signalling in cancer growth and survival. 
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Part of the ability of tumour cells to evade programmed cell death is derived from 
survival signals supplied by the stromal compartment. Since there is increasing 
evidence that the tumour stroma may be crucial in determining the invasive and 
metastatic potential of many cancers, understanding the biology of the activated 
stellate cell and its stroma has therapeutic potential. There may be benefit, for 
example, in reducing the cross-activation of the stellate cells and stromal cells by 
inhibitors of PDGF, VEGF and other mediators, many of which are becoming 
commercially available. Animal models have been used to suggest that Sonic 
Hedgehog (SHH) signalling promotes the migration and invasion of human 
pancreatic myofibroblasts thereby increasing the desmoplastic and stromal reaction, 
(Madhevan, Von Hoff  et al 2007).  
 
 
Other compounds have been identified as potential key players in the 
chemoresistant nature of pancreatic cancer. Fibroblast activating protein, which is 
seen in the activated stellate cell, is one of the factors implicated with the 
development of the stromal compartment and has recently been identified as a 
possible prognostic indicator for PDA, (Min et al, 2012). It alters the extracellular 
matrix, making it a more favourable environment for tumour invasion. Disruption of 
this fibroblast activating protein effect has been found to hinder tumour invasion, 
(Lee, Mullins et al, 2011; Santos et al, 2009), making it a potentially useful 
chemotherapeutic target.  
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5.1.2 Hedgehog (Hh) signaling and chemoresistance  
The hedgehog signalling pathway has proved to be a key player in the development 
and proliferation of PDA. This pathway was previously thought to stimulate the 
epithelial cells of tumours, resulting in tumour progression. It has since been shown 
that this pathway is activated in the stromal compartment (Yauch et al, 2008). 
Hedgehog stimulates stromal proliferation via paracrine signalling and inhibition of 
this pathway has shown to have therapeutic potential. 
 
The expression of Hh ligands and essential components of the pathway, including 
PTCH and SMO, have been reported in up to 70% of human pancreatic ductal 
adenocarcinoma specimens (Thayer et al., 2003). In addition, several studies have 
proposed that Hh ligands produced by tumour cells activate Hh signalling and 
tumour cell growth in an autocrine/ juxtacrine manner (Thayer et al., 2003, Pasca di 
Magliani et al., 2006). Previously, research focused heavily on the presence of 
hedgehog signalling in the pancreatic epithelium but research performed by a 
Cambridge group led by Olive and Tuveson found that the hedgehog pathway is in 
fact effected within the stromal compartment, (Olive et al., 2009).  
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Sonic Hedgehog (SHH) binds to the Patched-1 (PTCH1) receptor. In the absence of 
the SHH ligand, PTCH1 inhibits Smoothened (SMO), a downstream protein in the 
pathway. (Taipale et al, 2002). The binding of SHH relieves SMO inhibition, leading 
to activation of the GLI transcription factors Gli1 and Gli2 (activators) and the Gli3 
(repressor). Activated Gli accumulates in the nucleus and controls the transcription 
of hedgehog target genes. PTCH1 has recently been reported to repress 
transcription of hedgehog target genes through a mechanism independent of 
Smoothened suggesting the existence of a non-canonical pathway, (Rahnama et al., 
2006).  
 
Yauch and his group reported that for hedgehog–expressing tumours lacking 
mutations in the pathway, hedgehog signalling was indeed occurring in the stroma 
and not the cancer epithelial cells, (Yauch et al., 2008).  They demonstrated that the 
hedgehog ligand from the cancer cell was activating the adjacent stroma. This data 
was corroborated with evidence by Olive and Tuveson who showed, using mouse 
models, that a hedgehog inhibitor could deplete the stroma and re-vascularise poorly 
perfused tumours, giving evidence that the stroma can be targeted by hedgehog 
antagonists. A smoothened inhibitor when used in combination with Gemcitabine to 
treat genetically modified mice was found to increase the median survival by more 
than 2 fold, (Olive/Tuveson et al, 2009). These KPC mice (KrasLSL.G12D/+; 
p53R172H/+; PdxCretg/+) had pancreas-specific KrasG12D and Trp53R172H mutations, 
(Olive/Tuveson et al, 2009). 
 
193 
 
The sequence of molecular events that connect Smoothened to the Gli transcription 
factors is poorly understood and requires further investigation as this pathway can 
prove a useful target in the management of pancreatic cancer. Further therapeutic 
manipulations in the future may involve reversing the activation of stellate which is 
an area that has not been studied. Thus far, the activated phenotype of stellate cells 
has been shown to be reversed by ligands of the peroxisome proliferator-activated 
receptor-gamma (PPARγ) pathway, as well as antioxidants, (Haber et al, 1999; Cat 
B et al, 2006).  
 
5.1.3 Stromal density and chemoresistance 
The density of stroma is also believed to be chemoprotective in that it hinders 
adequate drug delivery to an already resistant cancer. Notably, PDA has a 
particularly prolific desmoplastic reaction making it comparable to breast cancer 
where greater than 90 percent of cells in the stroma are pancreatic stellate cells. 
Studies have attempted to perforate this dense barrier in order to access the tumour 
thereby facilitating better drug delivery. They showed a 60% increase in Gemcitabine 
concentration in the tumours if preceded by a hedgehog inhibitor, and the 
combination of this inhibitor with Gemcitabine more than doubled mouse survival 
compared with Gemcitabine alone, (Olive/Tuveson et al, 2009). 
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Olive and colleagues have shown that the use of hedgehog inhibitors can alter 
communication between the tumour and stroma via the hedgehog pathway, 
interrupting the feedback loop necessary for stromal activation and development and 
resulting is stromal depletion. This depleted stroma becomes less of a barrier to 
chemotherapeutic intervention as drug delivery to the tumour is somewhat 
enhanced. 
 
 
5.2 High throughput screen results of stellate cancer associated fibroblasts 
There is currently very little data on the chemosensitivity of stellate cancer 
associated fibroblasts. Previous work has implicated stellate CAFs and their 
secretions in cancer progression when cultured with tumour cells. (Vonlaufen et al, 
.2008). Other studies have identified a role of extracellular matrix proteins in the 
acquired resistance to anticancer drugs. This study used in vitro models to show that 
resistance to cytotoxic drugs was dependent on these proteins. (Miyamoto et al, 
2004). The actual mechanism was not identified. Further work is therefore needed to 
profile the role of these stellate cells in the chemoresistant nature of PDAC. 
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Primary non-immortalised stellate cells were cultured from wedge resections of PDA, 
described in Materials and Methods, and then screened under the same conditions 
as the PDA epithelial cell lines. These explants were cultured from samples taken 
within 5mm from the tumour edge (figure 2.1) and verified as a pure fibroblast culture 
using immunohistochemistry as shown in figure 2.2.  They were expanded to an 
early passage 3 or 4 and to 70% confluence prior to storage in liquid nitrogen for 
future use. These cells were profiled using array CGH and displayed no copy 
number variations thereby confirming their genetic stability. The immortalised 
pancreatic stellate cell line displayed the same immunohistochemistry as that of the 
non-immortalised group. Both models were screened as described below. 
 
 
 
The full Ashworth library of chemotherapeutic agents were used for the primary and 
immortalised stellate cells in the same manner as for the PDA cell lines. The results 
obtained were represented as heat maps, bar graphs and histograms which 
confirmed quality control of the HTS screens. Below are the results of the screens for 
each pancreatic stellate cell line. For quality control, the z prime factor is an 
indication of the signal to noise ratio of the CTG reading (assay output quantification) 
between the untreated cells (DMSO only, 0.2% volume to volume ratio (v/v)) and the 
cell death control. The z prime factor for all screens ranged form 0.5 to 0.78. It is 
essentially the ratio between the blue dots (positive control) and red dots as seen on 
the histograms). A screen with a value of 0.5 or higher was considered an excellent 
quality. The spearman rank correlation is another indication of the quality control of 
the screen. 
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5.2.1 Cell survival HTS results for PF3 
                    
      A.  
QC: PF3 primary stellate cells
 
    B.
PF3 PF3 PF3
 
Figure 5.1 Quality control heat map, bar graph and box plot for PF3. Figure a shows PF3 
cell line screen results plate configuration and histograms with good quality control and 
output of the screen for this cell line. In B, the bar graphs have a normal distribution for 
positive and negative controls indicating a successful screen throughout replicates 1, 2 and 
3.  
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Figure 5.2 Cell Survival HTS results for primary stellate cell line PF3.  
 
The cell survival curve for the primary fibroblast explant PF3 has shown sensitivity to 
Dasantinib at low concentrations of 10nM (-8) with a cell survival of 0.5. Results 
showed that there was no sensitivity to Gemcitabine or Paclitaxel. At 100nM (-7) 
concentrations of the Pi3K/mTOR inhibitor, BEZ-235, there was a moderate 
response with cell survival of 0.6. 
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5.2.2 Cell survival HTS results for PF18 
                       
A. 
QC:PF18 primary stellate cells
 
B.
PF18 PF18 PF18
 
 
Figure 5.3 Quality control heat map, bar graph and box plot for PF18. Figure a shows PF18 
cell line screen results plate configuration and histograms with good quality control and 
output of the screen for this cell line. In b, the bar graphs have a normal distribution for 
positive and negative controls indicating a successful screen throughout replicates 1, 2 and 
3.  
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Figure 5.4 Cell Survival HTS results for primary stellate cell line PF18.  
 
 
 
 
PF18 was sensitive to Dasantinib, Flavopiridol and Doxorubicin at 100nM. The cell 
survival fraction was 0.5 in response to each drug. Results showed that there was 
some sensitivity to Gemcitabine and Paclitaxel at the lower concentrations but this 
response plateaud at higher concentrations up to and including 1000nM. 
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5.2.3 Cell survival HTS results for PF20 
 
  A.
QC:PF20 primary stellate cells
 
B.
PF20 PF20 PF20
 
 
Figure 5.5 Quality control heat map, bar graph and box plot for PF18. A) PF18 cell line 
screen results plate configuration and histograms with good quality control and output of the 
screen for this cell line. B), the bar graphs have a normal distribution for positive and 
negative controls indicating a successful screen throughout replicates 1, 2 and 3.  
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Figure 5.6 Cell Survival HTS results for primary stellate cell line PF20.  
 
This primary non- immortalised stellate cell culture has shown a response to 
Dasantinib, BEZ-235 and Flavopiridol with survival fractions all < 0.5 only a 30% cell 
survival in cells exposed to Flavopiridol. These cells appeared to have some 
response to the heat shock protein inhibitors although limited. 
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5.2.4 Cell survival HTS results for Immortalised human pancreatic Stellate cells 
Quality Control 
 
A.   
Stellate	  cells	  QC:	  OK
 
B.
Screen1-­‐Stellate	  
 
Screen1-­‐Stellate Screen1-­‐Stellate
 
 
Figure 5.7 Quality control heat map, bar graph and box plot for Immortalised Human 
pancreatic stellate cells. Figure A shows Human pancreatic stellate cell line (HPSC) screen 
results plate configuration and histograms with good quality control and output of the screen 
for this cell line. In B, the bar graphs have a normal distribution for positive and negative 
controls indicating a successful screen throughout replicates 1, 2 and 3.  
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5.2.5 Repeat cell survival HTS results for Immortalised human pancreatic 
stellate cells  
 
 A.  
Screen	  2	  stellate
 
B.
Screen2	  stellate Screen2-­‐ stellate Screen2-­‐stellate
 
 
Figure 5.8 Quality control heat map, bar graph and box plot for Immortalised Human 
pancreatic stellate cells screen 2. Figure A shows HPSC cell line screen results plate 
configuration and histograms with good quality control and output of the screen for this cell 
line. In B, the bar graphs have a normal distribution for positive and negative controls 
indicating a successful screen throughout replicates 1, 2 and 3. 
 
 
 
 
 
 
204 
 
 
Figure 5.9 Cell Survival HTS results for Immortalized Human pancreatic stellate cells.  
 
 
The immortalised stellate cells responded well to all of the main chemotherapeutic 
compounds with cell survival being less than 50% with Vinorelbine, 17 AAG heat 
shock protein inhibitors and Paclitaxel at the very low 10µM concentration of each 
drug.  There is still a noted 40% cell death will all the drugs listed at the lowest 
concentration of 1nM. These cells seem more sensitive than their PDA counterparts.  
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5.2.6 Comparison of cell survival at low concentration of 10nM  
 
Table 5.1 below shows cell survival following exposure to 10nM concentrations of 
each compound via high throughput screening. At 10nM the primary non-
immortalised cell lines were resistant to most of these compounds. There was some 
response in all three primary cell lines to the PI3K/mTOR inhibitor compound (BEZ-
235) and the BCR-ABL/SRC inhibitor (Dasantinib) even at this low concentration. 
The immortalised stellate cells we sensitive to all the common hits, even at this low 
concentration, with the exception of the smoothened inhibitor GDC-0449, to which 
there was no response. The greatest response was seen on exposure to the heat 
shock protein inhibitor (17 AAG) and the microtubule suppressor, (Paclitaxel). Both 
the immortalised and non-immortalised groups of stellate cells were resistant to the 
smoothened inhibitor, (GDC-0449). 
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Cell survival for common hits seen from the Ashworth High Throughput 
Screen compound library (10nM concentrations) 
Plate 10 compound hits PF3 PF18 PF20 Immortalised stellate cells 
17AAG 
HSP inhibitor 
1 1 0.8 0.4 
BEZ-235 
PI3K/mTOR inhibitors 
0.6 0.8 0.7 0.5 
BI-2536 
PLKi 
1 1 1 0.6 
Dasantinib 
BCR-ABL/Src inhibitor 
0.6 0.8 0.7 0.6 
Doxorubicin 
DNA Intercalator 
1 1 0.8 0.6 
Flavopiridol] 
CDKi 
1 1 1 0.6 
Gemcitabine 
DNA repair inhibitor 
1 0.7 1 0.6 
Paclitaxel 
Microtubule suppressor 
1 0.6 1 0.4 
Everolimus 
mTOR inhibitor 
1 1 0.7 0.5 
GDC-0449 
Smoothened inhibitor 
1 1 1 1 
 
Table 5.1 Cell survival z scores at 10nM concentrations of each compound. This table 
shows the z scores for the primary and immortalised stellate cells. Scores of 1 indicates no 
cell death and values less than 0.5 show a more than 50% cell death. 
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5.2.7 Comparison of cell survival at higher concentration of 100nM  
Table 5.2 compares the cell survival of the primary stellate cells and the 
immortalised stellate cells at 100nM concentrations of the common hits. Both the 
immortalised and non-immortalised groups of stellate cells were resistant to the 
GDC-0449 smoothened inhibitor.  All cells were sensitive to Dasantanib (BCR-
ABL/Src inhibitor)  with cell survival ≤ 0.5. Even at this higher concentration the 
primary non immortalised stellate cells showed limited or no response to 
Gemcitabine.  
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Cell survival for common hits seen from the Ashworth High Throughput 
Screen compound library (100nM concentrations) 
Plate 10 compound hits PF3 PF18 PF20 Immortalized stellate cells 
17AAG 
HSP inhibitor 
1 1 0.8 0.5 
BEZ-235 
PI3K/mTOR inhibitors 
0.6 0.8 0.5 0.3 
BI-2536 
PLKi 
1 1 1 0.2 
Dasantinib 
BCR-ABL/Src inhibitor 
0.4 0.5 0.4 0.4 
Doxorubicin 
DNA Intercalator 
1 0.5 0.7 0.5 
Flavopiridol] 
CDKi 
0.9 0.5 0.3 0.3 
Gemcitabine 
DNA repair inhibitor 
1 0.7 1 0.4 
Paclitaxel 
Microtubule suppressor 
1 0.6 1 0.2 
Everolimus 
mTOR inhibitor 
1 1 0.7 0.4 
GDC-0449 
Smoothened inhibitor 
1 1 1 1 
 
Table 5.2 This table shows cell survival z scores following exposure to 100nM 
concentrations of each compound via high throughput screening. Scores of 1 indicates no 
cell death and values less than 0.5 show a more than 50% cell death. 
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5.3 Discussion 
 
Direct and indirect interactions between tumour cells and their microenvironment 
have been identified as potential molecular targets to overcome chemoresistance. 
For example, cancer-associated fibroblasts have been shown to protect MCF-7 cells 
against apoptosis by the topoisomerase inhibitor, Doxorubicin and the PARP-1 
inhibitor, ABT-888. These oestrogen receptor positive (MCF-7) cells, when exposed 
to these drugs, in co-culture with fibroblasts, showed no affect on cell viability. This is 
believed to be due to the increase in mitochondrial activity, induced by the caveolin-1 
depleted fibroblasts, which protects these cells from apoptosis. When cultured on 
their own MCF-7 cells displayed an 11.6 fold reduction in viability with Doxorubicin 
and a 6.8 fold reduction in viability with ABT-888. This is an example of the active 
role of stellate cells in chemoresistance, (Martinez-Outschoorn et al., 2011). 
 
 
In the high throughput drug screens performed, the primary and immortalised stellate 
cell lines here both displayed sensitivity to the BCR-ABL/Src inhibitor (Dasantinib) and 
PI3kinase/mTOR inhibitor compound BEZ-235. There was a significant response to 
Dasantinib, across all the cell lines at the higher concentration of 100nM. The 
immortalized stellate cell line however, responded also to Gemcitabine, the 
microtubule poison Paclitaxel, the heat shock protein inhibitor compound 17 AAG 
and PI3kinase/mTOR inhibitor compound BEZ-235 at the lower 10nM concentrations 
of each compound.  
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As previously described, hedgehog produced by the epithelial cancer cells binds to 
smoothened receptors in the stroma. This paracrine activity leads to the disinhibition 
of Patched and a canonical production of Gli transcription proteins. These 
transcription factors are believed to be involved in stromal proliferation, tumour 
development and progression. Of note, neither the primary, nor immortalized stellate 
cell lines responded to the smoothened inhibitor when treated individually. This may 
be due to the presence of a non-canonical pathway involving Gli transcription factors 
that is independent of smoothened activation.  
 
 
 
Overall the immortalised stellate cell line appeared less resistant to 
chemotherapeutic compounds in this drug library in comparison to the primary non-
immortalized group. These cells were derived from chronic pancreatitis specimens 
and not pancreatic cancer and this may be a contributing factor. The cells however 
have the same phenotype when immunostained. The primary non-immortalised 
cells, which were indeed cancer associated, within 5mm of the tumour margin, were 
not found to have any homozygous genetic changes and therefore this would not be 
a contributing factor in the difference in sensitivity. The presence and role of 
heterozygous and epigenetic changes is yet to be elucidated. 
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Chapter 6 - Conclusion 
 
The focus of this study was to elucidate any changes and behaviour of the stellate 
cancer associated fibroblast that may play a role in tumour progression and 
chemoresistance. It has been shown by several studies that pancreatic stellate cells 
play an integral role in tumour growth and development as tumours that are seeded 
with these stellate cells show 100 percent more growth in vivo, as opposed to when 
they were seeded on their own. 
 
 
On stimulation, the tumour microenvironment undergoes changes during which, the 
more active extracellular matrix becomes an oasis for the tumour and supports its 
cell proliferation, invasion and angiogenesis. There are multiple pathways through 
which this may occur but the exact mechanisms are not yet fully understood. Apart 
from their physical presence in the activated state, factors derived from stellate cells 
also play a role in tumour growth and angiogenesis, (Orimo2 et al, 2005). These 
factors may also oppose the action of chemotherapeutic drugs and the biology of the 
stellate cancer associated fibroblast to date makes them a plausible target in order to 
obtain a better response to chemotherapy. 
 
 
Despite the duality in findings previously reported, this study has found no 
homozygous genetic changes in the stellate CAFs of pancreatic ductal 
adenocarcinoma. However, the presence of heterozygous and/or epigenetic 
changes is yet to be fully excluded in this group and their effects if any, identified.  
The arrayCGH platform used showed no change in genotype in these tumour-
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juxtaposed cells in neither the explanted cells (5mm from the tumour margin), nor the 
intermingled fibroblasts obtained by laser captured microdissection. It therefore 
offers support to the suggestion that the mechanism by which these cells contribute 
to the aggressive nature of the disease may lie in the cross talk that occurs between 
these activated fibroblasts and the PDA epithelial cell as well as the signalling 
pathways involved.  
 
 
Having found that the stellate cancer associated fibroblast does not acquire 
homozygous genetic mutations in the similar fashion to its epithelial counterpart; its 
genetic stability may make them more sensitive to chemotherapeutic agents. Multiple 
targets have been suggested as proposed therapies to different aspects of stellate 
cell differentiation and interaction, (Gonda et al, 2009); however, their efficacy has 
not been validated. As yet very little drug sensitivity data exists for PDA models and 
none for the stellate cells at all.  
 
 
High Throughput Screening has never been done on PDA cell lines and pancreatic 
stellate cells and this is the first attempt to profile this group of cells using a large 
drug library with the common chemotherapeutic agents currently being used. Among 
the compounds identified in this screen were, heat shock protein inhibitors, Pi3 
kinase inhibitors, BCR-ABL/Src inhibitors, DNA intercalators, CDK inhibitors, DNA 
repair inhibitors, microtubule suppressors, and mTOR inhibitors. 
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The stellate cells appeared more responsive to the drugs in the compound library 
compared to the PDA cell lines. This may be due to the fact that they have no 
genetic homozygous changes that may convey the degree of resistance seen in their 
PDA counterparts. They may have heterozygous or epigenetic changes but their 
behaviour in the drug library suggest that thus far these cells are responsive. This 
sensitivity may favour them as potential targets for therapeutic management of this 
disease. 
 
Although it is not yet possible to make definitive statements about a particular drug 
being a good candidate for treatment, the findings from the HTS screens performed 
can highlight new possible drugs such as Dasantinib, which may be useful in 
combination with Gemcitabine and Paclitaxel in the management of pancreatic 
cancer. This data serves as a starting point to dissect drug sensitivity in this very 
hard to treat subtype of cancer. 
 
The findings of this drug screen have identified compounds to that lead to a 50% or 
more cell death as well as those to which there is no response.  This panel of cell 
lines have displayed a limited cell death to some of the more commonly used 
chemotherapeutic agents in pancreatic cancer such as Gemcitabine. This may 
indeed be linked to the genetic changes in the PDAC models however there is 
currently insufficient data to corroborate this. There were, however, varying degrees 
of sensitivity in these cell lines, which may suggest that PDAC may not necessarily 
be inherently chemoresistant. 
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Chapter 7 - Future work 
 
A) Drug screen of co-cultured stellate and epithelial cells  
This is currently underway pending successful co-transfection of both epithelial and 
stellate lines with the appropriate bioluminescent markers.  It is believed that co-
cultures can be used to study cancer cell interactions with the stromal environment 
to help elucidate the role of stromal variation in tumour types. I believe this can be 
extrapolated to include the role that these stromal fibroblast play in conferring 
chemoresistance to these cancer cells and to what degree.  
  
 
Development of bioluminescent markers for PDA cell lines and stellate cells 
As described in chapter 2. The bioluminescent marker Renilla and firefly luciferase 
were constructed prior to transfection of the cell lines. The PDA cell line MiaPaCa-2 
was the only cell line to successfully be transfected with the bioluminescent markers 
and it has been shown that the cells perform in a same manner as the parent cell 
line. In order to successfully complete this procedure however, a more successful, 
less cumbersome method of developing a marker is underway in order to transfect 
all lines involved. Dr Claus Jorgensen and his team at ICR are undertaking this.  
 
 
 
 
 
 
215 
 
Plasmid Transfection  
 
Plasmid transfection was done using the TransIT®-2020 Transfection Reagent and 
Protocol. The cell lines were cultured 24 hours prior to transfection in 6 well plates. 
Cells were plated at 6x105 in a volume of 2.5ml per well and incubated overnight at 
37ºC and 5% humidified CO2.  Immediately prior to transfection the TransIT-2020 
Reagent: DNA complex was prepared.  For the 6 well plate used, 250 µl of Opti-
MEM I Reduced-Serum Medium, 2.5µg of Plasmid DNA (Firefly luciferase) and 7.5µl 
of TransIT-2020 Reagent was mixed to a 2.5ml volume per well. The serum free 
media and plasmid DNA stock were mixed together by gentle pipetting. TransIT-
2020 Reagent was added to this mixture and mixed. This was left to form complexes 
for 15 to 30 minutes. The complex was added drop wise to each well and gentle 
rocking was used for even distribution. The cells were incubated for 72 hours and 
assayed for successful transfection. 
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The picture above shows the plasmid transfection with Firefly luciferase. Successful 
transfection of more than 80% of the epithelial cell line was seen. Based on the colour bar 
and above, the presence of green or above indicates good transfection. 
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Co-culture of epithelial and stellate cells  
The identical plate 10 screen will be performed on bioluminescent marked stellate 
and epithelial cell lines as described above. Cells will be marked with either Firefly or 
Renilla luciferase and co-cultured in a 1:1 ratio of PDA to stellate cell onto the 384 
well plate, maintaining the total cell count to 1000 cells per well. After 24 hours these 
cells were subjected to plate 10 screening as previously described and data 
analysed accordingly.  
 
 
 
In vivo experiments 
Orthotopic mouse models of carcinoma progression are well suited to the rapid 
preclinical testing of potential therapies. A xenograft model of PDA and stellate cell 
cells will be set up in nude mice, (BALB/cnu/nu). Twenty four nude mice will be 
injected with different ratios of cancer to stellate cells. Each limb of 6 nude mice 
injected with a stellate cell: tumour cell ratio of 0:1, 1:1, 2:1 and 4:1 respectively with 
total cell count of 1X106 cells per mouse. The samples will be injected in 50µl of PBS 
and checked twice weekly and tumours weighed and reviewed three times a week. 
The tumours will be excised at 12 to 15mm and sent for staining. Following the initial 
pilot study, this experiment will be used to observe the pattern of tumour progression 
with varying ratios of stellate cell present in vivo. 
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Combination drug screens 
The efficacy of anticancer drugs needs to be evaluated in the context of their ability 
to target stellate CAFs and metabolically uncouple fibroblasts from epithelial cancer 
cells. This may involve combination drug screens with drug that have shown a 
significant response in both cancer and stellate cell including Oxaliplatin which has 
been included in several drug trials but was absent from the Ashworth drug library. 
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B) Identification of epigenetic and heterogeneous variations in CAFs that 
lead to its role in tumourigenesis or chemoresistance  
 
SNP Arrays 
 Single nucleotide polymorphism or SNP is a DNA sequence variation in which a 
single nucleotide in the genome differs between paired chromosomes in an 
individual and usually two alleles are involved. As mentioned previously, this study 
thus far shows no CNV, i.e., no homozygous deletions. This does not rule out 
epigenetic changes or a heterogeneous population of cells. Normal tumours have a 
50% decrease in one of the alleles due to a possible contaminated normal. Using 
SNP 6 Arrays we can look for a pure population of active fibroblasts and review 
regions with loss of heterozygosity or aberrations that do not necessarily result in 
copy number variations but may have aetiological significance in carcinogenesis or 
chemosensitivity. SNP will allow the review of that which is copy neutral and 
homozygous neutral. i.e. the silent deletion of one allele and its replacement with a 
duplicate copy of its neighbouring allele. 
 
Micro RNA 
MicroRNA has a role in gene activation. This will need to be performed on 
prospective samples for fresh frozen tissue including miRNAs such as Mir-21. 
 
The integrity of the stromal reaction and its ability to effect a response 
The question can be answered with the use of in vivo mouse experiments. They 
already grow in vitro and the immortalised stellate multiply rapidly in vitro. This data 
will be compared to studies that suggest that CAFs are unable to clone 
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Appendix 1 
                      Quality control z factor scores for cell lines 
 
ASPC1 z factor score: 0.75 
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HPAC z factor score: 0.79  
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PANC1 z factor score: 0.78 
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                                                         PL5 z factor score= 0.78 
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MiaPaCa2 z factor score =0.89 
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PL45 z factor score= 0.83 
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MiaPaCa2 z factor score = 0.89 
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MiaPaCa2RLuc z factor score = 0.60 
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PF3 z factor score: 0.56 
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PF18 z factor score: 0.64 
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PF20 z factor score = 0.65 
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Stellate screen 1: z factor score = 0.78 
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Stellate screen 2: z factor = 0.8 
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